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ABSTRACT	Environmental	enteropathy	(EE)	is	thought	to	underlie	stunting,	a	widely	prevalent	phenomenon	in	the	developing	world	with	lifelong	detrimental	consequences.	EE	is	characterised	by	increased	intestinal	permeability	and	reduced	absorptive	capacity	in	a	chronically	inflamed	gut,	and	occurs	in	nutritionally	vulnerable	populations.	Deficits	of	amino	acids	and	micronutrients	may	cause	intestinal	immune	and	barrier	dysfunction,	mediated	through	cellular	nutrient	sensing	pathways.	Mechanistic	target	of	rapamycin	complex	1	(MTORC1)	is	the	most	important	of	these,	and	is	of	particular	interest	in	EE	due	to	its	roles	in	both	epithelial	and	immune	cell	function.	It	was	hypothesised	that	supplementation	with	the	amino	acids	(AA)	L-Glutamine,	L-Tryptophan	and	L-Leucine	+/-	high	dose	multiple	micronutrients	(MM)	could	modify	the	abnormal	small	intestinal	histology	and	permeability	seen	in	EE,	and	would	modify	lamina	propria	lymphocyte	(LPL)	MTORC1	signalling.	A	randomised	controlled	trial	was	therefore	undertaken.	Assessments	of	many	of	the	patho-physiological	domains	of	EE	(absorptive	area;	mucosal	inflammation;	microbial	translocation;	permeability;	systemic	immune	activation;	host-microbiota	interactions;	enterohumoral	signalling),	as	well	as	LPL	MTORC1	signalling,	were	performed	in	84	healthy	adult	Zambians	with	EE	before	and	after	16	weeks’	supplementation.	AA	supplementation	improved	villus	height,	whereas	AA	with	MM	supplementation	improved	in	vivo	barrier	permeability.	Supplementation	did	not	affect	LPL	MTORC1	signalling;	however,	MTORC1	activity	correlated	with	villus	height	and	the	size	of	the	LP	TH1	population.	Metabonomics	identified	several	potentially	relevant	metabolites	which	were	upregulated	by	the	interventions.	Of	note,	other	observed	abnormalities	(e.g.	elevated	translocation/activation	markers;	depressed	levels	of	GLP2)	did	not	change	with	supplementation	and	were	mainly	not	correlated	with	the	improvements	in	histology	and	permeability,	suggesting	that	one	or	more	pathophysiological	domains	(e.g.	absorptive	area;	permeability)	may	be	independently	modifiable.		These	results	and	others	explored	in	this	thesis	provide	new	insights	into	the	complex	relationship	between	nutrition,	intestinal	health,	and	EE.	
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CHAPTER	1	
INTRODUCTION	
	
1.1 Stunting	and	its	consequences	in	the	developing	world	
Stunting	(low	height-for-age)	affects	nearly	180	million	children	under	the	age	of	5	worldwide,	living	almost	exclusively	in	the	developing	world	(Black	et	al.,	2008;	de	Onis	et	al.,	2012).	Improvements	in	living	standards	have	resulted	in	the	overall	prevalence	of	stunting	nearly	halving	from	almost	50%	in	1980	to	just	over	25%	in	2010	(de	Onis	et	al.,	2012,	2000).	These	improvements	are	largely	due	to	impressive	gains	in	Asia;	the	prevalence	of	stunting	in	sub-Saharan	Africa	has	remained	stubbornly	unchanged	at	about	40%	(de	Onis	et	al.,	2012,	2000;	Figure	1.1).	In	Zambia,	for	example,	40.1%	of	under-fives	are	stunted	(height-for-age	Z	score	–2	or	greater)	and	17.2%	are	severely	stunted	(height-for-age	Z	score	–3	or	greater)	(Central	Statistical	Office,	2014).	
Figure	1.1.	Global	prevalence	of	stunting	in	children	under	the	age	of	5.	Zambia,	a	land-locked	
country	in	southern	Africa,	is	highlighted.	Modified	from	Black	et	al.,	2008.	
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Childhood	stunting	has	deleterious	lifelong	and	intergenerational	effects	on	morbidity,	mortality,	and	economic	productivity	(Dewey	and	Begum,	2011;	Richard	et	al.,	2013),	and	therefore	has	consequences	on	the	individual	and	population	level	(Figure	1.2).	These	include	
• Increased	risk	of	metabolic	syndrome	(Victora	et	al.,	2008)	
• Increased	risk	of	coronary	artery	disease	(Stein	et	al.,	1996)	
• Increased	maternal	and	perinatal	morbidity	and	mortality	(Black et al., 
2008; Özaltin et al., 2010; World Health Organization, 1995)	
• Impaired	cognitive	development	and	reduced	educational	achievement	(Victora	et	al.,	2008)	
• Increased	susceptibility	to	immunisable	infectious	disease	in	childhood	due	to	reduced	immunisation	effectiveness	(Victora	et	al.,	2008)	
• Reduced	life	expectancy	in	childhood,	with	a	greater	than	four-fold	risk	of	death	in	childhood	in	those	with	HAZ	≥	–3	(long-term	data	are	not	yet	available	due	to	the	immaturity	of	the	relevant	cohort	studies)	(Black	et	al.,	2008;	Özaltin	et	al.,	2010)	
• Reduced	earnings	in	adulthood,	even	when	corrected	for	educational	level	(Victora	et	al.,	2008)	
• Increased	risk	of	stunting	in	children	of	stunted	mothers	(Gough	et	al.,	2016;	Victora	et	al.,	2008)		
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Figure	1.2.	Long	term	and	intergenerational	consequences	of	stunting.	HAZ,	Height-for-age	Z	
score.	
	
Stunting	and	its	sequelae	are	a	consequence	of	multiple	interacting	deleterious	pathological	processes.	Stunting	may	therefore	be	used	as	a	biomarker	to	measure	the	effectiveness	of	interventions	aimed	at	improving	adult,	peri-conception,	pregnancy	and	early	childhood	outcomes.	
	
↑	Childhood	stunting	(HAZ	≥	–2)	
↑	Lifelong	morbidity	
↓	Cognitive	development	&	educational	attainment		
↓	Earnings	
↓	
↑	Maternal	&	neonatal	morbidity	&	mortality	
↓	Food,	sanitation,	health,	and	financial	security	
↑	Risk	of	IUGR	&	low	birth	weight	
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1.2 Causes	of	stunting:	undernutrition,	infection,	WASH,	
and	environmental	enteropathy	
1.2.1 Introduction	
Several	lines	of	evidence	suggest	that	the	aetiology	of	stunting	is	multifactorial,	but	remains	incompletely	explained.	Populations	affected	by	stunting	are	also	characterised	by	unhygienic	living	environments	without	access	to	clean	water	and	sanitation,	by	food	insecurity	(with	varying	degrees	of	overt	and	subclinical	malnutrition),	by	high	rates	of	exposure	to	gastrointestinal	pathogens	in	particular,	and	by	a	high	prevalence	of	HIV.	Numerous	interventional	trials	have	attempted	to	improve	stunting	and	its	sequelae	by	targeting	these	presumed	causes;	unfortunately,	none	have	been	successful.	
	
1.2.2 Inadequate	protein-energy	and	/	or	micronutrient	intake	
The	prevalence	of	stunting	(low	height-for-age	Z	score,	HAZ)	does	not	predict	the	prevalence	of	wasting	(low	weight-for-height	Z	score,	WHZ),	and	countries	with	similar	stunting	prevalences	may	have	vastly	different	prevalences	of	wasting	(Black	et	al.,	2008),	suggesting	that	dietary	intake	in	itself	is	not	sufficient	to	explain	stunting.	
	
1.2.2.1 Effects	of	protein-energy	supplementation	Impoverished	populations,	even	if	not	overtly	malnourished,	tend	to	subsist	on	a	diet	that	includes	poor	protein	diversity	and	which	is	relatively	carbohydrate	
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heavy.	A	meta-analysis	of	complementary	feeding	supplements	in	food	insecure	populations,	with	or	without	a	nutrition	education	programme,	suggested	improved	HAZ	scores	by	0.41	Z	scores	(Bhutta	et	al.,	2008).	
	
1.2.2.2 Effect	of	micronutrient	supplementation	Zinc	supplementation	has	a	small	beneficial	effect	on	stunting	on	infants	and	older	children	(0.35	Z),	with	an	associated	reduction	in	diarrhoeal	episodes	and	death	in	this	age	group	(Bhutta	et	al.,	2008).	Multiple	micronutrient	supplementation	in	pregnancy	provides	a	modest	reduction	in	risk	of	low	birthweight	(OR	0.83)	and	small	for	gestational	age	(OR	0.92)	(Bhutta	et	al.,	2008;	Haider	and	Bhutta,	2015).	Iron	and	vitamin	A	supplements	do	not	improve	growth,	although	vitamin	A	supplementation	reduces	childhood	mortality	(Bhutta	et	al.,	2008).	Iron	supplementation	appears	to	increase	the	risk	of	infectious	complications	including	diarrhoea,	and	death	due	to	(undertreated)	malaria	(Sazawal	et	al.,	2006).	
	
1.2.3 Infectious	disease	burden	
The	number	of	diarrhoeal	episodes	is	a	risk	factor	for	stunting	(Black	et	al.,	2008).	It	was	initially	postulated	that	stunting	was	the	result	of	frequent	acute	infections,	enteric	or	otherwise,	which	would	limit	the	potential	for	catch-up	growth	normally	observed	in	otherwise	healthy	children.	However	it	was	clearly	demonstrated	in	the	early	1990s	in	children	from	the	Gambia	that	abnormal	intestinal	permeability	persisted	even	during	periods	of	asymptomatic	good	health,	and	that	growth	velocity	was	inversely	correlated	to	intestinal	permeability	(as	assessed	by	
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lacutulose:mannitol	recovery	ratio)	(Lunn	et	al.,	1991).	Consistent	with	this,	a	pooled	analysis	of	the	effect	of	diarrhoeal	episodes	on	stunting	at	two	years	of	age	found	evidence	of	a	small	height	deficit	only	(Richard	et	al.,	2013):	in	other	words,	children	exhibit	catch-up	growth	in	between	diarrhoeal	episodes	but	remain	stunted,	and	diarrhoeal	illness	per	se	is	not	causative.		
Rates	of	asymptomatic	helminth	carriage	in	stunted	populations	is	high.	However	deworming	treatment	in	children	up	to	the	age	of	16	results	in	very	small	improvements	in	height	(0.14cm	after	1	year)	and	weight	(0.24kg	after	1	year)	(Bhutta	et	al.,	2008).	
	
1.2.4 Water,	sanitation,	and	hand	washing	(WASH)		
A	programme	of	multiple	hygiene	interventions	has	been	estimated	to	reduce	the	risk	of	diarrhoeal	episodes	by	30%	(Bhutta	et	al.,	2008).	This	will	have	a	direct	and	significant	effect	on	reducing	childhood	mortality	from	diarrhoeal	illness,	but	is	estimated	to	have	a	minor	reduction	of	up	to	2.4%	on	stunting	prevalence	(Bhutta	et	al.,	2008).	This	has	subsequently	been	confirmed	in	large	randomised	controlled	trials	(Luby	et	al.,	2018;	Null	et	al.,	2018).	
	
1.2.5 The	need	for	novel	mechanisms	and	interventions	
Correction	of	undernutrition,	micronutrient	supplementation,	control	of	infectious	disease,	and	hygiene	/	sanitation	interventions	all	have	important	roles	in	reducing	short-term	childhood	mortality,	but	have	been	shown	to	have	only	minor	effects	on	
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childhood	stunting	and	its	lifelong	consequences.	It	is	estimated	that	even	with	99%	coverage	with	an	aggressive	combination	of	interventions	to	reduce	disease	burden	(e.g.	deworming;	mosquito	net	provision),	improve	sanitation	(e.g.	hand	washing	interventions),	improve	general	nutrition	(e.g.	breast	feeding	promotion),	and	correct	micronutrient	deficiencies,	just	over	1/3	of	stunting	is	preventable	(Bhutta	et	al.,	2008;	Table	1.1).	Although	highly	prevalent	in	stunted	populations,	these	problems	therefore	do	not	explain	the	high	prevalence	of	stunting	observed,	implicating	other	factors	in	its	pathogenesis.	In	recent	years,	attention	has	therefore	shifted	towards	environmental	enteropathy,	which	is	now	thought	to	mediate	many	of	the	pathological	processes	resulting	in	stunting.	
	
Intervention	(99%	coverage)	 Relative	reduction	in	stunting	
prevalence	at	3	years	
General	nutrition	interventions	 15.5%	
Micronutrient	interventions	 17.4%	
Disease	control	interventions	 2.7%	
All	interventions	combined	 35.5%	
Table	1.1.	Effect	of	interventions	with	99%	at-risk	population	coverage	on	stunting	prevalence	
at	three	years.	Modified	from	Bhutta	et	al.,	2008.	
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1.3 Environmental	enteropathy	(EE)	
1.3.1 Environmental	enteropathy:	an	acquired,	reversible	
disorder	of	poverty	
A	number	of	investigations	into	overt,	symptomatic	diarrhoea	and	malabsorption	in	the	tropics	in	the	early	1960s	used	apparently	asymptomatic,	healthy	and	well-nourished	adults	and	children	from	the	same	population	as	control	subjects.	Unexpectedly,	these	studies	uniformly	identified	a	high	prevalence	of	abnormal	intestinal	absorptive	capacity	and	permeability	(as	measured	by	urinary	sugar	recovery)	and	/	or	varying	degrees	of	villous	blunting,	crypt	hypertrophy,	villous	fusion,	and	mucosal	inflammation)	in	these	controls	(Lindenbaum	et	al.,	1972).	
Studies	in	American	soldiers	and	Peace	Corps	volunteers	stationed	in	Thailand	(Keusch	et	al.,	1972)	and	in	Peace	Corps	volunteers	in	modern-day	Bangladesh	(Lindenbaum	et	al.,	1966b)	showed	that	the	condition	was	acquired,	and	that	these	abnormalities	were	similar	to	those	observed	in	the	native	population	(Lindenbaum,	1968).	Furthermore,	post	mortem	examination	of	foetal	and	neonatal	intestine	showed	that	these	abnormalities	were	not	present	in	utero	or	at	birth,	and	only	became	apparent	during	early	childhood	(Chacko	et	al.,	1969).	Similarly,	although	not	present	in	neonates,	persistent	abnormalities	in	small	intestinal	absorption	and	permeability	were	observed	from	as	little	as	3	months	of	age,	and	these	abnormalities	were	correlated	with	growth	faltering	(Lunn	et	al.,	1991).	
These	changes	were	reversible,	as	demonstrated	by	prospective	assessment	of	small	bowel	histology	and	absorption.	Peace	Corps	volunteers	who	had	lived	in	India	or	Pakistan	returned	to	histological	and	absorptive	normality,	usually	within	
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two	years	after	returning	to	the	United	States	(Lindenbaum	et	al.,	1972,	1971).	Furthermore,	intestinal	structure	and	function	in	adult	students	from	endemic	areas	moving	to	the	United	States	to	study	also	normalised	with	time	(Gerson	et	al.,	1971).	
Based	on	these	initial	studies	and	others	which	were	exclusively	conducted	in	the	tropics,	the	condition	was	labelled	‘tropical	enteropathy’.	However,	an	extensive	worldwide	study	clearly	demonstrated	that	the	observed	abnormalities	were	not	observed	in	some	affluent,	‘tropical’	populations	(such	as	Singapore	and	Qatar)	(Menzies	et	al.,	1999),	and	the	condition	is	therefore	more	correctly	termed	‘environmental	enteropathy’	(EE)	or	‘environmental	enteric	dysfunction’	(EED).	EE	is	strongly	associated	with	stunting,	and	is	highly	prevalent	in	stunted	populations	irrespective	of	climate,	and	in	particular	is	associated	with	household	wealth	(Kelly	et	al.,	2004b;	Menzies	et	al.,	1999).	For	example,	in	a	poor	urban	community	in	Zambia	where	the	prevalence	of	childhood	stunting	is	approximately	40%,	EE	is	virtually	universal	among	overtly	healthy	adults	(Kelly	et	al.,	2004b).	
Increasing	evidence	suggests	that	the	severity	of	EE,	as	well	as	being	reversible,	has	a	seasonal	component.	In	general,	populations	with	EE	live	in	tropical	or	sub-tropical	climates	with	well-defined	wet	and	dry	seasons.	Studies	from	enteropathic	populations	in	urban	Zambia	(Kelly	et	al.,	2004b)	suggest	a	deterioration	in	histological	features	and	sugar	permeability	/	absorption	during	the	wet	season.	Heavy	rains	in	populations	with	inadequate	sewerage	and	sanitation	are	at	high	risk	of	potable	water	contamination	and	faecal-oral	transmission	of	intestinal	infections.	Furthermore,	undernutrition	may	be	exacerbated	during	this	period:	in	the	rainy	season	crops	are	growing	and	are	unavailable	for	consumption	(for	this	
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reason	the	rainy	season	is	colloquially	known	as	the	‘hungry	season’	in	populations	whose	nutritional	intake	is	precarious	and	heavily	reliant	on	subsistence).	The	role	of	nutrition	in	EE	is	discussed	in	section	1.3.4	below.	
Multiple	well	conducted	prospective	cohort	studies	provide	good	evidence	that	environmental	conditions,	in	particular	access	to	clean	water	and	good	sanitation,	are	implicated	in	the	severity	of	EE.	In	rural	Bangladesh	for	example,	children	from	‘clean’	households	(defined	using	objective	markers	of	water	cleanliness	and	sanitation	infrastructure)	had	significantly	increased	linear	growth,	reduced	lactulose:mannitol	ratios	(indicating	reduced	permeability	and	improved	absorption)	,	and	reduced	serum	anti-endotoxin	IgG	compared	to	children	from	‘dirty’	households,	after	adjustment	for	confounders	(Lin	et	al.,	2013a).	
	
1.3.2 Environmental	enteropathy:	features,	pathophysiology,	and	
possible	aetiologies	
1.3.2.1 Histological	abnormalities	and	deficits	in	intestinal	absorptive	
capacity	The	original	reports	of	EE	described	a	spectrum	of	architectural	abnormalities	in	proximal	small	bowel	biopsies	(Figure	1.3),	progressing	from	blunted	but	otherwise	normal	‘finger-like’	villi	through	‘leaves’,	ridges,	and	convolutions	and	finally	to	atrophy	as	the	severity	of	the	enteropathy	increased	(Schenk	et	al.,	1972,	1968;	Schenk	and	Klipstein,	1972).	With	modern	high	definition	endoscopes,	these	abnormalities	which	previously	could	only	be	appreciated	under	the	dissecting	microscope	can	now	be	readily	visualised	in	vivo	(Figure	1.4,	p.27).	Histologically,	these	correspond	to	varying	degrees	of	crypt	hypertrophy,	villous	atrophy,	and	
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villous	fusion	(Lindenbaum	et	al.,	1966a;	Figure	1.5),	resulting	in	a	reduction	in	proximal	small	bowel	absorptive	area.	
	
Figure	1.3.	Morphological	features	of	EE	as	seen	under	the	dissecting	microscope	in	increasing	
order	of	severity.	Top	left,	normal	villi.	Top	right,	predominant	leaves	(fused	villi).	Bottom	left,	
ridges	with	convolutions.	Bottom	right,	subtotal	atrophy.	Taken	from	England,	1968;	Sheehy	et	
al.,	1968.		
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Figure	1.4.	High	definition	endoscopic	images	of	proximal	small	intestinal	mucosa	in	EE,	
demonstrating	increasingly	severe	enteropathic	changes.	Top	left,	relatively	normal	mucosa	in	
an	unaffected	affluent	patient.	Top	right,	predominant	leaves.	Bottom	left,	ridges	with	
convolutions.	Bottom	right,	subtotal	atrophy.	
	
Figure	1.5.	Typical	histological	features	of	the	proximal	small	intestine	in	EE.	Fused	villi,	crypt	
hypertrophy,	villous	atrophy,	and	gross	lamina	propria	inflammatory	infiltrate	are	evident.	
H&E	section	of	an	endoscopic	biopsy	taken	from	a	participant	in	the	current	study.	
0	 100	 200µm	
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Although	these	abnormalities	are	observed	only	in	the	proximal	small	bowel,	they	result	in	significantly	reduced	absorptive	capacity.	Xylose	recovery,	for	example,	is	reduced	by	approximately	50%	in	asymptomatic	adults	(Kelly	et	al.,	2004b;	Menzies	et	al.,	1999).	However,	the	clinical	relevance	of	this	is	uncertain.	An	early	study	in	Bangladeshi	children	showed	that	although	xylose	malabsorption	in	children	with	EE	is	correlated	with	carbohydrate	malabsorption,	an	estimated	>90%	of	ingested	carbohydrate	was	still	absorbed	overall	and	no	effect	was	observed	on	protein	or	fat	absorption	(Brown	et	al.,	1981).	
Conversely,	zinc	homeostasis	is	perturbed	in	EE,	where	there	is	impaired	capacity	to	resorb	endogenous	zinc	in	the	distal	small	bowel	regardless	of	zinc	status,	resulting	in	net	loss	of	zinc	(Manary	et	al.,	2010).	There	is	a	strong	positive	correlation	between	the	severity	of	enteropathy	as	assessed	by	lactulose	:	mannitol	ratio	and	excretion	of	endogenous	zinc	(and	an	inverse	relationship	to	resorption)	(Manary	et	al.,	2010).	
It	is	unknown	to	what	extent	the	endoscopic,	microscopic,	and	histological	abnormalities	observed	in	EE	correlate	with	each	other.	In	particular,	the	correlation	between	endoscopic	features	and	histology	and	/	or	barrier	dysfunction	has	not	been	established.	
	
1.3.2.2 Intestinal	barrier	dysfunction	The	healthy	intestinal	mucosa	provides	a	physical	and	functional	barrier	against	constant	microbial	and	dietary	antigen	exposure,	while	at	the	same	time	mediating	the	uptake	and	absorption	of	most	ingested	nutrients	and	water.	Impairment	or	
	 29	
dysregulation	of	barrier	function	is	characterised	by	increased	permeability,	which	can	result	in	both	the	translocation	of	microbes	and	microbial	products	into	the	host	and	loss	of	nutrients	and	water	into	the	gut	lumen.		
An	impaired	small	intestinal	mucosal	barrier	is	a	canonical	feature	of	EE.	Increased	intestinal	permeability	(as	measured	by	urinary	sugar	recovery	assays)	in	EE	is	correlated	with	pathological	abnormalities	of	intestinal	barrier	function	and	growth.	Growth	velocity	is	inversely	correlated	to	intestinal	permeability	(Lunn	et	al.,	1991)	and	positively	correlated	with	bacterial	translocation	as	measured	by	plasma	LPS	levels	(Campbell	et	al.,	2003a).	Chronic	endotoxaemia	in	EE	depresses	IGF1	secretion,	providing	a	mechanism	of	growth	suppression	and	stunting	(Prendergast	et	al.,	2014).	
Barrier	dysfunction	may	result	from	physical	defects	in	the	mucus	barrier	or	epithelium,	or	functional	defects	in	permeability	or	mucosal	immune	function.		
	
Dysfunction	of	the	mucus	barrier	
The	mucus	barrier	provides	a	physical,	biochemical	and	anti-microbial	barrier	to	microbiological	insults.	The	small	intestinal	mucus	layer	is	porous	to	allow	the	uptake	of	fluid,	electrolytes	and	nutrients.	The	mucus	layer	is	continuously	replaced,	resulting	in	the	expulsion	of	trapped	bacteria.	Bacterial	invasion	through	this	layer	is	further	limited	by	a	diffusion	gradient	of	secreted	antimicrobial	peptides	(AMP)	and	IgA	(Johansson	and	Hansson,	2016).	The	mucus	barrier	also	moulds	the	commensal	microbiota	through	the	excretion	of	anti-microbial	immunoglobulins	and	peptides,	and	in	the	expression	of	glycoproteins	which	can	
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promote	the	proliferation	and	diversification	of	anti-inflammatory	bacterial	species.		
It	is	increasingly	recognised	that	mucus	composition	and	production	is	tightly	regulated,	but	clinical	consequences	of	mucous	barrier	defects	have	not	been	well	studied.	Mucin	defects	are	sufficient	to	produce	colitis	in	mice	(Heazlewood	et	al.,	2008),	and	may	be	a	risk	factor	for	the	development	of	ulcerative	colitis	(UC)	in	humans	(Visschedijk	et	al.,	2016).	Although	the	mucus	barrier	in	EE	and	other	conditions	of	undernutrition	have	not	been	specifically	studied,	diffuse	intestinal	glycosaminoglycation	defects	occur	in	kwashiorkor	(Amadi	et	al.,	2009)	which	is	likely	to	include	mucus	modifications.	The	microbial	implications	of	this	are	unknown.	
The	antimicrobial	properties	of	mucus	in	EE	is	discussed	in	section	below.	
	
Defects	in	transcellular	epithelial	barrier	integrity	
All	intestinal	epithelial	cell	types	appear	to	be	generated	from	intestinal	stem	cells	(ISC),	which	reside	in	stereotyped	positions	(the	‘+4’	position)	in	the	stem	cell	niche	located	at	the	base	of	intestinal	crypts.	On	differentiating,	epithelial	cells	migrate	upwards	out	of	the	crypt	towards	the	intestinal	luminal	surface	(in	the	colon)	or	villus	(in	the	small	intestine),	with	the	exception	of	Paneth	cells,	which	remain	near	the	base	of	the	small	intestinal	crypts	(van	der	Flier	and	Clevers,	2009).	Senescent	epithelial	cells	at	the	villous	tips	undergo	apoptosis	and	are	shed	into	the	intestinal	lumen.	This	is	an	active	process,	where	adjacent	cells	‘squeeze	out’	the	dying	cell	while	re-establishing	tight	junction	integrity	between	the	new	
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neighbours,	thus	preventing	any	epithelial	breach.	This	has	been	demonstrated	most	elegantly	using	confocal	laser	endomicroscopy	(CLE)	in	vivo	(Kiesslich	et	al.,	2012).	
Most	obviously,	defects	in	epithelial	integrity,	renewal	or	maturation	result	in	erosions	and	ulcers.	These	are	physical	breaches	in	the	epithelial	barrier	which	may	be	apparent	macroscopically	(for	example	in	vivo	at	endoscopy),	microscopically	in	vivo	using	CLE	(Kiesslich	et	al.,	2007),	or	histologically.	An	elegant	CLE	study	in	a	mouse	model	using	fluorophore-labelled	dextrans	has	demonstrated	that	in	vivo	microscopic	epithelial	defects	(visible	by	CLE	but	not	endoscopically)	result	in	the	bidirectional	leakage	of	macromolecules	similar	in	size	(MW	10kDa)	to	physiologically	relevant	microbial	proteins	such	as	LPS.	Interestingly,	these	epithelial	defects	may	result	in	influx,	efflux,	both	simultaneously,	or	none	(Kiesslich	et	al.,	2012).	We	have	recently	described	similar	defects	in	EE	(Kelly	et	al.,	2016).	
Strikingly,	even	very	significant	mucosal	defects	(such	as	those	created	therapeutically	for	mucosal	resections	for	polyps)	in	otherwise	normal	guts	do	not	normally	result	in	disease,	due	to	poorly	understood	immune	regulatory	crosstalk	(Turner,	2009).	
	
Defects	in	paracellular	epithelial	barrier	integrity	
Under	normal	circumstances,	paracellular	flux	is	tightly	regulated	and	is	the	primary	determinant	of	trans-epithelial	transport	due	to	the	relative	impermeability	of	transcellular	pathways	(Shen	et	al.,	2009;	Turner,	2009).	
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Paracellular	permeability	is	determined	by	the	composition	and	function	of	tight	junctions	(TJ),	apical	protein	complexes	which	together	with	adherens	junctions	and	desmosomes	bind	epithelial	cells	together.	TJ	complexes	include	claudins,	occludins,	zonulins	and	myosin	light	chain	kinase	(Turner,	2009).	
Intestinal	TJ	demonstrate	variable	degrees	of	leak	which	allows	the	non-selective	passage	of	molecules	including	proteins	up	to	about	50Å	(5nm)	in	the	crypt	and	6Å	(0.6nm)	at	the	villus	tip	(Shen	et	al.,	2009).	This	‘leak	pathway’	demonstrates	size	but	not	charge	selectivity	and	is	modified	by	inflammatory	signals	including	T	cell	activation,	TNFα,	NFκB	and	IFN	(Clayburgh	et	al.,	2005;	Tang	et	al.,	2010;	Turner,	2009;	Watson	et	al.,	2005;	Zolotarevsky	et	al.,	2002).	In	contrast,	tight	junction	pores,	formed	by	claudins,	form	a	second	‘charge	selective	pathway’	which	limits	the	passage	of	molecules	larger	than	approximately	4Å	(0.4nm).	The	number	and	function	of	pores	also	appears	to	be	regulated	by	immune	signalling	(Turner,	2009).	TJ	defects	have	been	implicated	in	contributing	to	disease	severity	in	a	murine	model	of	colitis	(Su	et	al.,	2009)	,	and	TJ	pores	(and	thus	permeability)	may	be	upregulated	in	inflammatory	bowel	disease	(Heller	et	al.,	2005;	Zeissig	et	al.,	2007).	
Claudins	and	other	TJ	proteins	are	responsible	for	sealing	epithelial	gaps	associated	with	physiological	apoptotic	cell	shedding	events	(Marchiando	et	al.,	2011).	We	have	previously	demonstrated	that,	although	these	processes	appear	to	be	intact	in	individuals	with	EE,	the	extent	of	the	epithelial	defects	means	that	the	claudin	system	is	unable	to	seal	the	epithelial	defects	(Kelly	et	al.,	2016).	
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Abnormalities	of	the	adaptive	mucosal	immune	system	
The	mucosal	immune	compartment	provides	an	immunological	barrier	to	reinforce	the	physical	barriers	provided	by	the	epithelium	and	mucus	layers.	Innate	and	adaptive	arms	both	play	important	roles,	with	deficits	resulting	in	either	suppressed	mucosal	defence	(allowing	microbial	invasion)	or	pathologically	enhanced	inflammation	(resulting	in	maladaptive	host	tissue	damage).	The	regulation	of	pro-	and	anti-inflammatory	responses	in	the	face	of	continuous	exposure	to	dietary	and	microbial	antigens	are	exceptionally	complex	and	remain	incompletely	understood,	including	in	EE.	
Lamina	propria	(LP)	lymphocytes	are	normally	predominantly	antigen-experienced	CD4+	T	cells,	with	a	smaller	proportion	of	CD8+	cells	also	present	(Shale	et	al.,	2013).	LP	lymphocytes	consist	of	circulating	effector	memory	T	cells,	tissue	resident	T	cells	and,	in	the	secondary	lymphoid	organs	of	the	intestine	including	Peyer’s	patches	and	lymphoid	follicles,	naïve	and	central	memory	T	cells	(Sallusto	et	al.,	2004;	Schenkel	and	Masopust,	2014).	The	specific	makeup	and	contributions	of	these	different	T	cell	populations	in	human	health	and	disease	is	largely	unknown.	
The	immunological	features	of	EE	are	not	well	documented	and	studies	are	conflicting.	The	inflammation	observed	in	EE	is	IFNγ	predominant,	indicating	a	TH1-type	response	(Campbell	et	al.,	2003a,	2003b;	Veitch	et	al.,	2001).	In	children	with	EE	there	is	a	four-fold	increase	in	intra-epithelial	lymphocytes	(IEL),	and	a	ten-fold	increase	in	activated	cytotoxic	T	lymphocytes	(Campbell	et	al.,	2003b).	However	in	two	studies	in	adults,	there	were	no	differences	in	IEL	density	between	adults	with	EE	and	unaffected	controls	(Veitch	et	al.,	2001;	Wood	et	al.,	1991).	
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The	immunological	characteristics	of	the	LP	compartment	in	EE	have	not	been	studied	extensively.	A	study	in	Gambian	children	with	EE	suggested	that	LP	T	lymphocyte	density	increased	with	worsening	nutritional	status	(WHZ),	and	the	CD4+	and	CD8+	cells	were	present	in	roughly	equal	proportions,	in	contrast	to	‘normal’	lamina	propria	in	UK	controls	where	the	CD4+	to	CD8+	ratio	was	2:1	(Campbell	et	al.,	2003b).	There	were	also	elevated	densities	of	B	lymphocytes	compared	to	UK	controls	(Campbell	et	al.,	2003b).	In	adults,	LP	CD3+	cells	are	predominantly	activated	(median	87%	HLA-DR+	in	Zambians	with	EE,	compared	to	65.5%	in	white	South	African	controls)	(Veitch	et	al.,	2001).	
LP	plasma	cells	secrete	immunoglobulins	into	the	mucosa,	where	immunoglobulins	(predominantly	but	not	exclusively	IgA)	are	actively	transported	across	the	epithelium	and	secreted	into	the	mucus	barrier	(Kaetzel	et	al.,	1991).	This	component	of	the	adaptive	immune	response	protects	against	pathogenic	bacteria,	and	also	promotes	the	establishment	of	the	host	commensals.	Studies	of	secreted	intestinal	IgA	in	malnourished	children	are	conflicting	(Rytter	et	al.,	2014);	the	role	of	IgA	in	asymptomatic	individuals	with	EE	has	not	been	studied.	
	
Paneth	cell	and	antimicrobial	peptide	dysfunction		
Antimicrobial	peptides	(AMP)	are	secreted	into	mucus	by	Paneth	cells	in	the	small	intestinal	crypt.	A	number	of	peptides	are	secreted	which	have	powerful	antimicrobial	properties,	and	which	play	an	important	role	in	regulating	the	host	microbiota.	
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Paneth	cells	granule	depletion	is	more	prevalent	and	AMP	expression	is	downregulated	in	EE	(Dhaliwal	et	al.,	2003;	Kelly	et	al.,	2004a),	and	in	HIV	negative	adults	is	inversely	correlated	with	the	histological	severity	of	enteropathy	(Kelly	et	al.,	2006).	Intriguingly,	nutrient	deprivation	in	an	animal	model	results	in	autophagy	of	Paneth	cells	and	impaired	AMP	production	(Hodin	et	al.,	2011).	
	
1.3.2.3 The	microbiota	and	dysbiosis	in	environmental	enteropathy	The	complex	reciprocal	relationship	between	the	microbiota,	diet	and	mucosal	inflammation	has	only	recently	been	appreciated,	and	remains	poorly	understood.	The	microbiota	has	been	implicated	as	being	a	causative	agent	in	a	number	of	conditions	characterised	by	intestinal	inflammation	including	inflammatory	bowel	disease	and	necrotising	enterocolitis.	It	is	now	also	accepted	that	the	intestinal	microbiota	also	has	important	effects	on	nutrient	harvest	and	mucosal	immune	homeostasis.	The	study	of	the	effects	of	the	microbiota	in	undernutrition	and	overt	malnutrition	is	still	in	its	infancy.	
	
Microbiological	insights	
In	kwashiorkor,	the	microbiota	is	immature	and	is	less	responsive	to	therapeutic	nutritional	supplementation	(Smith	et	al.,	2013).	Compared	to	Western	subjects,	asymptomatic	children	and	adults	living	in	EE-endemic	areas	have	significantly	different	microbiota,	as	assessed	by	faecal	16S	rRNA	sequencing	(De	Filippo	et	al.,	2010;	Lin	et	al.,	2013b).	In	a	study	in	Bangladesh,	the	microbiota	was	also	less	stable	over	time	(Lin	et	al.,	2013b),	a	finding	also	observed	in	a	Malawian	
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kwashiorkor	study	(Smith	et	al.,	2013).	In	rural	Burkina	Faso,	Bacteroidetes	are	significantly	enriched	and	Firmicutes	are	depleted	(De	Filippo	et	al.,	2010),	mirroring	the	pro-inflammatory	microbiota	observed	in	IBD.	Conversely,	in	urban	Bangladesh,	the	opposite	is	true	(Lin	et	al.,	2013b).	These	studies	did	not	investigate	the	role	of	the	microbiota	in	enteropathy	or	stunting,	so	the	significance	of	these	findings	is	unclear.	
Non-pathogenic	microbes	are	frequently	isolated	from	stool	samples	in	individuals	with	EE.	In	one	study	in	urban	Zambia,	for	example,	Citrobacter	rodentium	was	overrepresented	(Kelly	et	al.,	2004b).	This	bacterium,	although	not	classically	pathogenic	in	humans,	is	pro-inflammatory	and	induces	ulcerative	colitis	in	murine	models.	Non-pathogenic	intestinal	parasites	in	the	stool	of	individuals	with	EE	are	also	frequently	identified,	and	serve	as	a	marker	of	unsanitary	living	conditions.	The	possible	role	of	these	microbes,	generally	considered	to	be	non-pathogenic,	in	promoting	and	perpetuating	the	intestinal	inflammation	observed	in	EE	is	unknown;	furthermore,	the	contribution	of	non-bacterial	microbes	(especially	parasites)	to	the	microbiota	has	not	been	studied.	
	
Dietary	intake,	the	microbiota,	and	nutrient	harvest	
Populations	where	EE	and	stunting	are	prevalent	also	have	a	diet	low	in	animal	fat	and	protein	but	high	in	starch,	fibre,	and	plant	polysaccharides,	resulting	in	major	differences	in	the	microbiota	compared	to	a	‘Western’	diet	(De	Filippo	et	al.,	2010;	Grześkowiak	et	al.,	2012;	Turnbaugh	et	al.,	2009;	Wu	et	al.,	2011;	Yatsunenko	et	al.,	2012).	The	resulting	microbiota	influences	body	composition	and	nutrient	energy	
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harvest	(Jumpertz	et	al.,	2011;	Turnbaugh	et	al.,	2006),	but	may	also	promote	the	establishment	of	pro-	or	anti-inflammatory	microbes	(Devkota	et	al.,	2012).	
	
Effect	of	the	immune	response	on	the	microbiota	
Microbes	may	promote	pro-	or	anti-inflammatory	responses	in	the	host.	In	turn,	the	host’s	immunological	response	in	conjunction	with	dietary	intake	can	modulate	the	microbiota.	Paneth	cell	degranulation	and	antimicrobial	peptide	release	occurs	in	response	to	a	number	of	immunological	and	microbiological	triggers	(Bevins	and	Salzman,	2011a).	Interestingly,	commensal	bacteria	are	relatively	resistant	to	antimicrobial	peptides	(Cullen	et	al.,	2015);	the	effect	of	the	subtle	abnormalities	of	Paneth	cell	function	observed	in	EE	(Dhaliwal	et	al.,	2003;	Kelly	et	al.,	2004a,	2006)	on	the	microbiota	is	unknown.	
The	prevalence	of	helminth	infection	in	stunted	populations	is	high.	Although	the	specific	immunological	consequences	of	this	in	EE	have	not	been	studied,	helminthic	infection	results	in	a	predominant	TH2-type	response,	and	also	results	in	a	significantly	impaired	TH1	/	TH17	and	innate	immune	response	to	GI	pathogens	including	Salmonella	Typhimurium	and	C.	rodentium	in	mice	models	(Chen	et	al.,	2005;	Su	et	al.,	2014).	
	
Modulation	of	the	gut	barrier	by	the	microbiota	
Tight	junctions	are	the	target	of	many	microbial	virulence	factors.	Enteropathogenic	and	enterohaemorrhagic	E.	coli,	Vibrio	cholerae,	rotaviruses,	
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Salmonella	Typhimurium	and	others	produce	effector	molecules	which	disrupt	TJ	protein	production	and	utilisation	(König	et	al.,	2016).	‘Anti-inflammatory’	bacteria	such	as	VSL#3,	Lactobacillus	rhamnosus,	and	L.	helveticus	appear	to	promote	TJ	protein	expression	and	function	in	animal	models	and	in	vitro	models	(Mennigen	et	al.,	2009;	Miyauchi	et	al.,	2009;	Zareie	et	al.,	2006);	presumably	‘pro-inflammatory’	bacteria	will	have	the	opposite	effect	although	this	has	not	yet	been	demonstrated.	The	immune	signalling	response	provoked	by	microbial	inflammation	also	has	effects	on	TJ	structure	and	function,	as	described	above.	
	
1.3.2.4 Biomarkers	and	environmental	enteropathy	There	is	an	unmet	need	for	biomarkers	in	EE.	A	variety	of	blood,	stool	and	urine	markers	have	been	trialled	(Table	1.2)	but	none	used	alone	or	in	combination	are	sufficiently	sensitive	or	specific	for	diagnostic	or	prognostic	purposes	(Guerrant	et	al.,	2016;	Keusch	et	al.,	2014;	Prendergast	et	al.,	2015).	
More	recently,	metabonomic	studies	have	begun	to	identify	putative	markers	of	impaired	gut	structure	and	function	in	EE	(Claus	and	Swann,	2013;	Farràs	et	al.,	2018;	Guerrant	et	al.,	2016;	Mayneris-Perxachs	et	al.,	2016;	Mayneris-Perxachs	and	Swann,	2018),	but	more	work	is	required	to	confirm	validity	and	applicability.	
Blood	abnormalities	are	also	common	but	non-specific.	Frequently	encountered	abnormalities	include	anaemia	(macro-,	normo-	and	microcytic)	due	to	chronic	inflammation	and	/	or	micronutrient	deficiencies;	elevated	inflammatory	markers	such	as	CRP	(generally	low	level,	in	contrast	to	the	levels	seen	in	severe	acute	malnutrition);	and	low	plasma	micronutrient	levels	(e.g.	retinoids;	zinc;	iron).	 	
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Biomarker	 Origin	 EE	domain	assessed	 Comment	
LPS	 Plasma	 Intestinal	permeability;	microbial	translocation	 Bacterial	product;	detection	in	blood	implies	translocation	
Anti-LPS	IgG	 Plasma	 Microbial	translocation	 Quantifies	host	adaptive	response	to	systemic	LPS	
sCD14	 Plasma	 Systemic	immune	activation;	microbial	translocation	 Marker	of	innate	immune	activation;	secreted	by	activated	monocytes	/	macrophages	in	response	to	LPS	
LBP	 Plasma	 Systemic	immune	activation;	microbial	translocation	 Acute	phase	reactant	in	response	to	systemic	LPS;	agonist	for	TLR	signalling	and	monocyte	activation	
MBL	 Plasma	 Systemic	immune	activation;	microbial	translocation	 Acute	phase	protein;	binds	to	bacterial	carbohydrate	residues	
CRP	 Plasma	 Systemic	immune	activation	 Non-specific	marker	of	systemic	immune	activation	
Citrulline	 Plasma	 Absorptive	capacity	 Biproduct	of	enterocyte	glutamine	meta-bolism;	used	as	a	marker	of	enterocyte	mass	
iFABP	 Plasma	 Intestinal	barrier	damage	 Released	from	damaged	enterocytes;	higher	levels	observed	in	EE	than	in	coeliac	disease	
α1AT	 Stool	 Intestinal	permeability	 Serum	protein	detectable	in	stool	from	abnormally	permeable	intestine	
MPO	 Stool	 Intestinal	inflammation	 Secreted	by	activated	neutrophils	/	mono-cytes	/	macrophages	in	inflamed	intestine	
Calprotectin	 Stool	 Intestinal	inflammation	 Secreted	by	activated	neutrophils	/	mono-cytes	/	macrophages	in	inflamed	intestine	
Neopterin	 Stool	 Intestinal	inflammation	 Secreted	by	activated	neutrophils	/	mono-cytes	/	macrophages	in	inflamed	intestine	
L:M	
(and	others)	
Urine	 Intestinal	permeability;	absorptive	capacity	 Assesses	systemic	absorption	of	absorbable	and	non-absorbable	sugars	
Table	1.2.	Selection	of	biomarkers	previously	used	in	studies	of	EE.	CRP,	C	reactive	protein;	LPS,	
lipopolysaccharide;	α1AT,	α1-anti-trypsin;	LBP,	LPS	binding	protein;	MPO,	myeloperoxidase;	
iFABP,	intestinal	fatty	acid	binding	protein;	MBL,	mannose	binding	lectin;	sCD14,	soluble	CD14;	
L:M,	urinary	lactulose	:	mannitol	recovery	ratio;	TLR,	toll-like	receptor.	
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1.3.3 Co-existent	causes	of	enteropathy:	similarities	&	differences	
Patients	with	EE	invariably	have	a	number	of	histological	abnormalities	including	reduced	VH:CD	ratio	due	to	villous	atrophy	and	/	or	crypt	hypertrophy,	intra-epithelial	lymphocytosis,	and	LP	lymphocyte	infiltration.	These	findings	are	non-specific	and	are	observed	in	other	small	bowel	enteropathies	(Table	1.3,	p.42).	Other	causes	of	enteropathy	which	are	highly	prevalent	in	populations	with	EE	and	which	may	coexist	with	it	include	HIV	infection	(asymptomatic	/	well	controlled,	as	well	as	HIV-AIDS),	helminth	and	other	parasite	infections,	and	severe	acute	malnutrition	(SAM).	
HIV	infection	results	in	a	dramatic	and	early	decline	of	LP	CD4+	populations.	Despite	the	resultant	systemic	and	mucosal	activation,	asymptomatic	HIV	infection	appears	to	have	subtle	(if	any)	additional	effects	on	small	intestinal	morphometry,	absorption	/	permeability,	and	anti-microbial	peptide	expression	in	populations	affected	by	EE	(Dhaliwal	et	al.,	2003;	Kelly	et	al.,	2004b,	2006);	in	other	words,	the	primary	pathophysiological	mechanism	of	the	observed	defects	in	the	intestinal	barrier	appears	to	be	mediated	through	EE.	
The	relative	contribution	of	helminth	infection	to	the	pathophysiology	of	EE	has	not	been	studied;	however	treatment	with	anti-helminthics	may	improve	intestinal	function	(section	1.5.1	below).	
Although	not	proven,	SAM	is	likely	to	occur	on	a	background	of	EE,	as	it	invariably	affects	individuals	from	populations	where	the	prevalence	of	EE	is	high.	However,	the	role	of	EE	and	pre-existing	barrier	dysfunction	in	the	pathogenesis	of	SAM	is	unknown.	The	villus	atrophy	/	crypt	hypertrophy	observed	in	SAM	appears	to	be	
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similar	to	‘background’	EE,	although	functional	deficits	such	as	microbial	translocation	are	significantly	greater	(Amadi	et	al.,	2017).	
Tropical	sprue,	although	histologically	similar,	is	an	uncommon	condition	with	overt	malabsorptive	symptoms	which	may	affect	individuals	with	EE.	It	is	not	described	in	sub-Saharan	Africa.	
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Table	1.3.	Small	bowel	enteropathies.	C,	clinical;	M,	microbiological;	E,	endoscopic;	H,	histology;	F,	functional	tests	(sugar	absorption	etc.);	S,	serological;	D,	
duodenum;	J,	jejunum;	I,	ileum;	LMIC,	low	and	middle	income	country.	Modified	from	Louis-Auguste	and	Kelly,	2017.
Condition	 Presumed	
aetiology	 Diagnosis	 Intestinal	distribution	Populations	affected	 Villus				atrophy	 Mucosal	inflammation	Barrier	defect	 Systemic	inflammation	Malabsorption	Management	Mortality	
EE	 Undernutrition;	dysbiosis	 E;	H;	F	 DJ	 LMIC	 +	/	+++	 ++	 +	 +	 +	 ?	 (–)	
Kwashiorkor	 Undernutrition;	dysbiosis	 C	 DJI	 LMIC	 +	/	+++	 ++	 ++	 ++	 ++	 Nutrition;	antibiotics	 +++	
Marasmus	 Undernutrition	 C	 DJI	 LMIC	 +	/	+++	 ++	 +	 +	 +	 Nutrition	 ++	
Coeliac	
disease	
Cross–reactivity	to	dietary	gluten	 S;	H	 DJ	 Caucasian	 +	/	+++	 ++	 –	 –	 ++	 Dietary	restriction	 –	
Tropical	
sprue	
Infectious	 C	 D	 Caribbean;	South	Asia	 +	/	+++	 ++	 +/–	 –	 ++	 Antibiotics;	folate	 –	
Crohn’s	 Dysregulated	immunity;	dysbiosis	 E;	C;	H	 (J)I	 Western	 +	 +++	 ++	 ++	 +	 Nutrition;	immune-modulation	 –	
Helminths	
and	Giardia	
Infectious	 M;	S	 DJ	 LMIC	 +	/	++	 +	 +	 –	 +	 Antimicrobials	 –	
HIV	(early	or	
well	
controlled)	
Inflammatory	/	immune	mediated	 M;	S	 DJI	 Worldwide	 +	 ++	 +	 +	 +	 Antivirals	 –	
HIV–AIDS	 Infectious	 C;	M;	H;	S	 DJI	 Predom.	LMIC	 +	/	+++	 +++	 +++	 +++	 +++	 Antivirals	/	antimicrobials	 +++	
Disuse		 Lack	of	trophic	stimuli	 C;	H	 DJI	 Western	 +	/	+++	 +	 +	 –	 –	 Enteral	nutrition	 –	
	 43	
1.3.4 Case	definitions	and	diagnostic	criteria	
Despite	its	frequently	dramatic	laboratory	features,	EE	is	an	asymptomatic	disorder	(Prendergast	and	Kelly,	2012).	
EE	is	primarily	characterised	by	
1. Increased	small	intestinal	permeability	and	impaired	barrier	function	2. Reduced	proximal	small	intestinal	absorptive	area	
in	an	asymptomatic	individual	living	in	an	at-risk	environment.		
The	similarities	and	differences	between	EE	and	other	conditions	resulting	in	similar	abnormalities	of	the	small	bowel	mucosa	are	outlined	in	Table	1.3	above,	although	individuals	with	EE	may	have	other	co-existing	enteropathies.	
Histological	assessment	of	small	intestinal	tissue	is	the	current	gold	standard	method	for	identifying	and	assessing	EE.	However,	small	intestinal	tissue	is	obtained	endoscopically,	a	resource-intensive	technology	which	is	not	widely	available	in	the	populations	affected	by	EE.	Furthermore,	endoscopy	with	biopsies,	although	extremely	safe,	is	more	dangerous	in	paediatric	populations,	and	is	therefore	not	generally	used	in	the	assessment	of	children.	
A	commonly	used	surrogate	of	intestinal	function	is	non-invasive	urinary	sugar	recovery	assays.	Early	studies	of	EE	demonstrated	significant	abnormalities	using	these	tests	and	in	paediatric	populations,	EE	is	generally	defined	as	abnormal	sugar	permeability	/	absorption	in	a	population	known	to	be	affected	by	EE	(Denno	et	al.,	2014).		
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There	are	therefore	no	universally	agreed	diagnostic	criteria	for	EE.	This	is	due	to	the	absence	of	sufficiently	sensitive	and	specific	biomarkers,	and	the	difficulty	in	obtaining	small	intestinal	and	other	bodily	tissue	from	paediatric	individuals.	The	identification	of	reproducible	and	non-invasive	methods	for	robustly	assessing	the	gut	in	EE	is	therefore	an	area	of	considerable	interest.	
	
1.4 Role	of	nutrition	in	environmental	enteropathy	
1.4.1 Nutritional	deficiencies	in	Zambia	
Subclinical	as	well	as	overt	micronutrient	deficiencies	implicated	in	mucosal	and	systemic	immunity	and	intestinal	epithelial	function,	including	retinols	and	zinc,	affect	nearly	20%	of	Zambian	adults	and	65%	of	Zambian	infants	(Gibson	et	al.,	2011;	Kelly	et	al.,	2008).	
Dietary	protein	diversity	in	impoverished	communities	tends	to	be	limited	and	plant	based.	The	staple	diet	in	Zambia	is	nshima,	a	maize-based	dough.	Maize	protein	is	relatively	indigestible	and	therefore	of	poor	quality	(Joint	WHO/FAO/UNU	Expert	Consultation,	2007).	It	is	phytate-rich	which	inhibits	zinc	and	iron	absorption	in	particular	(World	Health	Organization	et	al.,	1996),	and	processing	/	production	results	in	destruction	of	niacin.		
	
1.4.2 Rationale	for	nutritional	therapy	in	EE	
Several	clinical	phenomena	confirm	an	association	between	nutritional	status	and	intestinal	health	and	absorptive	capacity.	Exclusion	of	enteral	nutrients	in	
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otherwise	normal	humans	(for	example,	small	intestine	anatomically	out	of	continuity	from	the	nutrient	stream	or	in	patients	with	anorexia	nervosa	(Winter	et	al.,	2000))	results	in	villous	atrophy	and	increased	intestinal	permeability;	recovery	with	enteral	feeding	is	enhanced	with	L-Glutamine	and	L-Arginine	supplementation	(Buchman	et	al.,	1995).	Enteral	exclusion	in	normal	humans	also	results	in	a	reduction	in	brush	border	disaccharidase	activity	(Guedon	et	al.,	1986).	These	abnormalities	are	also	evident	in	severe	acute	malnutrition	(Burman,	1965;	Campos	et	al.,	1979),	although	other	pathophysiological	processes	including	EE	are	likely	to	be	contributing.	
Nutrient	deprivation	alters	TJ	structure	and	function,	and	is	associated	with	increased	levels	of	pro-inflammatory	IFNγ	and	TNFα	and	reduced	levels	of	anti-inflammatory	IL-10	in	animal	models	(Demehri	et	al.,	2016;	Yang	et	al.,	2009),	as	well	as	humans	(Ralls	et	al.,	2015).	This	results	in	increased	small	intestinal	permeability.	
Glutamine	is	the	preferred	fuel	source	for	small	intestinal	enterocytes.	Enteral	glutamine	supplementation	improves	gut	permeability	via	an	effect	on	tight	junctions,	inhibits	mucosal	atrophy,	and	improves	intestinal	permeability	in	animal	models	of	physiological	stress	(Zhang	and	Jiang,	2015;	Zou	et	al.,	2010).	These	effects	may	be	mediated	through	MTOR	signalling	(Boukhettala	et	al.,	2012;	Coëffier	et	al.,	2013;	Nakamura	et	al.,	2012;	Xi	et	al.,	2012;	Yi	et	al.,	2015).	
Furthermore,	protein-energy	malnutrition	is	associated	with	a	variety	of	innate	and	acquired	immunological	abnormalities	(Rytter	et	al.,	2014)	–	most	obviously	in	the	poor	rates	of	vaccine	immunogenicity	in	stunted	populations,	and	in	the	infectious	mortality	observed	in	severe	acute	malnutrition.	The	relative	
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contributions	of	EE	and	undernutrition	to	these	phenomena	have	not	been	established	and	are	likely	to	be	interlinked.	However	there	is	increasing	evidence	from	animal	and	in	vitro	models	to	support	a	direct	effect	of	undernutrition	on	impaired	immune	function,	with	further	evidence	that	correcting	undernutrition	can	correct	the	immunological	abnormalities	(Iyer	et	al.,	2012).	
Several	micronutrients	have	established	roles	in	adaptive	and	acquired	immunity,	of	which	vitamins	A	and	D	are	best	studied	(Mora	et	al.,	2008;	Ross,	2012).	Vitamin	A	deficiencies	in	particular	(even	in	the	absence	of	clinically	overt	deficiency)	is	associated	with	increased	mortality	in	the	developing	world.	Other	micronutrients	including	zinc	and	selenium	have	purported	benefits	on	immune	function,	although	their	mechanisms	of	action	are	largely	unknown.	
	
1.4.3 Clinical	trials	of	nutritional	interventions	in	EE	
1.4.3.1 Protein-energy	supplementation	trials	Most	interventional	trials	for	EE	have	been	conducted	in	children,	using	lactulose	:	mannitol	ratios	and	/	or	growth	as	a	clinical	endpoint.	A	number	of	studies	in	children		have	looked	at	protein-energy	supplementation,	with	or	without	micronutrient	supplementation	and/or	educational	programmes	(Adu-Afarwuah	et	al.,	2007;	Bhandari	et	al.,	2001;	Gartner	et	al.,	2007;	Kuusipalo	et	al.,	2006;	Lartey	et	al.,	1999;	Obatolu,	2003;	Oelofse	et	al.,	2003;	Owino	et	al.,	2007;	Rivera	et	al.,	2004;	Roy	et	al.,	2005;	Santos	et	al.,	2005;	Schroeder	et	al.,	2002).	The	interventions	used	are	heterogeneous,	and	include	milk-based,	cereal/legume-based,	or	lipid-dense	ready-to-use	therapeutic	food	(RUTF)-based	supplements.	
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These	studies	did	not	investigate	intestinal	permeability	or	other	markers	of	the	physiological	abnormalities	observed	in	stunted	populations	with	EE.	Robust	systematic	reviews	have	shown	that	optimising	protein-energy	intake	has	only	modest	effects	on	stunting	of	up	to	0.7	HAZ	scores	(Bhutta	et	al.,	2008;	Dewey	and	Adu-Afarwuah,	2008).	
	
1.4.3.2 Amino	acid	supplementation	trials	A	small	number	of	studies	have	investigated	the	effect	of	glutamine	supplementation	on	weight	gain,	growth	and	barrier	function	in	EE	in	infants	and	children	only.	Infants	with	EE	supplemented	with	L-Glutamine	over	a	five	month	period	did	not	show	any	improvements	in	growth	or	intestinal	permeability	(as	measured	by	lactulose	:	mannitol	ratio)	when	compared	with	an	isonitrogenous,	isocaloric	mix	of	non-essential	amino	acids	in	Gambia	infants	(Williams	et	al.,	2007).	
An	enteral	glutamine	supplement	in	hospitalised	moderately	to	severely	malnourished	children	resulted	in	improvements	in	intestinal	permeability	(as	measured	by	lactulose	:	mannitol	ratio)	but	did	not	show	any	benefit	in	terms	of	weight	gain	compared	to	an	isonitrogenous	control	(Lima	et	al.,	2005).	
	
1.4.3.3 Lipid	supplementation	trials	Daily	supplementation	with	n-3	long-chain	polyunsaturated	fatty	acids	(DHA	and	EPA)	for	6	months	improved	some	nutritional	measures	including	MUAC	and	skin	fold	thickness,	but	did	not	improve	growth,	intestinal	permeability	(as	measured	
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by	lactulose	:	mannitol	ratio),	or	cognitive	development	in	Gambian	infants,	compared	to	olive	oil	placebo	(van	der	Merwe	et	al.,	2013).	
	
1.4.3.4 Micronutrient	supplementation	trials	A	two	week	course	of	zinc	sulphate	20mg/day	(equivalent	to	approximately	4.6mg	of	elemental	zinc)	given	to	one-	to	three-year-old	children	in	rural	Malawi	protected	against	a	deterioration	in	urinary	lactulose	:	mannitol	ratio	which	was	observed	in	the	placebo	group	(Ryan	et	al.,	2014).	
Multiple	micronutrient	supplementation	appears	to	have	subtle	effects	on	the	histological	features	of	EE	in	urban	Zambian	adults	(Kelly	et	al.,	2010,	1999;	Louis-Auguste	et	al.,	2014).	In	rural	Malawian	children,	MM	supplementation	results	in	a	modest	but	significant	improvement	in	lactulose	:	mannitol	ratio	(Smith	et	al.,	2014).	
	
1.5 Other	interventions	for	environmental	enteropathy	
1.5.1 Antimicrobial	interventions	
A	seven	day	course	of	Rifaximin,	a	non-absorbable	semi-synthetic	antibiotic,	did	not	improve	intestinal	permeability	as	measured	by	lactulose	:	mannitol	ratio	in	rural	Malawian	children	(Trehan	et	al.,	2009).	
Helminth	infection	is	common	in	impoverished	communities,	and	may	contribute	directly	and	indirectly	(through	secondary	effects	on	the	bacterial	microbiome)	to	intestinal	dysfunction.	A	dose	of	albendazole	given	to	1-3	year	old	children	in	a	
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placebo	controlled	trial	in	rural	Malawi	protected	against	a	deterioration	in	urinary	lactulose	:	mannitol	ratio	after	34	days	(Ryan	et	al.,	2014).	
Modification	of	the	microbiome	through	the	use	of	probiotics	has	also	been	trialled.	A	30	day	treatment	with	a	daily	supplement	of	510	Lactobacillus	GG	did	not	improve	lactulose	:	mannitol	or	urinary	sucrose	:	lactulose	ratios	(Galpin	et	al.,	2005).	
	
1.5.2 WASH	interventions	
The	introduction	of	WASH	interventions	in	a	stunted	population	is	expected	to	reduce	the	prevalence	of	stunting	at	three	years	of	age	by	only	2.4%,	although	the	incidence	of	diarrhoeal	episodes	might	be	reduced	by	30%	(Bhutta	et	al.,	2008).	More	recently,	robust	clinical	trials	of	WASH	interventions	have	failed	to	demonstrate	any	benefit	on	linear	growth	(Luby	et	al.,	2018;	Null	et	al.,	2018),	although	effects	on	intestinal	permeability	were	not	directly	assessed.	
	
1.5.3 Other	interventions	for	EE	
Mesalazine,	a	5-aminosalicylic	acid	commonly	used	for	the	treatment	of	ulcerative	colitis,	has	been	used	as	an	adjunctive	treatment	in	severe	acute	malnutrition	on	a	background	of	EE	(Jones	et	al.,	2014).	Although	there	were	some	improvements	in	plasma	inflammatory	markers	compared	to	placebo,	there	was	no	improvement	in	lactulose	:	mannitol	ratio.	
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1.6 The	mechanistic	target	of	rapamycin	complex	1	
(MTORC1)	cellular	nutrient	sensing	pathway	and	its	
therapeutic	potential	in	environmental	enteropathy	
The	mechanistic	(previously	‘mammalian’)	target	of	rapamycin	(MTOR)	complexes	are	the	most	important	global	cellular	nutrient	and	energy	sensors,	and	function	as	a	critical	checkpoint	in	cellular	differentiation,	division,	and	metabolism	(Efeyan	et	al.,	2015;	Laplante	and	Sabatini,	2012,	2009).	Many	of	the	abnormalities	described	above	could	be	related	to	MTOR	biology,	which	will	now	be	reviewed.	
	
1.6.1 MTOR	and	the	MTOR	complexes	
MTOR	is	an	evolutionarily	highly	conserved	serine/threonine	kinase	which	can	form	two	different	protein	complexes	(Table	1.4	and	Figure	1.6).	The	MTOR	complexes	integrate	growth,	nutrient,	and	cytokine	signals	from	the	cellular	milieu	(Figure	1.7,	p.52).	MTORC1	and	MTORC2	activation	is	an	indication	of	the	readiness	and	appropriateness	for	a	cell	to	survive,	grow,	divide,	or	differentiate	(Figure	1.8,	p.52).	Outside	of	cancer	biology,	MTORC1	signalling	has	been	best	studied	in	immune	cells,	and	T	lymphocytes	in	particular.	
	 	
	 51	
		
Figure	1.6.	The	MTOR	complexes	and	their	constituent	proteins.	Taken	from	Zhou	and	Huang,	
2010.	
	
	
Protein	 Name	 Complex	 Function	
MTOR	 Mechanistic	target	of	rapamycin	 Both	 Ser	/	Thr	kinase;	finally	activated	by	disinhibition	of	TSC	signalling	
DEPTOR	 DEP	domain-containing	MTOR-interacting	protein	 Both	 MTOR	inhibitor;	degrades	on	MTOR	activation	
mLST8	 Mammalian	lethal	with	SEC13	protein	8	 Both	 Unknown	
PRAS40	 40	kDa	Proline-rich	AKT	substrate	 MTORC1	 MTORC1	inhibitor;	mediates	AKT	signalling	
Raptor	 Regulatory-associated	protein	of	MTOR	 MTORC1	 Scaffold	protein	with	regulatory	roles;	mediates	AMPK	signalling;	binds	activated	RAG	GTPase/Ragulator	complex	
mSin1	 Mammalian	stress-activated	protein	kinase-interacting	protein	1	 MTORC2	 Scaffold	protein	
Rictor	 Rapamycin-insensitive	companion	of	MTOR	 MTORC2	 Scaffold	protein,	promotes	AKT	signalling	
Protor	 Protein	observed	with	Rictor	 MTORC2	 MTORC2	kinase	enhancer	
Table	1.4.	MTOR	complex	1	and	2	constituent	proteins	and	their	functions.		
	 52	
	
Figure	1.7.	Overview	of	the	integration	of	global	cellular	status	signals	by	MTORC1.	Green	
arrows	represent	activation;	red	arrows	represent	inhibition.	
	
	
Figure	1.8.	Overview	of	MTORC1	signalling.	Taken	from	Ben-Sahra	and	Manning,	2017.	
	
molecular functions of these protein complexes are still
emerging but are influence by the presence or absence of
specific amino acids, such as leucine and arginine [8!!
,9!!], which promote the accumulation of Rag heterodi-
mers containing GTP-bound RagA/B in complex with
GDP-bound RagC/D. In this amino acid-stimulated state
the Rag heterodimer, bound to the Ragulator, serves as a
docking site for mTORC1 at the lysosome, thereby
facilitating its subsequent activation by the Rheb GTPase
[4].
A subpopulation of Rheb (Rheb1 and Rheb2/Rhebl1)
resides at the lysosomal surface and, in the GTP-bound
state, is essential for mTORC1 activation [10,11!!]. The
only established regulator of Rheb is a GTPase-activating
protein (GAP) complex comprised of the tuberous scle-
rosis complex (TSC) proteins TSC1 and TSC2 and the
TBC domain protein TBC1D7, referred to as the TSC
complex [2,12]. Within this complex, TSC1 scaffolds
TSC2 and TBC1D7 together and stabilizes them. While
the molecular function of TBC1D7 is unknown, TSC2
possesses the GAP activity toward Rheb and is regulated
by multi-site phosphorylation downstream of several pro-
tein kinase signaling pathways. In this manner, the TSC
complex integrates signals from growth factor pathways,
such as the PI3K–Akt and Ras–Erk pathways, and stress
response kinases, such AMPK, which is activated in
response to cellular energy depletion. Pro-growth signals
from growth factor and nutrient sensing pathways inhibit
the TSC complex to promote the accumulation of Rheb-
GTP and its activation of mTORC1, while growth-sup-
pressing signals, including growth factor withdrawal,
nutrient depletion or cellular stress, activate the TSC
complex to decrease Rheb-GTP levels and shut down
mTORC1 signaling.
Growth factor signaling through the PI3K–Akt pathway,
and perhaps other signals, regulate mTORC1 by influ-
encing co-localization of the TSC complex with Rheb at
the lysosomal surface [11!!,13]. The Akt-mediated phos-
phorylation of TSC2 results in immediate release of the
TSC complex from Rheb, allowing Rheb to become GTP
loaded and activates mTORC1 [11!!]. While signals
relaying the presence of exogenous growth factors and
sufficient intracellular nutrients and energy are both
required for full activation of mTORC1, nutrient and
energy signals from within the cell are dominantly
required for mTORC1 to perceive signals propagated
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1.6.2 Cellular	nutrient	sensing	by	MTORC1	
1.6.2.1 Amino	acids	Amino	acids	are	necessary	for	MTORC1	activity.	Deficiencies	of	amino	acids,	and	branched	chain	amino	acids	(BCAA)	and	essential	amino	acids	(EAA)	in	particular,	result	in	profound	inhibition	of	MTORC1	activity	(Avruch	et	al.,	2009;	Cobbold	et	al.,	2009;	Sancak	et	al.,	2008).	L-Leucine,	a	BCAA,	is	the	canonical	MTOR	agonist	(Hara	et	al.,	1998).		
The	amino	acid	sensing	mechanisms	driving	MTOR	signalling	are	incompletely	understood.	Full	MTORC1	activation	occurs	once	the	MTORC1	complex	has	been	recruited	to	the	lysosomal	surface	via	the	RAG	GTPase-Ragulator	complex	(Sancak	et	al.,	2008;	Zoncu	et	al.,	2011);	Figure	1.9),	which	signals	lysosomal	(and	thus	intracellular)	amino	acid	sufficiency	detected	by	the	amino	acid	transporter	SLC38A9	(Rebsamen	et	al.,	2015;	S.	Wang	et	al.,	2015).	This	pathway	is	particularly	responsive	to	lysosomal	L-Glutamine,	L-Leucine	and	L-Arginine	levels,	but	other	mechanisms	exist,	interacting	with	several	aspects	of	the	MTORC1	machinery.	For	example,	there	is	also	a	RAG	/	Ragulator	independent	pathway	for	L-Glutamine	sufficiency	signalling	(Jewell	et	al.,	2015).	Given	that	different	upstream	mechanisms	are	involved	in	AA	sensing,	it	is	unsurprising	that	the	presence	of	different	amino	acids	can	have	differential	and	synergistic	effects	on	MTORC1	activation.	For	example,	L-Glutamine	supplementation	has	a	synergistic	effect	on	MTORC1	activity	after	EAA	administration	(Jewell	et	al.,	2015).	
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Figure	1.9.	MTORC1	activation	at	the	lysosomal	surface	requires	amino	acid	sufficiency,	which	
may	be	detected	by	numerous	mechansims.	Taken	from	Efeyan	et	al.,	2015.	
	
1.6.2.2 Glucose	and	global	energy	status	Glucose	independently	modulates	the	activity	of	the	RAG	GTPases	through	unknown	mechanisms	(Efeyan	et	al.,	2013).	Cellular	carbohydrate	levels	are	also	sensed	by	glucokinase.	This	low	affinity	kinase	converts	glucose	to	glucose	6-phosphate	which	is	subsequently	consumed	by	glycolysis,	resulting	in	increased	levels	of	ATP	and	reduced	levels	ADP	and	AMP.	The	increased	ATP:ADP	and	ATP:AMP	ratio	inhibits	AMPK,	which	functions	as	a	surrogate	marker	of	glucose	sufficiency	(Efeyan	et	al.,	2015).	ATP:ADP	and	ATP:AMP	ratios	also	reflect	global	cellular	energy	stores	and	are	similarly	measured	by	AMPK	signalling.	AMPK-induced	phosphorylation	in	a	low	energy	environment	inhibits	MTORC1	activity	directly	through	the	phosphorylation	of	Raptor	and	indirectly	through	the	phosphorylation	of	the	inhibitory	tuberous	sclerosis	complex	protein	2	(TSC2)	(Gwinn	et	al.,	2008;	Inoki	et	al.,	2003).	
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1.6.2.3 Oxygen	Hypoxia	inhibits	MTORC1	activity	through	the	upstream	induction	of	hypoxia-inducible	factor	(HIF)	signalling	via	the	regulatory	protein	REDD1.	Under	normoxia,	low	levels	of	REDD1	allow	binding	and	inhibition	of	TSC2	by	protein	14-3-3,	which	suppresses	the	inhibitory	function	of	the	TSC	complex	(DeYoung	et	al.,	2008).	In	turn,	MTORC1-mediated	phosphorylation	of	HIF	pathway	proteins	results	in	upregulation	of	glycolytic	pathways	which	provides	an	energy	burst	in	rapidly	dividing	activated	immune	cells,	but	may	also	drive	tumorigenesis	via	the	Warburg	effect	in	mutated	cells	(Cheng	et	al.,	2014;	DeYoung	et	al.,	2008;	Finlay	et	al.,	2012).	
	
1.6.2.4 Lipids	Lipid	sensing	pathways	remain	incompletely	understood,	but	feed	in	to	the	MTORC1	pathway	indirectly	via	the	global	energy	sensing	function	of	AMPK.	Lipids	appear	to	regulate	MTOR	signalling	primarily	by	promoting	lysosomal	recruitment	and	stability	of	the	MTOR	complexes.	Phosphatidic	acid	(PA),	produced	either	de	
novo	for	cell	membrane	synthesis	or	from	the	endogenous	degradation	of	cell	/	organelle	membranes,	signals	cellular	sufficiency	by	directly	stabilising	the	MTOR	complexes	(Foster,	2013;	Foster	et	al.,	2014),	and	promoting	MTOR	activation	by	binding	the	FKB12-Rapamycin	binding	domain	(Fang	et	al.,	2001;	Toschi	et	al.,	2009).	Lysosomally-derived	cholesterol	activates	the	lysosomal	amino	acid	transporter	SLC38A9	independently	of	its	amino	acid	sensing	roles,	promoting	MTORC1	activation	via	activation	of	RAG	GTPase	complex,	which	binds	the	MTORC1	complex	to	the	lysosome	(Castellano	et	al.,	2017).	
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1.6.2.5 Micronutrients	Several	micronutrients	appear	to	influence	MTOR	activity,	either	directly	or	indirectly.	Extracellular	zinc	results	in	MTORC1/S6K1	activation	through	the	PI3K/AKT	pathway	(Kim	et	al.,	2000),	and	zinc	chelation	inhibits	amino	acid-	and	insulin-mediated	phosphorylation	of	S6K1	via	MTORC1	(Lynch	et	al.,	2001),	suggesting	that	it	acts	directly	(at	MTOR)	and	indirectly	(via	PI3K/AKT).	
1,25-dihydroxycholecalciferol	(vitamin	D3)	promotes	tolerogenic	DCs	in	vitro,	including	antigen-specific	tolerance	(Ferreira	et	al.,	2015).	In	healthy	human	monocyte-derived	DCs,	vitamin	D3	promotes	tolerance	via	an	MTORC1-dependent	process	which	is	associated	with	increases	in	both	oxidative	phosphorylation	and	oxidative	glycolysis,	although	it	appears	that	it	is	the	glycolytic	enhancement	that	is	crucial	for	induction	of	tolerance	(Ferreira	et	al.,	2015).	This	is	in	contrast	to	the	adaptive	immune	system,	where	induction	of	glycolysis	by	MTORC1	activation	results	in	effector	functions	(discussed	in	section	1.6.6	below).	
	
1.6.3 Other	nutrient	sensing	pathways	
The	general	control	non-derepressible	2	(GCN2)	pathway	operates	synergistically	with	the	MTORC1	pathway,	by	signalling	amino	acid	depletion	(rather	than	amino	acid	sufficiency).	GCN2	binds	uncharged	tRNA	molecules,	and	does	not	discriminate	between	amino	acid	specificities	(Dong	et	al.,	2000).	This	allows	GCN2	to	respond	to	cellular	deficiencies	in	any	one	amino	acid	(via	its	tRNA).	Binding	of	uncharged	tRNA	activates	GCN2,	resulting	in	phosphorylation	and	activation	of	its	target	EIF2α	(Zhang	et	al.,	2002).	This	results	in	both	a	global	downstream	
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inhibition	of	protein	synthesis,	and	upregulation	of	catabolic	enzyme	pathways	involved	in	the	generation	of	essential	amino	acids	(Zhang	et	al.,	2002).	
In	parallel,	the	enterohumoral	system	senses	ingested	nutrients	and	secretes	a	variety	of	neurohumoral	effectors.	In	addition	to	their	canonical	effects	in	regulating	appetite,	gastrointestinal	motility,	and	metabolic	signalling,	many	of	these	may	also	have	secondary	effects	on	immune	function	and	gut	trophism	(Psichas	et	al.,	2015).	Glucagon-like	peptide	2	(GLP2),	for	example,	is	secreted	in	the	distal	ileum	in	response	to	luminal	amino	acids	delivery.	GLP2	stimulates	villus	growth	which	increases	small	intestinal	absorptive	area	and	thus	nutrient	(including	amino	acid)	absorption	(Drozdowski,	2009).	
	
1.6.4 Integration	of	signalling	through	MTORC1	
Full	activation	of	the	MTOR	complexes	results	in	translocation	from	the	cytosol	to	the	lysosomal	membrane.	Recruitment	of	MTORC1	from	the	cytosol	to	the	lysosomal	membrane	is	mediated	through	the	RAG	GTPases-Ragulator	complex	which	in	turn	is	activated	by	AA	abundance	(Efeyan	et	al.,	2015).	
RHEB	(Ras	homolog	enriched	in	brain)	activation	is	the	final	step	in	activation	of	the	MTORC1	complex.	RHEB	associates	with	MTORC1	at	the	lysosomal	surface.	RHEB	is	activated	by	a	number	of	nutrient	and	energy	signals	including	oxygen	levels,	ATP:AMP	ratio,	nutrient	levels,	WNT	signalling,	and	growth	factors	such	as	insulin,	mediated	through	the	inhibitory	TSC	complex.	RHEB	phosphorylates	and	activates	the	catalytic	domain	of	MTOR,	resulting	in	activation	of	its	kinase	ability.	
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Phosphorylation	of	MTOR	is	differentially	regulated,	depending	on	whether	it	is	part	of	MTORC1	or	MTORC2.	Full	activation	of	the	MTOR	kinase	requires	phosphorylation	at	multiple	sites	and	by	multiple	enzymes	including	RHEB,	P70S6	(Chiang	and	Abraham,	2005;	Holz	and	Blenis,	2005)	(thus	resulting	in	positive	feedback),	PI3K	(Acosta-Jaquez	et	al.,	2009),	and	auto-phosphorylation	(Acosta-Jaquez	et	al.,	2009)	in	an	amino	acid-dependent	manner.	
	
1.6.5 Downstream	effects	of	MTORC1	activation	
1.6.5.1 Activation	of	transcriptional	and	translational	programs	Globally,	MTORC1	signalling	promotes	anabolic	signals	and	inhibits	catabolic	signals	including	autophagy.	MTORC1	activation	promotes	cellular	anabolic	pathways,	namely	protein,	lipid	and	nucleotide	synthesis.	This	results	in	translation	and	protein	synthesis,	and	a	switch	towards	aerobic	glycolysis	to	provide	a	rapid	energy	boost.	Conversely,	MTORC1	inhibition	promotes	fatty	acid	oxidation,	prevents	new	transcription	programs,	and	promotes	autophagy	(Figure	1.8,	p.52	and	Figure	1.10	below).	
Activation	of	MTOR	complex	1	(MTORC1)	results	in	the	phosphorylation	of	eurkaryotic	initiation	factor	4E-binding	protein	1	(4EBP1)	and	ribosomal	protein	S6	kinase	1	(S6K1	or	P70S6K1).	Phosphorylated	4EBP1	dissociates	from	EIF4E,	allowing	it	to	form	the	EIF4F	translation	initiation	complex.	Phosphorylated	S6K1	targets	ribosomal	P40S6	(rS6)	among	others,	permitting	translation	(Figure	1.10).	Activation	of	MTOR	complex	2	(MTORC2)	results	in	phosphorylation	of	AKT	(also	
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known	as	protein	kinase	B),	which	among	other	functions	promotes	MTORC1	activity	by	phosphorylating	and	inhibiting	TSC2	(Figure	1.7,	p.52).	
	
Figure	1.10.	Downstream	effects	of	MTORC1	activation.	Green	arrows	represent	
phosphorylation	and	activation;	red	arrow	represents	phosphorylation	and	inhibition.			
EIF4F	(the	end	result	of	4EBP1	phosphorylation)	and	S6K1	appear	to	be	primarily	involved	in	upregulating	translation-	and	metabolism-related	proteins.	This	occurs	through	a	global,	co-ordinated	upregulation	of	a	number	of	metabolic	and	synthetic	programs	involved	in	cell	proliferation	and	metabolism.	Functionally,	MTOR-mediated	(particularly	MTORC1-mediated)	translation	promotes	a	number	of	metabolic	and	translational	programs,	including	ribosomal	biogenesis	(Chauvin	et	al.,	2014;	Hsieh	et	al.,	2012),	post-translational	modification	(Hsieh	et	al.,	2012),	
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biosynthesis	(Düvel	et	al.,	2010a;	Hsieh	et	al.,	2012),	aerobic	glycolysis	(Düvel	et	al.,	2010a),	pentose	phosphate	pathway	(Düvel	et	al.,	2010a),	and	nucleotide	synthesis	(Ben-Sahra	et	al.,	2016,	2013;	Robitaille	et	al.,	2013).	Functionally	and	transcriptionally,	4EBP1	appears	to	be	the	most	important	mediator	of	MTORC1’s	downstream	upregulated	transcriptional	program	(Chauvin	et	al.,	2014;	Thoreen	et	al.,	2012,	2009).	
MTORC1-mediated	phosphorylation	of	S6K1	and	4EBP1	is	required	but	not	sufficient	for	the	initiation	of	cap-dependent	translation.	Activated	MTORC1	phosphorylates	the	first	of	numerous	4EBP1	residues.	Subsequent	full	phosphorylation,	which	is	not	fully	MTORC1	dependent,	results	in	the	release	of	eukaryotic	initiation	factor	4E	and	cap-dependent	translation	(Gingras	et	al.,	2001,	1999).	
Similarly,	rS6	is	sequentially	phosphorylated	at	multiple	sites,	with	the	initiation	of	phosphorylation	undertaken	exclusively	by	activated	S6K1	(Ferrari	et	al.,	1991;	Pende	et	al.,	2004;	Roux	et	al.,	2007).	In	turn,	initial	phosphorylation	and	activation	is	exclusively	mediated	by	MTORC1	(Salmond	et	al.,	2009).	
	
1.6.5.2 Cell	growth	and	cell	cycle:	transcriptional	and	translational	control	The	G1/S	phase	transition	is	the	crucial	transition	point	in	rapidly	replicating	cells	including	enterocytes	and	activated	immune	cells	(Massagué,	2004).	These	cells	must	respond	to	different	external	stimuli,	for	example	growth	factors	for	enterocytes	and	activation	signals	for	immune	cells.	MTORC1	balances	the	‘request’	for	proliferation	via	the	PI3K	/	AKT	pathway	against	the	‘readiness’	of	the	
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cell	to	divide	in	terms	of	nutrient	availability.	MTORC1	is	one	of	the	critical	nodes	that	licenses	cells	to	proceed	through	G1/S	(Massagué,	2004).	
	
1.6.5.3 Metabolic	reprogramming	Although	oxidative	phosphorylation	is	far	more	efficient	in	terms	of	energy	per	unit	of	substrate	(protein,	carbohydrate	or	lipid)	compared	to	glycolysis,	glycolysis	is	able	to	provide	a	rapid	burst	of	cellular	energy	which	can	be	used	by	stimulated	cells.	MTORC1	supports	this	increased	energy	requirement	by	promoting	aerobic	glycolysis	(the	Warburg	effect)	by	activating	the	downstream	HIF1α	pathway	which	results	in	upregulation	of	numerous	glucose	transporters	as	well	as	glycolytic	enzymes	(Düvel	et	al.,	2010a;	Finlay	et	al.,	2012).	Furthermore,	MTORC1	inhibits	lipolysis	and	β-oxidation	of	free	fatty	acids	(Düvel	et	al.,	2010a;	Ricoult	and	Manning,	2013);	by	promoting	lipogenesis	this	also	has	the	secondary	effect	of	providing	an	intracellular	lipid	store	for	cell	membrane	and	organelle	creation.	
	
1.6.5.4 Autophagy	MTORC1	is	a	critical	negative	regulator	of	autophagy	(Hosokawa	et	al.,	2009;	Kim	et	al.,	2011).	MTORC1	phosphorylates	Unc	51-like	kinase	1	(ULK1)	and	Autophagy	Related	Protein	13	(ATG13).	Thus	inactivated,	the	ULK1	complex	is	unable	to	initiate	construction	of	the	autophagosome.	Unsurprisingly,	AA	deficiencies	(and	MTORC1	inhibition)	promotes	ULK1	activity	(in	conjunction	with	positive	regulation	from	AMPK	(Ben-Sahra	and	Manning,	2017;	Kim	et	al.,	2011)),	resulting	
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in	autophagy	and	recycling	of	cellular	organelles,	replenishing	the	cell’s	intracellular	amino	acid	(as	well	as	lipid,	carbohydrate	and	nucleic	acid)	stores.		
	
1.6.6 MTORC1	signalling	and	the	immune	response,	with	
particular	reference	to	CD4+	T	cell	differentiation	&	function	
MTORC1	signalling	has	been	best	studied	in	T	lymphocyte	(particularly	CD4+	T	lymphocyte)	differentiation	and	function.	However,	it	is	increasingly	implicated	in	all	branches	of	innate	and	adapted	immunity	(Table	1.5).	In	general,	MTORC1	activity	is	required	for	a	robust	and	effective	activated	immune	cell	response,	for	example	in	promoting	aerobic	glycolysis,	the	production	of	effector	cytokine	production,	and	rapid	cell	proliferation;	conversely,	cells	stimulated	in	an	environment	resulting	in	MTORC1	inhibition	tend	to	be	anergic	(e.g.	impaired	cytokine	production;	memory	cell	generation).	
Table	1.5.	Summary	of	main	effects	of	MTORC1	signalling	in	immune	cells.	
Cell	type	 Effect	of	MTORC1	
activation	
Effect	of	MTORC1	
inhibition	
References	
CD4+		 TH1	TH2	TH17	generation	 Treg	generation	 (Waickman	and	Powell,	2012)	
CD8+		 Teff		generation	 Tmem	generation	 (Araki	et	al.,	2009a)	
B	 	 Reduced	plasma	cell	generation	and	antibody	secretion	 (Jones	et	al.,	2016)	
NK	 Effector	functions	 Anergy	 (Donnelly	et	al.,	2014)	
Dendritic	cells	 Activation	 Anergy	 (Krawczyk	et	al.,	2010)	
Monocytes	 Trained	immunity	 Impaired	survival	and	antigen	response	 (Cheng	et	al.,	2014)	
Innate	lymphoid	 Conflicting	 Conflicting	 (Weichhart	et	al.,	2015)	
NLRP3	
inflammasome	
Activation	 	 (Moon	et	al.,	2015)	
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1.6.6.1 CD4+	T	cells	MTOR	signalling	has	important	roles	in	CD4+	cell	differentiation	and	homeostasis.	T	cells	lacking	MTOR	are	unable	to	differentiate	into	effector	(TH1,	TH2	or	TH17)	subtypes,	and	default	to	a	Treg	phenotype	(Delgoffe	et	al.,	2009).	MTORC1	signalling	is	required	and	sufficient	for	TH1	and	TH17	differentiation	(Delgoffe	et	al.,	2011).	Conversely,	TH2	differentiation	requires	MTORC2	signalling,	which	does	not	affect	TH1	/	TH17	differentiation	(Delgoffe	et	al.,	2011).	On	the	other	hand,	MTORC1	inhibition	by	EAA	deprivation	results	in	FOXP3	expression	and	Treg	differentiation;	conversely	TH1	/	TH17	production	results	from	EAA	replete	environments	(Cobbold	et	al.,	2009).	
MTORC1	activation	in	undifferentiated	T	cells	results	in	preferential	differentiation	to	the		TH1	immunophenotype	through	TBET	transcription	(Delgoffe	et	al.,	2011)	and	then	also	phosphorylation	and	activation	of	the	TBET	transcription	factor	(Chornoguz	et	al.,	2017).	TBET+	cells	treated	with	Rapamycin	fail	to	express	IFNγ	despite	appropriate	stimulation	(Chornoguz	et	al.,	2017).	Similarly,	Mtorc1	signalling	is	important	for	the	maintenance	of	Tregs	(Zeng	et	al.,	2013).	
As	in	other	cell	types,	MTORC1	activity	inhibits	T	cell	autophagy	(Li	et	al.,	2006).	MTORC1	activation	results	in	a	metabolic	shift	to	aerobic	glycolysis	which	supports	effector	T	cell	functions	(Liu	et	al.,	2014;	Maciolek	et	al.,	2014;	Waickman	and	Powell,	2012).	
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1.6.6.2 MTORC1	inhibition:	clinical	effects	and	implications	Intriguingly,	several	studies	have	consistently	demonstrated	that	MTOR	inhibition	in	mice	(and	other	eukaryotes)	extends	life	by	approximately	10%	(Harrison	et	al.,	2009;	Johnson	et	al.,	2013).	Furthermore,	nutrient	(caloric)	restriction	also	has	a	life-extending	effect	(Fontana	et	al.,	2010;	Johnson	et	al.,	2013),	and	in	fruit	flies	and	rodents	it	appears	to	be	essential	amino	acid	(EAA)	restriction	that	confers	benefit	(Mair	et	al.,	2005;	Miller	et	al.,	2005;	Orentreich	et	al.,	1993).	In	mice	at	least,	age-related	changes	in	immune	cell	populations	is	influenced	by	the	MTOR	pathway,	and	inhibition	is	associated	with	longevity	(Neff	et	al.,	2013;	Selman	et	al.,	2009);	indeed,	the	effect	on	longevity	does	not	appear	to	be	a	general	effect	on	ageing	but	is	mediated	through	reductions	in	age-related	morbidity	/	mortality	in	various	organ	systems	including	immunosenescence	(Neff	et	al.,	2013).	The	extent	to	which	these	findings	can	be	extrapolated	to	humans	is	unknown.		
A	six	week	trial	of	MTOR	inhibition	with	a	rapamycin	analogue	(RAD001)	in	elderly	volunteers	resulted	in	significantly	improved	seroconversion	rates	and	antibody	titres	to	parenterally	administered	influenza	immunisation,	which	was	associated	with	a	reduction	in	peripheral	CD4+	and	CD8+	lymphocytes	expressing	Programmed	Death-1	(PD-1,	an	inhibitory	and	pro-apoptotic	lymphocyte	receptor	upregulated	in	immunosenescence)	(Mannick	et	al.,	2014).	However	these	results	may	not	be	applicable	to	the	non-senescent	mucosal	immune	system	of	EE,	or	to	enterally	administered	vaccines.	
The	role	of	MTORC1	inhibition	in	the	immune	response	to	pathogens	is	largely	unknown.	However,	there	is	some	evidence	that	MTORC1	inhibition	does	result	in	a	clinically	relevant	shift	away	from	effector	functions,	as	would	be	expected	from	
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the	in	vitro	data.	In	mice	and	non-human	primates,	inhibition	of	MTORC1	with	rapamycin	promotes	and	accelerates	the	generation	of	memory	CD8+	T	cells	in	response	to	viral	infection	and	vaccination	(Araki	et	al.,	2009b),	and	inhibits	effector	functions	by	preventing	TBET	expression	(Rao	et	al.,	2010).	Similarly,	pharmacological	MTORC1	inhibition	in	a	mouse	DSS	colitis	model	resulted	in	reduced	TH1	and	TH17	LP	expansion	and	activation	and	promotes	Treg	LP	populations	(Hu	et	al.,	2016).	
	
1.6.6.3 Potential	role	of	MTORC1	signalling	in	T	cell	plasticity	Experienced	immune	cells	are	no	longer	viewed	as	being	terminally	differentiated.	T	cell	plasticity	describes	the	flexibility	in	immunophenotype	and	function	observed	in	non-naïve	T	cells	exposed	to	polarising	conditions.	Responding	to	mixed	cues,	naïve	cells	may	differentiate	into	‘hybrid’	cells,	and	experienced	cells	may	lose	their	original	function	or	gain	additional	function.	In	humans,	significant	plasticity	of	TH17	cells	has	been	demonstrated	(to	/	from	TH1,	TH2,	and	Treg)	(Brucklacher-Waldert	et	al.,	2014;	Cosmi	et	al.,	2014;	Sawant	and	Vignali,	2014;	Vahedi	et	al.,	2013).	Cells	with	mixed	phenotypes	appear	to	have	functions	in	between	their	parent	types.	
Treg	to	TH1-like	transitions	have	been	observed	in	mouse	models	(Hua	et	al.,	2018)	as	well	as	humans	PBMCs	(Chowdary	Venigalla	et	al.,	2012).	TBET+	FOXP3+	lamina	propria	lymphocytes	are	described	in	IBD,	where	they	are	correlated	with	the	clinical	severity	of	inflammation	(Li	et	al.,	2017).	Indeed,	loss	of	Treg	suppressor	function	and	a	switch	towards	a	TH1	or	TH17	phenotype	has	been	observed	in	infection,	and	autoimmune	conditions	(Kitz	et	al.,	2016).	In	humans,	the	
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suppressor-to-TH1	phenotype	is	at	least	partly	mediated	through	PI3K-AKT	signalling	(Kitz	et	al.,	2016)	and	therefore	the	MTORC1	system.	Constitutive	MTORC1	stimulation,	for	example,	will	lead	to	loss	of	FOXP3	expression	and	thus	loss	of	the	Treg	immunophenotype,	even	in	the	absence	of	inflammation	(Sawant	and	Vignali,	2014).	
Thus,	modulation	of	MTORC1	signalling,	in	conjunction	with	other	appropriate	cellular	signals,	may	be	implicated	in	CD4+	plasticity,	although	this	has	not	been	directly	investigated.	
	
1.6.7 MTORC1	signalling	and	the	intestinal	barrier	
More	recently,	MTORC1	signalling	has	also	been	implicated	in	intestinal	barrier	and	absorptive	function.	Its	roles	here	have	not	been	fully	defined.	
	
1.6.7.1 Ion	exchange	Clinical	use	of	rapamycin	(sirolimus)	is	commonly	associated	with	non-infectious	watery	diarrhoea	(Joint	Formulary	Committee,	2018),	and	administration	of	rapamycin	in	mice	and	rats	also	results	in	a	watery	diarrhoea	(Yang	et	al.,	2015).	This	appears	to	be	at	least	partly	mediated	through	a	down-regulation	of	sodium-hydrogen	exchanger	3	(NHE3)	expression	on	the	ileal	brush	border,	resulting	in	reduced	Na+/H+	exchange	(Yang	et	al.,	2015).	This	is	associated	with	both	reduced	levels	of	phospho-rS6	(indicating	reduced	MTORC1	and	S6K1	activity)	and	phospho-AKTSer473	(indicating	reduced	MTORC2	activity).	
	 67	
	
1.6.7.2 Epithelial	cell	growth	and	villous	atrophy	Intestinal	atrophy	is	commonly	noted	after	non-enteral	feeding,	for	example	in	post-surgical	or	ITU	patients	on	total	parenteral	nutrition.	Mice	fed	amino	acid-free	chow	demonstrate	mucosal	atrophy	(as	assessed	by	a	reduction	in	total	mucosal	height	and	villous	density),	which	is	associated	with	a	reduction	in	enterocyte	phospho-rS6	levels,	reflecting	reduced	MTORC1	/	S6K1	signalling.	The	protective	effect	of	oral	amino	acid	administration	was	negated	by	the	parenteral	administration	of	rapamycin	(Nakamura	et	al.,	2012).	Furthermore,	oral	rapamycin	can	independently	induce	small	intestinal	mucosal	atrophy	in	rabbits	(Dias	et	al.,	1998).	MTORC1	activity	in	the	normal	fed	state	is	most	marked	in	the	crypt	(Nakamura	et	al.,	2012).	These	findings	are	consistent	with	a	role	for	amino	acid-mediated	MTORC1	signalling	in	intestinal	stem	cells	in	promoting	mucosal	regeneration.	
L-Gln	supplementation	promotes	growth	in	intestinal	porcine	epithelial	cells	(IPEC1)	via	MTORC1,	independently	of	AMPK	signalling	(Yi	et	al.,	2015).	L-Arg	supplementation	similarly	promotes	cell	growth	and	proliferation	and	protects	against	LPS-induced	death	via	MTORC1	signalling	in	IPEC1	cells	(Tan	et	al.,	2010).	
Dietary	L-Arg	supplementation	in	piglets	improved	small	intestinal	weight	and	villous	height	and	reduced	rates	of	IEC	apoptosis,	and	this	was	associated	with	increased	levels	of	MTORC1	activation	(Wang	et	al.,	2012).	
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1.6.7.3 Intestinal	permeability	and	tight	junction	function	Rabbits	administered	oral	rapamycin	demonstrate	an	increase	in	transepithelial	conductance	and	inulin	flux	(Dias	et	al.,	1998),	implicating	MTORC1	signalling	in	the	maintenance	of	TJ	integrity.	In	a	variety	of	in	vitro	models,	MTORC1	signalling	is	implicated	in	maintaining	TJ	integrity.	For	example,	butyrate	in	a	mouse	intestinal	epithelial	cell	line	protects	against	LPS-induced	TJ	permeability	by	upregulating	MOTRC1	signalling	which	is	associated	with	increased	abundance	of	claudins	3	and	4	(Yan	and	Ajuwon,	2017).	Exogenous	zinc	in	Caco-2	cells	increases	transepithelial	resistance	and	reduces	TJ	permeability	through	increasing	signalling	through	the	PI3K/AKT/MTORC1	pathway,	which	is	associated	with	increased	expression	of	the	TJ	protein	ZO-1	(Shao	et	al.,	2017).	L-Trp	supplementation	in	a	porcine	intestinal	epithelial	cells	results	in	upregulation	of	a	variety	of	TJ	proteins	associated	with	MTORC1	activation	(H.	Wang	et	al.,	2015).	
L-Gln	supplementation	has	similar	physiological	effects,	and	results	in	enhanced	AMPK	signalling	(Wang	et	al.,	2016)	(with	presumed	downstream	enhancement	of	MTORC1	signalling).	
	
1.6.7.4 Nutrient	uptake	Administration	of	rapamycin	in	rabbits	results	in	increased	active	D-glucose	uptake.	Fructose	uptake	is	unaffected	(Dias	et	al.,	1998).	On	the	other	hand,	jejunal	uptake	of	three	of	six	fatty	acids	tested	(18:0	[stearic],	18:2	[linoleic],	and	18:3	[linolenic])	is	reduced	per	unit	of	mucosa	(Dias	et	al.,	1998).	Interestingly,	only	linolenic	acid	(18:3)	ileal	uptake	was	reduced	with	rapamycin,	while	12:0	(lauric)	and	18:2	(linoleic)	uptake	was	increased	(Dias	et	al.,	1998).	
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Finally,	MTORC1	stimulation	upregulates	the	apical	glucose	transporter	GLUT1	(Düvel	et	al.,	2010b;	Finlay	et	al.,	2012).	
	
1.6.7.5 Paneth	cells,	intestinal	stem	cells,	and	enterocytes	As	well	as	having	crucial	roles	in	regulating	and	maintaining	the	intestinal	stem	cell	niche	and	intestinal	stem	cell	renewal	(Clevers	and	Bevins,	2013),	Paneth	cells	play	an	important	role	in	regulating	the	microbiome	and	host	defence	(Bevins	and	Salzman,	2011b),	partly	through	antimicrobial	peptides	(section	1.3.2.2,	p.34).	
Caloric	restriction	in	mice	results	in	increased	intestinal	stem	cell	proliferation	and	Paneth	cell	proliferation,	but	with	reductions	in	mucosal	/	small	intestinal	mass	and	villous	atrophy	and	with	villi	containing	more	immature	enterocytes.	These	effects	are	mediated	by	caloric	restriction-induced	MTORC1	inhibition	in	Paneth	cells	(Yilmaz	et	al.,	2012).	The	net	effect	is	that	in	conditions	of	starvation,	the	intestine	promotes	self-renewal	over	villous	growth	and	differentiation	(Yilmaz	et	al.,	2012).	Furthermore,	dietary	restriction	induces	autophagy	in	Paneth	cells	(Hodin	et	al.,	2011).	
	
1.7 Summary	
Environmental	enteropathy	is	thought	to	underlie	the	phenomenon	of	stunting,	a	widely	prevalent	disorder	in	the	developing	world	with	lifelong	detrimental	consequences.	EE	is	characterised	by	a	number	of	intestinal	and	systemic	physiological	abnormalities,	primarily	pathologically	increased	intestinal	
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permeability	and	reduced	small	intestinal	absorptive	capacity	on	a	background	of	a	chronically	inflamed	gut.	Although	associated	with	undernutrition,	sanitation	and	GI	infections,	interventional	studies	addressing	these	concerns	have	not	resulted	in	improvements	in	stunting	and	/	or	the	features	of	EE.	Novel	and	practical	therapies	are	therefore	required.	Furthermore,	little	is	known	about	the	relationship	between	the	histological	abnormalities,	intestinal	barrier	function,	and	role	of	the	mucosal	immune	system.	
Populations	affected	by	EE	are	prone	to	undernutrition.	Nutrition	has	several	important	effects	on	the	small	intestinal	barrier	and	mucosal	immune	compartment.	Nutritional	status,	dietary	intake,	the	intestinal	epithelial	barrier,	the	mucosal	immune	compartment,	and	the	microbiota	have	complex	and	interdependent	relationships	that	remain	incompletely	understood.	There	is	laboratory	and	some	clinical	evidence	supporting	the	role	of	micronutrients	and	/	or	amino	acid	supplements	in	maintaining	intestinal	health,	and	also	some	evidence	of	benefit	in	EE.	Both	amino	acid	and	micronutrient	deficiencies	may	be	particularly	relevant	for	intestinal	immune	and	barrier	function	in	individuals	with	nutritionally	poor	intake,	and	represent	attractive	targets	for	therapeutic	intervention.	
Global	(protein-energy	malnutrition;	starvation;	severe	acute	malnutrition)	and	specific	(vitamin	A	and	D	deficiencies;	glutamine	deprivation)	deficits	have	significant	effects	on	absorptive	capacity	and	the	mucosal	immune	response.	These	effects	are	mediated	through	cellular	nutrient	sensing	pathways.	The	MTORC1	pathway	is	the	most	important	known	cellular	nutrient	sensing	mechanism,	and	is	perhaps	the	most	relevant	for	intestinal	disorders	due	to	its	effects	on	both	
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immune	cell	and	epithelial	function.	Nutrient,	and	in	particular	amino	acid,	sufficiency	activates	MTORC1	signalling.	This	encourages	naïve	CD4+	T	cells	(and	other	immune	cells)	to	differentiate	into	effector	T	cells,	and	promotes	an	effector-like	immunophenotype	in	differentiated	T	cells.	In	the	intestinal	mucosa,	MTORC1	signalling	may	have	beneficial	effects	on	intestinal	permeability	and	epithelial	growth.	The	role	of	MTORC1	signalling	in	the	intestinal	immune	compartment,	and	its	relationship	to	nutrient	availability,	is	unknown.		
	
1.8 Hypothesis,	aims,	and	scope	of	this	thesis	
It	was	hypothesised	that	high	dose	multiple	micronutrient	supplementation	and	/	or	specific	amino	acid	supplementation	can	modify	some	of	the	canonical	features	of	EE	(namely	small	intestinal	morphometry	and	permeability),	and	that	supplementation	would	concurrently	modify	lamina	propria	CD4+	lymphocyte	MTORC1	signalling	(Figure	1.11).	A	phase	II	double	blind	randomised	placebo-controlled	trial	was	therefore	conducted	in	Zambian	adults	with	environmental	enteropathy.	
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Figure	1.11.	Hypothesis.	a,	Inter-relationship	between	nutrient	availability,	nutrient	sensing	
through	MTORC1,	small	intestinal	barrier	function	and	EE.	b,	Rationale	for	amino	acid	and	/	or	
micronutrient	supplementation	in	EE.		
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1.8.1 Aims	
The	following	aims	are	based	on	the	primary	and	secondary	outcomes	and	exploratory	analyses	from	the	trial	(outlined	in	Chapter	2).	
	
1.8.1.1 Aims	(primary	outcomes)	1. To	assess	the	effect	of	supplementation	on	small	intestinal	histology	as	assessed	by	morphometry.	2. To	assess	the	effect	of	supplementation	on	intestinal	barrier	dysfunction	as	assessed	by	confocal	laser	endomicroscopy.	3. To	assess	the	effect	of	supplementation	on	lamina	propria	CD4+	T	cell	MTORC1	signalling.		
1.8.1.2 Aims	(secondary	outcomes)	1. To	investigate	the	effect	of	supplementation	on	plasma	markers	of	microbial	translocation	and	immune	activation	(sCD14,	CRP,	LPS).	2. To	investigate	the	effect	of	supplementation	on	metabonomic	profile.	3. To	investigate	the	effect	of	supplementation	on	anthropometry	and	body	composition.		
1.8.1.3 Exploratory	analyses	1. To	investigate	the	effect	of	supplementation	on	lamina	propria	CD4+	MTORC1	signalling	and	TBET	transcription.	2. To	investigate	the	characteristics	of	the	lamina	propria	immune	compartment.	3. To	investigate	the	effect	of	supplementation	on	plasma	Glucagon-like	peptide	2	levels.	
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1.8.2 Thesis	outline	
The	bulk	of	this	thesis	describes	the	AMAZE	trial	(Amino	acids	and	/	or	multiple	Micronutrients	in	Adult	Zambians	with	environmental	Enteropathy).		
Chapter	2	is	an	abbreviated	version	of	the	full	trial	protocol,	and	details	how	the	trial	was	set	up	and	undertaken.	
Chapter	3	is	the	main	methods	chapter,	and	discusses	the	experimental	methods	chosen	to	study	the	intestinal	barrier	as	well	as	describing	the	experimental	procedures	undertaken	including	preliminary	/	proof-of-concept	work.	
Chapter	4	provides	the	results	of	the	trial’s	primary	outcomes.	
Chapter	5	provides	the	results	of	the	trial’s	secondary	outcomes	and	exploratory	analyses.	
Chapter	6	provides	a	general	discussion.	
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2 	
CHAPTER	2	
AMINO	ACIDS	AND	/	OR	MULTIPLE	MICRONUTRIENTS	
IN	ADULT	ZAMBIANS	WITH	ENVIRONMENTAL	ENTEROPATHY	
(THE	AMAZE	STUDY):	TRIAL	OVERVIEW	
	
2.1 Introduction	
The	effects	of	multiple	micronutrient	(MM)	and	/	or	amino	acid	(AA)	supplementation	in	healthy	adult	volunteers	with	EE	were	assessed	in	a	double	blind,	randomised,	placebo-controlled	trial	using	a	2×2	factorial	design.	Participants	were	randomised	to	receive	MM	supplementation	or	placebo,	with	or	without	an	amino	acid	supplement	of	L-Glutamine,	L-Leucine	and	L-Tryptophan	or	placebo,	daily	for	16	weeks.	Participants	underwent	a	number	of	clinical,	laboratory	and	endoscopic	assessments	before	and	after	the	supplementation	period	to	provide	a	global	insight	into	the	effects	of	the	intervention	on	the	various	pathophysiological	domains	of	EE.	Outcomes	were	analysed	according	to	HIV	status,	or	together	if	there	was	no	evidence	of	an	effect	of	HIV.		The	following	paragraphs	summarise	the	study	protocol.	The	data	collection	instruments,	patient	information	sheet	and	consent	forms	are	included	in	Appendices	1-3	(p.205).		
2.2 Study	setting	and	participants		
Healthy	adult	volunteers	were	recruited	from	an	impoverished	urban	community	on	the	outskirts	of	Lusaka,	Zambia.	The	research	clinic	was	located	in	this	community,	staffed	by	a	full-time	research	nurse	and	two	full-time	clinical	research	assistants.	Endoscopies,	flow	cytometry,	ELISAs,	and	body	composition	analyses	were	performed	at	the	University	of	Zambia	School	of	Medicine	in	the	University	Teaching	Hospital,	Lusaka.	
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As	in	previous	studies	in	this	cohort,	inclusion	criteria	were	intentionally	broad	to	allow	truly	representative	sampling,	and	temporary	exclusion	criteria	considered	the	possible	confounding	effects	of	recent	infectious	diarrhoea,	antibiotic	use	and	NSAID	use.		
2.2.1 Inclusion	criteria	
• Age	between	18	and	60	years	
• Resident	in	B	section,	Misisi	compound	
• Able	to	give	informed	consent		
2.2.2 Exclusion	criteria	
• Pregnancy	(by	self-report)	
• Breast	feeding	
• Antibiotic	use	within	previous	4	weeks	(defined	as	antibiotics	taken	regularly	for	more	than	24	hours)	
• Regular	NSAID	use	within	previous	4	weeks	(defined	as	NSAID	taken	regularly	for	more	than	72	hours)	
• Diarrhoea	within	previous	4	weeks	(defined	as	three	or	more	watery	stools	for	more	than	24	hours)	
• Significant	comorbidity	precluding	endoscopy	with	sedation	(at	discretion	of	researcher)	
• Therapeutic	anticoagulation	or	bleeding	diathesis	precluding	endoscopic	biopsies	
• Unwilling	to	undergo	HIV	testing	
• Untreated	helminth	/	Giardia	infection,	or	helminth	/	Giardia	infection	treated	within	six	months	
• BMI	<	18	
• Unwilling	to	consent	to	long-term	storage	of	samples	Participants	were	eligible	to	enrol	in	the	study	once	any	exclusion	criteria	had	expired.	
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2.3 Recruitment	and	informed	consent	procedures	
A	robust	three-stage	system	of	screening,	recruitment	and	consent	was	used	which	has	been	developed	and	tailored	for	use	in	the	Misisi	study	population	over	many	years:	door-to-door	notification,	focus	groups	and	individual	face-to-face	counselling	leading	to	fully	informed	written	consent.	Following	qualitative	research	in	this	population	(Zulu	et	al.,	2014),	an	interactive	research	facilities	visit	was	also	incorporated	into	the	recruitment	and	consent	process	for	this	study.	Healthy	adult	participants	were	recruited	from	an	impoverished	community	living	in	Misisi	suburb	in	Lusaka,	where	previous	work	has	demonstrated	that	EE	is	virtually	universal	(but	present	in	varying	degrees	of	severity).	Experienced	field	workers	conducted	informal	door-to-door	discussions	in	B	Section	of	Misisi	compound	to	identify	potential	participants.	Potential	participants	were	told	what	the	study	involved	in	general	terms,	and	that	participation	was	voluntary.	Individuals	who	expressed	an	interest	in	participating	at	the	time	of	door-to-door	notification	were	invited	to	one	of	several	focus	group	meetings.	Individuals	who	had	previously	been	involved	in	our	clinical	studies	were	also	invited	to	attend.	The	focus	group	discussions	included	the	following:	
• Introduction	to	the	study	team	
• Introduction	to	the	study	
• Reading	of	the	participant	information	sheet	in	Nyanja,	which	is	universally	spoken	in	this	community.	Literacy	rates	in	Misisi	are	low	and	this	was	therefore	the	most	appropriate	method	for	conveying	this	information	
• Benefits	and	risks	of	being	involved	in	the	research	
• Previous	participants'	descriptions	of	being	involved	in	research	
• Questions	to	the	study	team	and	previous	participants	
• Invitation	to	attend	a	guided	tour	of	the	research	and	endoscopy	facilities	Potential	participants	who	were	unable	to	make	any	of	the	focus	group	meetings	were	invited	to	the	field	clinic	to	run	through	the	information	sheet	and	discuss	the	study	with	a	member	of	the	study	team.	
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Qualitative	research	undertaken	in	the	Misisi	community	has	identified	that	research	participants	have	some	misconceptions	with	regards	to	clinical	research,	and	in	particular	what	happens	to	the	samples	that	participants	provide	(Zulu	et	al.,	2014).	The	research	facilities	visit	was	designed	to	address	these	concerns	in	detail.	Potential	participants	were	invited	to	visit	the	research	and	endoscopy	facilities.	They	were	able	to	see	the	endoscopy	unit,	meet	endoscopy	staff,	and	were	given	demonstrations	of	the	endoscopy	equipment,	in	particular	the	taking	of	endoscopic	biopsies.	They	were	also	shown	the	laboratory	facilities	and	met	the	research	staff,	who	gave	explanations	and	demonstrations	of	what	happens	to	samples	once	they	have	been	taken.	They	were	shown	how	small	the	biopsies	and	blood	samples	are.	The	handling	and	storage	of	biological	specimens	was	also	explained	and	demonstrated.	Participants	were	invited	to	view	researchers	at	work	and	observe	experiments	being	conducted.	These	visits	were	informal	and	potential	participants	were	encouraged	to	ask	questions	at	any	time.	Individuals	who	wanted	to	participate	in	the	study	were	then	invited	to	attend	for	written	consent,	screening	and	enrolment	in	the	study.	Consenting	and	enrolment	occurred	at	least	48	hours	after	participants	had	attended	a	focus	group	meeting	or	study	explanation	visit.	Participants	were	invited	to	ask	further	questions	or	express	concerns.	If	they	were	happy	to	proceed,	they	were	asked	to	sign	or	thumbprint	the	consent	form,	which	was	read	out	to	them	in	Nyanja	if	they	were	unable	to	read.		
2.3.1 HIV	testing	
All	participants	who	were	not	known	to	be	HIV	positive	were	consented	for	HIV	testing.	HIV	counselling	and	testing	has	been	performed	by	the	research	clinic	nurse	both	as	part	of	standard	medical	care	in	the	Misisi	clinic	and	as	part	of	the	routine	research	process	in	our	recent	studies	for	over	15	years	(Kelly	et	al.,	2004,	2016).	HIV	testing	was	performed	using	the	UniGold	point-of-care	kit	(Trinity	Biotech	Plc,	Bray,	Ireland).	Positive	results	had	a	second	confirmatory	test	performed	using	an	alternative	point-of-care	kit.	There	were	no	cases	where	the	result	of	the	second	
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test	was	not	confirmatory.	New	diagnoses	were	referred	on	to	HIV	specialists	for	further	investigation	and	management	including	anti-retroviral	therapy	in	accordance	with	World	Health	Organization	and	Government	of	Zambia	Ministry	of	Health	guidelines	and	procedures	(Zambia	Ministry	of	Health,	2014).		
2.4 Study	flowchart	and	schedule	of	assessments	
Figure	2.1.	Study	flow	chart.		
16	week	supplementation	period	Clinical	review	every	4	weeks	
Baseline	endoscopy,	sample	collection	&	assessments	
Screening	&	enrolment	
Randomisation	
AA	/	MM	 Placebo	/	MM	 AA	/	Placebo	 Placebo	/	Placebo	
End	of	study	endoscopy,	sample	collection	&	assessments	
Analysis	
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Visit	number	 1	 2	 3	 4	 5	 6	 7	
Visit	type	 Screening	/	
Enrolment	
Pre-suppl.	
assessments	
4	week	visit	 8	week	visit	 12	week	
visit	
Post-suppl.	
assessments	
End	of	study	
visit	
Week	 -4	to	0	 0	 4	 8	 12	 16-19	 16-20	
History	&	physical	
examination	
X       
HIV	test	 X       
Stool	culture	 X       
CLE	&	duodenal	biopsies	  X    X  
Blood,	urine,	saliva,	
stool	samples	
 X    X  
Body	composition	&	
anthropometrics	
 X    X  
Compliance	&	AE	
monitoring	
  X X X  X 
Supplement	
administration	
 X X X X   
Table	2.1.	Assessment	and	visit	schedule.	CLE,	confocal	laser	endomicroscopy;	AE,	adverse	event.		
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2.5 Randomisation	and	blinding	procedures	
Each	amino	acid	/	matched	placebo	sachet	and	each	micronutrient	/	matched	placebo	pillbox	was	labelled	with	one	of	four	alphanumeric	characters	(A,	B,	C,	D	for	amino	acid	/	placebo;	1,	2,	3,	4	for	micronutrient	/	placebo).	Two	numbers	and	two	letters	were	randomly	assigned	by	the	manufacturer	to	active	supplement,	with	the	other	two	therefore	representing	placebo.	The	supplements	were	then	labelled	accordingly	by	the	manufacturer,	and	the	allocation	code	supplied	to	the	study	statistician.	The	code	was	known	to	the	manufacturer	and	to	the	study	statistician,	and	was	only	revealed	to	the	investigators	once	the	databases	had	been	locked.	After	completing	enrolment	and	baseline	assessments,	participants	were	randomly	allocated	to	one	of	the	16	possible	groups	(4	possible	AA	allocations	×	4	possible	MM	allocations)	in	blocks	of	16	using	a	validated	online	randomisation	service	(www.sealedenvelope.com;	accessed	10th	September	2015).	Participants	were	therefore	allocated	to	each	of	the	four	study	arms	in	a	1:1:1:1	ratio.		
2.6 Study	intervention	
2.6.1 Design	of	supplements	
2.6.1.1 Amino	acid	supplement	and	placebo	
Considerations	and	choice	of	amino	acids	
L-Glutamine,	L-Leucine	and	L-Tryptophan	were	selected	for	supplementation.	Amino	acid	supplementation	in	EE	is	an	attractive	therapeutic	target	due	to	its	potential	effects	on	epithelial	and	lymphocyte	MTORC1	signalling.	Amino	acids,	particularly	the	BCAA	L-Leucine	and	other	EAA	including	L-Tryptophan	appear	to	be	the	most	effective	activators	of	MTORC1	(Cobbold	et	al.,	2009)	and	therefore	are	of	particular	interest	for	supplementation.	L-Leucine	is	a	particularly	effective	MTORC1	agonist	(Cobbold	et	al.,	2009).	
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L-Tryptophan	is	a	precursor	of	niacin	(vitamin	B3).	Niacin	deficiencies	result	in	pellagra	(‘dermatitis,	diarrhoea,	dementia’)	which	is	frequently	observed	in	imporverished	populations,	and	which	causes	intestinal	inflammation	via	MTORC1	signalling	in	a	rodent	model	(Hashimoto	et	al.,	2012).	
L-Tryptophan	is	partially	metabolised	by	the	inducible	host	enzyme	indoleamine	2,3-dioxygenase	(IDO)	to	produce	kynurenines,	which	have	anti-inflammatory	effects	and	promote	Treg	differentiation	(McGaha	et	al.,	2012;	Murray,	2016;	Yan	et	al.,	2010).	This	pathway	also	results	in	L-Tryptophan	deprivation	and	thus	inhibition	of	MTORC1	(Metz	et	al.,	2012).	These	host	pathways	may	be	subverted	by	microbial	L-Tryptophan	uptake	(resulting	in	further	host	L-Tryptophan	depletion	and	diversion	away	from	host	kynurenine	production)	and	metabolism	(resulting	in	pro-	or	anti-inflammatory	metabolites	which	may	include	kynurenines)	(Cervenka	et	al.,	2017).	In	humans,	low	levels	of	L-Tryptophan	and	high	levels	of	kynurenines	are	correlated	with	IBD	activity	(Nikolaus	et	al.,	2017).	In	stunted	children	with	EE,	plasma	L-Tryptophan	levels	are	correlated	with	growth,	and	declines	with	age	(Kosek	et	al.,	2016).	Depending	on	the	population	studied,	the	kynurenine	to	tryptophan	ratio	(KTR,	with	high	ratios	indicative	of	high	IDO	activity)	is	moderately	inversely	correlated	to	growth:	a	high	KTR	and	therefore	greater	degree	L-Tryptophan	shunting	is	associated	with	greater	stunting	(Kosek	et	al.,	2016),	suggesting	that	L-Tryptophan	supplementation	may	be	relevant.	
L-Glutamine	activates	MTORC1	via	at	least	two	amino	acid	sensing	mechanisms,	and	has	synergistic	effects	when	co-administered	with	EAAs	(Jewell	et	al.,	2015).	L-Glutamine	is	also	the	preferential	fuel	for	enterocytes	(Rhoads	and	Wu,	2009;	Windmueller	and	Spaeth,	1974).	Studies	of	L-Glutamine	supplementation	in	EE	have	not	been	conducted	in	adults,	and	have	shown	conflicting	results	in	children	(Lima	et	al.,	2005;	Williams	et	al.,	2007).		
Amino	acid	supplement	dosage	Supplementation	with	the	recommended	nutritional	intake	(RNI)	of	L-Tryptophan	and	L-Leucine	for	a	70kg	adult	was	considered	to	be	an	adequate	dose.	The	RNI	for	
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L-Tryptophan	is	4mg/kg/day	and	the	RNI	for	L-Leucine	is	39mg/kg/day	(Joint	WHO/FAO/UNU	Expert	Consultation,	2007).	The	supplement	therefore	contained	L-Tryptophan	280mg	and	L-Leucine	2.79g.	
L-Glutamine	is	a	non-essential	amino	acid	and	therefore	does	not	have	RNI	values;	however	previous	enteral	L-Glutamine	trials	in	EE	or	HIV	enteropathy	have	used	supplements	varying	from	16.2	–	30g/day	or	0.25g/kg/day	(Bushen	et	al.,	2004;	Leite	et	al.,	2013;	Lima	et	al.,	2005;	Williams	et	al.,	2007),	and	enteral	L-Glutamine	supplementation	trials	in	critical	care	have	used	doses	up	to	0.5g/kg/day	(van	Zanten	et	al.,	2015).	A	dose	at	the	higher	end	of	those	previously	trialled	was	therefore	selected	(30g/day,	or	approximately	0.42g/kg/day).	The	active	supplement	contained	approximately	the	L-Tryptophan	and	L-Leucine	content	equivalent	of	150g	of	beef	(US	Department	of	Agriculture,	2018).	The	dosages	of	all	three	amino	acids	are	believed	to	be	safe	in	long	term	use	(Joint	WHO/FAO/UNU	Expert	Consultation,	2007;	Shao	and	Hathcock,	2008).		
Choice	of	placebo	In	order	to	avoid	the	possible	confounding	effect	of	an	isonitrogenous	placebo	(used	in	previous	L-Glutamine	supplementation	trials	in	EE	(Lima	et	al.,	2005;	Williams	et	al.,	2007))	on	MTORC1	activity,	an	isocaloric	placebo	was	used.	A	perfectly	taste	matched	placebo	was	not	possible;	however	the	slight	bitter	taste	of	L-Tryptophan	was	matched	with	the	addition	of	a	bitterant	(Sodium	hydrogen	sulphite,	E222)	in	the	placebo.		
Composition	and	presentation	The	final	composition	of	the	amino	acid	supplement	and	placebo	is	given	in	Table	2.2.	Both	supplements	were	custom	manufactured	by	Glanbia	Nutritionals	Deutschland	GmbH,	Orsingen-Nenzingen,	Germany.	The	amino	acid	supplement	and	matched	placebo	were	both	colourless,	odourless	fine	white	powders,	with	a	
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mildly	bitter	taste.	Active	and	placebo	supplements	were	distributed	in	identical	white	foil	packaging,	printed	with	one	of	the	four	supplement	codes.		
	 Active	 Placebo	
L-Glutamine	 29.9g	 –	
L-Tryptophan	 0.28g	 –	
L-Leucine	 2.79g	 –	
Maltodextrin	 –	 32.9g	
Sodium	hydrogen	
sulphite	(E222)	
–	 0.07g	
Total	 33g	 33g	
Table	2.2.	Amino	acid	and	matched	placebo	composition.		
2.6.1.2 Multiple	micronutrient	supplement	and	placebo	
Considerations	Individuals	living	in	impoverished	populations	tend	to	have	multiple	micronutrient	deficiencies,	including	our	study	population	in	Zambia	(Gibson	et	al.,	2011;	Kelly	et	al.,	2008).	Because	it	is	not	practical	to	assess	the	effects	of	every	micronutrient	individually,	micronutrient	interventional	trials	tend	to	supplement	with	multiple	micronutrients.	Furthermore,	multiple	micronutrient	supplementation	is	seen	by	many	nutritionists	as	preferable	to	single	nutrient	supplementation	as	it	more	closely	approximates	a	balanced	intake.	Given	the	high	prevalence	of	chronic	deficiencies,	high	dose	supplementation	is	preferable,	both	to	replenish	depleted	stores	and	to	maintain	adequate	physiological	levels.	Furthermore,	previous	work	in	this	study	population	demonstrated	that	lower	doses	did	not	reliably	increase	the	concentrations	of	the	micronutrients	in	blood	(Kelly	et	al.,	2008),	possibly	reflecting	the	very	malabsorptive	problem	which	we	are	trying	to	overcome.	
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Although	micronutrient	supplementation	is	safe,	iron	(due	to	the	risk	of	infectious	complications	(Sazawal	et	al.,	2006))	and	copper	(due	to	theoretical	concern	of	long-term	toxicity)	supplementation	must	be	limited.		
Available	formulations	A	high	dose	multiple	micronutrient	supplement	was	therefore	selected.	Many	commercially	available	micronutrient	supplements	are	available.	The	Immunace	Original	®	supplement	(manufactured	and	donated	by	Vitabiotics	Ltd.,	London,	UK)	was	selected.	This	has	low	levels	of	iron	and	copper,	and	the	retinoid	doses	in	the	supplement	(5000iu)	are	known	to	be	safe	even	in	pregnancy	(Rothman	et	al.,	1995;	WHO,	2004).	Furthermore,	no	adverse	events	were	recorded	with	this	supplement	in	a	previous	study	in	this	population	(Louis-Auguste	et	al.,	2014).		
Placebo	An	indistinguishable	placebo	was	manufactured	and	donated	by	Vitabiotics	Ltd.,	London,	UK,	consisting	of	only	the	excipients	present	in	the	active	supplement.		
Composition	and	presentation	The	final	composition	of	the	micronutrient	supplement	and	placebo	is	given	in	Table	2.3.	The	micronutrient	supplement	and	placebo	were	indistinguishable	tablets,	and	were	packaged	in	identical	plastic	light-proof	bottles	of	60	tablets,	labelled	with	one	of	the	four	supplement	codes.			 	
	 86	
	
Average	dose	
per	tablet	
Total	daily	
dose	
EC	RDA	 Multiples	of	
EC	RDA	per	
daily	dose	
Vitamin	A	RE	(µg)	 800	 1600	 800	 2	
Vitamin	D3	(µg)	 10	 20	 5	 4	
Vitamin	E	α-TE	(mg)	 40	 80	 12	 6.66	
Vitamin	K	(μg)	 70	 140	 75	 1.86	
Vitamin	C	(mg)	 150	 300	 80	 3.76	
Thiamin	(mg)	 18	 36	 1.1	 32.72	
Riboflavin	(mg)	 6	 12	 1.4	 8.58	
Niacin	NE	(mg)	 27	 54	 16	 3.38	
Vitamin	B6	(mg)	 10	 20	 1.4	 14.28	
Folic	acid	(μg)	 400	 800	 200	 4	
Vitamin	B12	(μg)	 14	 28	 2.5	 11.2	
Pantothenic	acid	(mg)	 20	 40	 6	 6.66	
Iron	(mg)	 8	 16	 14	 1.14	
Magnesium	(mg)	 60	 120	 375	 0.32	
Zinc	(mg)	 15	 30	 10	 3	
Iodine	(μg)	 200	 400	 150	 2.66	
Copper	(mg)	 500	 1000	 1	 1	
Manganese	(mg)	 4	 8	 2	 4	
Selenium	(μg)	 180	 360	 55	 6.54	
Chromium	(μg)	 100	 200	 40	 5	
L-Cystine	(mg)	 40	 80	 N/A	 N/A	
L-Carnitine	(mg)	 30	 60	 N/A	 N/A	
Citrus	Bioflavonoids	(mg)	 30	 60	 N/A	 N/A	
Excipients	 Microcrystalline	cellulose;	hydroxypropylmethylcellulose;	ethyl	cellulose;	propylene	glycol;	purified	talc;	titanium	dioxide;	iron	oxides;	glucose	syrup;	purified	talc;	magnesium	stearate;	silicon	dioxide;	polyvinylpolypyrrolidone;	acacia;	sucrose;	starch;	tri-calcium	phosphate;	dicalcium	phosphate;	medium	chain	tri-glycerides;	colloidal	silica;	maltodextrin;	butylated	hydroxyanisole	
Table	2.3.	Multiple	micronutrient	supplement	composition.	EC	RDA,	European	Community	
Recommended	Daily	Allowance	(European	Union,	2008);	RE,	retinol	equivalents;	α-TE,	alpha-
tocopherol	equivalents;	NE,	niacin	equivalents.	The	micronutrient	placebo	contained	only	the	
excipients	listed	above.		 	
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2.6.2 Trial	arms	
Participants	were	randomised	to	receive	multiple	micronutrients	or	placebo	and	amino	acids	or	placebo.	The	supplementation	period	was	16	weeks	(112	days).	Participants	were	instructed	to	take	both	supplements	with	their	main	meal	every	day,	at	any	time	of	day,	starting	the	day	after	the	baseline	endoscopy.	
• MM	/	placebo	arm:	two	Immunace	®	Original	capsules	plus	one	“amino	acid”	placebo	sachet,	taken	daily.	
• AA	/	placebo	arm:	amino	supplement	plus	two	“micronutrient”	placebo	capsules,	taken	daily.	
• MM	+	AA	arm:	two	Immunace	®	Original	capsules	and	one	amino	acid	sachet,	taken	daily.	
• Double	placebo	arm:	two	“micronutrient”	placebo	capsules	and	one	“amino	acid”	placebo	sachet,	taken	daily.		
2.6.3 Compliance	monitoring	
Participants	were	reviewed	every	four	weeks	by	one	of	the	research	team,	either	at	home	or	in	the	research	clinic.	Compliance	was	assessed	by	supplement	count.		
2.7 Endpoints	
All	outcomes	were	assessed	by	HIV	status.	The	following	trial	primary	and	secondary	outcomes	in	addition	to	a	number	of	other	exploratory	analyses	will	be	reported	here.		 	
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2.7.1 Primary	outcomes	
(i) Change	in	small	intestinal	histology	as	assessed	by	morphometry	according	to	treatment	allocation.	
(ii) Change	in	small	intestinal	barrier	dysfunction	as	assessed	by	confocal	laser	endomicroscopy	according	to	treatment	allocation.	
(iii)Change	in	lamina	propria	CD4+	T	cell	MTORC1	signalling	according	to	treatment	allocation.		
2.7.2 Secondary	outcomes	
(i) Change	in	plasma	markers	of	microbial	translocation	and	immune	activation	(sCD14,	CRP,	LPS)	according	to	treatment	allocation.	
(ii) Change	in	metabonomic	profile	according	to	treatment	allocation.	
(iii)Change	in	anthropometry	and	body	composition	according	to	treatment	allocation.		
2.7.3 Other	exploratory	analyses	
(i) Effect	of	supplementation	on	lamina	propria	CD4+	MTORC1	signalling	and	TBET	transcription.	
(ii) Characteristics	of	the	lamina	propria	immune	compartment.	
(iii)Effect	of	supplementation	on	plasma	Glucagon-like	peptide	2	levels.		
2.8 Statistical	considerations	
2.8.1 Sample	size	and	power	calculation	
The	study	followed	a	2×2	factorial	design	and	was	powered	to	demonstrate	the	superiority	of	MM	or	AA	over	placebo	in	HIV	negative	participants,	based	on	the	findings	of	preliminary	work	which	showed	a	potential	benefit	of	MM	supplementation	in	HIV	negative	individuals	(Louis-Auguste	et	al.,	2014).	A	15%	
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difference	in	morphometry	was	expected	to	be	associated	with	a	similar	degree	of	change	in	intestinal	permeability,	bacterial	translocation	and	metabonomic	profile.	Changes	of	this	magnitude	were	also	expected	to	result	in	clinically	meaningful	differences	in	intestinal	and	immune	function.	One	of	the	primary	endpoints	was	therefore	change	in	morphometry	(villous	height),	and	power	calculations	were	based	on	morphometric	data	from	a	previous	study	of	adults	with	enteropathy	in	Misisi	(Louis-Auguste	et	al.,	2014).	These	data	were	also	similar	to	a	previously	published	Misisi	morphometric	data	(Kelly	et	al.,	2004).	Sample	size	calculations	were	powered	for	main	effects	and	assumed	no	interaction	between	AA	and	MM	effects.		To	detect	a	difference	of	15%	between	an	intervention	and	the	corresponding	placebo	required	56	HIV	negative	participants	–	28	participants	given	the	supplement	and	28	given	the	corresponding	placebo	(expected	difference	in	villous	height	30µm;	standard	deviation	40µm;	power	0.8;	2-sided	α	0.05).	Therefore	14	participants	per	intervention	arm	were	required.	Allowing	for	a	20%	dropout	rate	and	30%	HIV	positive	rate	gave	a	total	of	100	participants	to	be	recruited.		
2.8.2 Statistical	analysis	
As	the	primary	outcomes	were	pathophysiological	parameters	in	participants	completing	the	study	intervention,	the	primary	analysis	was	per-protocol.	Due	to	relatively	small	sample	sizes,	non-parametric	tests	were	preferred.	Unless	otherwise	stated,	values	are	given	as	median	and	interquartile	range,	the	Mann-Whitney	U	test	was	used	for	independent	samples,	the	Wilcoxon	signed-rank	was	used	for	paired	samples,	and	Spearman’s	rho	was	used	for	correlations.	Parametric	tests	were	used	for	some	of	the	morphometry	data,	where	the	Shapiro-Wilk	test	confirmed	normality.	Univariate	2-way	ANOVA	was	used	to	examine	for	evidence	of	interaction	between	the	supplementation	arms,	and	data	were	examined	for	simple	effects	where	an	interaction	was	suggested.		
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Multivariate	statistical	modelling	techniques	were	used	to	analyse	metabonomic	profiles,	and	were	performed	by	Dr	Jonathan	Swann	and	Dr	Jordi	Mayneris,	Department	of	Surgery	and	Cancer,	Imperial	College	London.		
	
2.9 Data	collection	
Clinical,	demographic	and	endoscopic	data	was	recorded	on	paper	CRFs	by	a	member	of	the	study	team	at	each	study	visit	/	procedure.	Study	data	were	double	entered	by	trained	personnel	and	managed	using	REDCap	electronic	data	capture	tools	(Harris	et	al.,	2009)	hosted	at	Queen	Mary	University	of	London.	REDCap	(Research	Electronic	Data	Capture)	is	a	secure,	web-based	application	designed	to	support	data	capture	for	research	studies,	providing:	1)	an	intuitive	interface	for	validated	data	entry;	2)	audit	trails	for	tracking	data	manipulation	and	export	procedures;	3)	automated	export	procedures	for	seamless	data	downloads	to	common	statistical	packages;	and	4)	procedures	for	importing	data	from	external	sources.	A	data	check	was	performed	at	the	end	of	the	study	for	missing	or	implausible	values.	The	database	was	locked	and	unblinded	by	the	study	statistician	once	the	investigators	were	satisfied	with	the	quality	and	integrity	of	the	data.		
2.9.1 Recording	of	adverse	events	
AEs	and	SAEs	were	recorded	on	appropriate	case	report	forms	throughout	the	study,	and	the	severity	of	each	adverse	event	was	graded.	The	duration	of	the	adverse	event	and	postulated	relationship	to	the	study	drug	was	also	be	recorded.	If	the	AE	was	not	defined	as	serious,	the	AE	was	recorded	in	the	study	file	and	the	participant	was	followed	up	by	the	research	team.	The	AE	was	documented	in	the	participants’	medical	notes	(where	appropriate)	and	the	CRF.	SAE	reporting	was	conducted	in	accordance	with	the	Sponsor's	and	UNZABREC's	requirements.	
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2.10 Regulatory	aspects	
2.10.1 Ethical	approval	
The	study	was	carried	out	in	accordance	with	the	ethical	principles	in	the	Research	Governance	Framework	for	Health	and	Social	Care,	Second	Edition,	2005	and	its	subsequent	amendments	as	applicable	and	applicable	legal	and	regulatory	requirements.	The	study	team	followed	the	tripartite	harmonised	ICH	guideline	for	good	clinical	practice	E6(R1)	1996	with	post-step	4	corrections.	The	University	of	Zambia	Biomedical	Research	Ethics	Committee	(UNZABREC;	ref.	007-11-14)	had	statutory	responsibility	for	overseeing	study	ethics.	UNZABREC	approved	the	final	study	protocol	and	all	amendments,	the	case	report	forms,	patient	information	leaflets,	and	consent	forms.	A	further	favourable	non-binding	opinion	was	obtained	from	Queen	Mary	University	of	London	Ethics	of	Research	Committee	(QMERC;	ref.	QMERC2014/77).		
2.10.2 Sponsorship	
Study	sponsorship	was	provided	by	Queen	Mary	University	of	London	(ReDA	010299).		
2.10.3 Regulatory	approvals:	Zambia	
The	legislation	regulating	human	biomedical	research	in	Zambia	is	enacted	through	the	Health	Research	Act	(2013).	The	following	required	approvals	were	obtained:	1. Zambian	Medicines	Regulatory	Authority	(ZAMRA;	ref.	CT054)	2. National	Health	Research	Authority	(Zambia;	ref.	MH/101/23/10/1)	3. Material	transfer	agreement	
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2.10.4 Regulatory	approvals:	UK	
The	Medicines	and	Healthcare	Products	Regulatory	Authority	(MHRA)	provided	an	opinion	that	the	trial	was	regarded	as	‘non-CTIMP’	(Clinical	Trial	of	an	Investigational	Medicinal	Product)	for	the	purposes	of	the	Sponsor.	Storage	of	human	specimens	in	the	UK	was	approved	by	the	Barts	Health	Human	Tissue	Resource	Centre	on	behalf	of	the	Human	Tissue	Authority,	in	accordance	with	the	Human	Tissue	Act	2004.		
2.10.5 Trial	registration	
The	trial	was	registered	with	the	Pan-African	Clinical	Trials	Registry	(http://www.pactr.org/),	registration	number	PACTR201505001104412.		
2.11 Specific	ethical	considerations	
2.11.1 Consent	
The	study	population	has	high	levels	of	illiteracy	and	low	levels	of	formal	education.	The	3-stage	system	of	consent	which	was	used	(section	2.3,	p.	77)	which	permits	valid	informed	consent.	This	process	has	evolved	over	many	years	and	has	been	tailored	for	use	in	this	population.	Recent	qualitative	research	in	this	community	has	also	suggested	ways	of	improving	the	informed	consent	process	further	which	were	incorporated	into	this	study,	such	as	offering	guided	visits	to	the	research	facilities	(Zulu	et	al.,	2014).		
2.11.2 Supplements	
The	benefits	of	these	therapies	in	EE	are	potentially	great	but	currently	unknown,	which	justified	their	use	in	this	study.	A	commercially	available	high-dose	multiple	micronutrient	supplement	was	used	which	was	well	tolerated	in	a	previous	study	
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in	this	population	without	any	serious	adverse	events	(Louis-Auguste	et	al.,	2014).	The	micronutrient	supplement	and	the	amino	acid	supplement	are	believed	to	be	safe	even	in	long	term	administration.		
2.11.3 Endoscopies	
Participants	underwent	two	diagnostic	endoscopies	for	research	purposes	only.	Endoscopy	in	this	population	sometimes	reveals	potentially	serious	but	treatable	pathology	(such	as	peptic	ulcers	or	varices)	which	would	otherwise	have	gone	undiagnosed,	and	therefore	may	provide	a	direct	benefit.	Abnormal	pathology	identified	at	endoscopy	was	investigated	and	managed	and	/	or	referred	on	appropriately	and	free	of	charge	for	the	duration	of	the	study.	The	risk	to	participants	from	the	endoscopy	is	extremely	low,	and	was	performed	under	conscious	sedation	to	minimise	discomfort.		
2.11.4 HIV	testing	
HIV	infection	critically	affects	the	mucosal	immune	compartment.	All	participants	were	therefore	required	to	consent	to	HIV	testing	to	enrol	in	the	study,	and	a	number	of	participants	were	newly	identified	with	this	disease.	Effective	anti-retroviral	treatment	is	now	freely	available	in	Zambia,	and	early	diagnosis	is	therefore	beneficial	from	both	the	individual	and	population	perspective.	Consenting	for	HIV	testing	and	communication	of	results	was	performed	by	an	experienced	and	fully	trained	team	of	research	staff	and	counsellors.	HIV	counselling	and	testing	has	been	performed	by	this	team	both	as	part	of	standard	medical	care	in	the	Misisi	clinic	and	as	part	of	the	routine	research	process	for	several	years.	HIV	test	results	were	given	in	person	and	in	confidence	at	the	community	research	clinic.	With	their	consent,	newly	diagnosed	patients	were	referred	on	to	HIV	specialists	for	further	investigation	and	management	including	anti-retroviral	
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therapy,	in	accordance	with	WHO	/	Government	of	Zambia	Ministry	of	Health	guidelines	and	procedures	(Zambia	Ministry	of	Health,	2014).		
2.11.5 Compensation	for	participation	
As	in	our	previous	Misisi	studies,	participants	and	their	immediate	families	were	offered	healthcare	free	of	charge	during	working	hours	based	at	the	research	clinic	in	Misisi	for	the	duration	of	the	study.	Medication,	diagnostic	tests,	and	costs	related	to	inpatient	assessment	/	treatment	during	this	time,	regardless	of	cause,	were	also	provided	free	of	charge	if	required.	Misisi	participants	were	compensated	80	ZMW	(approx.	8	GBP	or	12	USD	in	2015)	for	each	of	the	hospital	visits	required	for	endoscopy	and	sample	collection,	which	is	an	appropriate	local	level	of	reimbursement.	Transport	to	/	from	the	endoscopy	unit	and	lunch	was	provided	free	of	charge.		
2.11.6 Local	/	cultural	issues	
The	research	team	has	been	conducting	clinical	research	in	this	population	cohort	for	over	twenty	years.	This	has	only	been	possible	through	establishing	an	excellent	relationship	with	the	Misisi	community	at	the	research	clinic,	and	with	experienced	and	dedicated	local	staff.		Qualitative	work	has	shown	that	previous	participants'	experience	of	being	involved	in	research	is	positive,	that	the	community	trusts	the	study	team,	and	that	they	would	consider	being	involved	in	further	research	projects	(Zulu	et	al.,	2014).	It	has	highlighted	that	major	reasons	for	volunteering	include	possible	future	medical	benefits	to	the	community	arising	from	the	research	and	access	to	healthcare.	The	major	reasons	for	not	wanting	to	participate	have	been	concerns	/	misconceptions	regarding	the	amount,	handling,	storage	and	use	of	samples	taken.	Peer	advice	not	to	participate	is	usually	based	on	these	misconceptions.	Importantly,	participating	in	a	laboratory	visit	addressed	their	concerns	and	improved	volunteers’	perceptions	(Zulu	et	al.,	2014).	
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2.11.7 Supplement	sharing	
Supplement	sharing	is	a	well	documented	issue	in	interventional	trials	in	the	developing	world.	In	order	to	limit	this,	during	the	focus	group	meetings,	face-to-face	consultations,	and	subsequent	study	visits	it	was	emphasised	to	participants	that:	
• the	supplement	was	of	unknown	benefit	
• there	was	an	equal	chance	of	receiving	inactive	placebo	
• the	best	chance	of	benefit	was	by	taking	the	full	supplement	dose	as	prescribed	
• the	safety	of	the	supplements	has	not	been	assessed	in	children	
• the	supplements	were	designed	for	adult	use	only	
• each	participant	had	been	individually	assessed	to	ensure	that	supplementation	was	suitable	for	him	/	her	
• the	supplements	were	not	for	sharing		
2.11.8 Use	of	a	placebo	arm	
Because	there	are	currently	very	limited	data	on	the	effects	of	micronutrient	or	amino	acid	supplementation	in	EE,	it	was	ethical	to	have	a	group	given	placebo	treatments	for	several	weeks	as	the	condition	of	equipoise	was	fully	met.	Furthermore,	participants	receiving	placebo	were	not	disadvantaged	by	being	involved	in	the	trial.	
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3 	
CHAPTER	3	
METHODS	
	
3.1 Overview	of	available	techniques	for	studying	the	
intestinal	barrier	in	environmental	enteropathy	
3.1.1 Light	microscopy	and	morphometry	
The	simplest	technique	for	studying	the	epithelial	barrier	is	by	light	microscopy	of	endoscopic	intestinal	biopsies.	In	particular,	well	orientated	endoscopic	biopsy	sections	can	be	used	to	measure	objectively	a	variety	of	morphometric	parameters.	These	objective	two	dimensional	measurements	provide	an	assessment	of	three	dimensional	features	including	villous	surface	area.		
3.1.2 Confocal	laser	endomicroscopy	
Confocal	laser	endomicroscopy	(CLE)	is	a	relatively	new	endoscopic	technique	which	allows	in	vivo	confocal	microscopic	images	of	the	intestinal	mucosa	to	be	obtained	at	the	time	of	endoscopy,	using	intravenous	fluorescein	as	a	fluorescent	contrast	agent.	Individual	cells	and	microscopic	defects	in	the	epithelium	can	be	readily	distinguished,	as	well	as	goblet	cells	and	IEL.	Structures	including	subepithelial	capillary	networks	can	also	be	identified.		
3.1.3 Immunohistochemistry	
Commercially	available	antibodies	to	various	tight	junction	proteins	and	different	epithelial	cell	types	exist,	and	can	be	used	to	visualise	cellular	distribution,	protein	expression	and	subcellular	localisation	of	these	proteins	using	standard	immunohistochemistry	techniques.	
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3.1.4 Advanced	microscopy	
Scanning	and	transmission	electron	microscopy	has	been	used	to	demonstrate	ultrastructural	detail	of	the	intestinal	barrier	including	by	using	endoscopic	biopsies,	but	has	not	previously	been	described	in	EE.		
3.1.5 Urinary	sugar	recovery	
These	tests	provide	a	safe	and	non-invasive	measurement	of	intestinal	permeability	and	absorptive	function,	and	as	such	are	suited	to	studies	of	enteropathy	in	children	in	particular.	Sugar	tests	have	therefore	become	widely	used	in	studies	of	enteropathy.	Studies	of	adults	and	children	with	EE	typically	show	reduced	urinary	recovery	of	absorbable	sugars	such	as	xylose	(indicating	impaired	absorptive	capacity)	and	increased	urinary	levels	of	inabsorbable	sugars	such	as	lactulose	(indicating	increased	intestinal	permeability).	The	assay	involves	administering	a	solution	containing	known	quantities	of	absorbed	and	non-absorbed	sugars.	All	urine	over	the	following	3-5	hours	is	collected	and	the	percentage	of	sugar	excreted	is	calculated	from	the	known	urinary	volumes	and	urinary	sugar	concentrations.		Results	are	usually	expressed	as	the	ratio	of	non-absorbable-to-absorbable	urinary	recovery	percentage	(such	as	lactulose	to	xylose).	Normally,	this	ratio	will	be	low;	conversely	in	the	highly	enteropathic	bowel,	significant	amounts	of	non-absorbable	sugars	will	be	taken	up	through	the	permeable	gut	barrier,	and	reduced	amount	of	absorbable	sugars	will	be	absorbed	due	to	a	reduced	absorptive	surface	area.		
3.1.6 Other	biomarkers	of	increased	intestinal	permeability	
Non-excreted	plasma	proteins	are	normally	excluded	from	the	intestinal	lumen,	but	may	leak	into	the	gut	lumen	and	become	detectable	when	there	is	pathological	permeability.	Of	these,	α1-antitrypsin	levels	(α1AT)	ELISA	is	well	established.	
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3.1.7 Other	absorption	studies	
Small	intestinal	selenium	and	zinc	absorption	can	be	assessed	by	measuring	plasma	selenium	and	zinc	levels	before	and	after	administration	of	a	test	solution.	Zinc	and	selenium	physiology	is	complex.	Zinc	is	absorbed	in	the	proximal	small	bowel,	and	secreted	in	the	distal	small	bowel.	Thus	plasma	zinc	levels	reflect	the	balance	between	these	two	processes.		
3.1.8 Plasma	biomarkers	of	microbial	translocation	and	immune	
activation	
Plasma	levels	of	microbial	translocation	and	immune	activation	markers	can	be	quantified	by	ELISA.	Furthermore,	plasma	LPS	levels	can	be	quantitatively	assayed	using	the	Limulus	amoebocyte	assay,	a	colorimetric	technique	which	has	been	widely	taken	up	as	the	standard	for	LPS	detection	in	pharmaceutical	and	biomedical	applications.		
3.1.9 Summary:	choice	of	methods	used	
The	methods	chosen	were	selected	due	to	local	experience,	resource	limitations,	and	logistical	support.	Obtaining	small	intestinal	tissue	is	a	unique	resource	in	this	field,	and	formalin	fixed	/	paraffin	embedded	tissue	has	the	additional	advantage	of	allowing	further	histological	sections	and	staining	to	be	done	in	the	future	if	needed	(including	immunohistochemistry,	which	at	the	time	of	the	study	was	not	readily	available	at	the	research	facility	in	Zambia),	and	of	being	readily	and	safely	exportable	for	analysis	in	other	facilities.	CLE	is	resource	intensive,	but	similarly	the	output	(confocal	images)	can	be	digitally	recorded	and	stored	for	analysis	at	a	future	time.	A	CLE	system	was	recently	installed	in	the	research	unit	in	Zambia	and	was	available	for	use.	
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Measuring	plasma	levels	of	antigens	of	interest	by	ELISA	is	feasible	in	Zambia.	A	biomarker	panel	consisting	of	plasma	LPS,	CRP	and	sCD14	was	chosen	to	provide	assessments	of	bacterial	translocation	and	systemic	immune	activation.	Urinary	sugar	recovery	assays	are	well	established,	but	facilities	for	analysis	do	not	exist	in	Zambia	and	therefore	requires	exporting	of	the	samples	on	dry	ice.	Although	samples	were	taken,	unfortunately	due	to	unforeseen	problems	with	equipment	failure	in	the	UK	it	was	not	possible	to	analyse	urinary	sugar	recovery	in	the	timeframe	of	this	work,	although	this	is	planned	for	the	future.	Measurement	of	plasma	levels	of	micronutrient	metals	using	optical	emission	spectrophotometry	was	planned	using	available	research	facilities	in	Zambia.	Although	samples	were	taken,	it	was	not	possible	to	analyse	these	in	the	timeframe	of	this	work	due	to	equipment	problems,	although	again	this	is	planned	for	the	future.		
3.2 Morphometric	analysis	of	endoscopic	small	intestinal	
biopsies	
3.2.1 Principle	
Small	intestinal	absorptive	area	(a	two	dimensional	surface	covering	a	three	dimensional	structure)	can	be	estimated	in	various	ways.	In	recent	years	a	number	of	potentially	promising	optical	techniques	such	as	optical	coherence	tomography	are	being	developed,	but	as	yet	none	of	these	novel	techniques	are	sufficiently	developed	or	validated	to	be	used	in	vivo	for	examination	of	the	small	bowel.	Direct	assessment	of	small	intestinal	structure	has	traditionally	been	assessed	by	morphometry,	which	measures	various	defined	parameters	in	small	intestinal	architecture.	This	established	technique	has	the	disadvantage	that	it	requires	invasive	tests	(endoscopy)	to	obtain	tissue	samples,	and	is	time	consuming.	Morphometry	allows	the	direct	assessment	of	a	number	of	structural	parameters.	Histological	sections	provide	a	two-dimensional	cross	section	of	a	three-
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dimensional	structure,	such	that	2D	cross-sectional	villus	area	reflects	3D	villus	volume,	and	2D	villus	perimeter	reflects	3D	villus	surface	area.		Enteropathies	generally	demonstrate	variable	and	patchy	microscopic	changes;	however,	previous	work	in	this	study	population	has	demonstrated	that	intra-subject	variance	is	low	(i.e.	the	enteropathic	abnormalities	observed	in	EE	are	stable	when	samples	taken	from	different	parts	of	the	small	bowel	are	compared	in	any	given	individual)	(Kelly	et	al.,	2004).		
3.2.2 Method	
Standard	endoscopic	biopsies	were	taken	from	the	distal	duodenum	at	the	end	of	the	endoscopy	procedure.	2-3	biopsies	were	orientated	on	acetate	strips	under	the	dissecting	microscope	and	fixed	in	4%	formaldehyde	immediately	post-procedure	and	subsequently	paraffin	embedded.	4	μm	sections	were	stained	with	haematoxylin	&	eosin	as	per	standard	protocols.	Embedding,	sectioning,	and	H&E	staining	was	performed	by	Mr	Isaac	Mweemba,	Department	of	Histopathology,	University	Teaching	Hospital,	Zambia.	Stained	sections	were	first	assessed	for	adequacy	of	orientation	by	a	single	investigator	blinded	to	treatment	allocation	(JL-A),	where	both	crypts	and	villi	were	seen	in	longitudinal	section	(Figure	3.1).	Adequately	orientated	sections	were	then	digitised	using	a	NanoZoomer	S210	digital	slide	scanner	(Hamamatsu	Photonics	UK	Ltd,	Welwyn	Garden	City,	UK).	Sections	were	reviewed	using	NDP.view2	v2.3.11	(Hamamatsu	Photonics	KK,	Hamamatsu,	Japan).	Areas	of	sections	suitable	for	analysis	were	exported	as	TIFF	files	at	100X	magnification.		Images	were	analysed	using	a	custom	macro	written	in	ImageJ	(Appendix	4,	p.219).	Briefly,	the	image	was	thresholded	and	the	villus-crypt	interface	identified	visually.	A	villus	bounding	box	was	automatically	drawn,	measuring	maximal	villus	height	(VH)	and	maximal	perpendicular	villus	width	(VW).	Cross	sectional	villus	area	(VA,	as	a	measure	of	villus	compartment	volume)	and	villus	perimeter	(VP,	as	a	measure	of	epithelial	surface	area)	were	automatically	measured.	Lines	measuring	crypt	depth	(CD)	and	muscularis	mucosae	underlying	the	villi	of	interest	were	drawn	by	eye	and	automatically	measured	(Figure	3.2).	Recorded	
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parameters	were	mean	VH,	VW	and	CD,	and	VP	and	VA	per	unit	length	of	muscularis	mucosae	(arbitrarily	set	at	100μm).	
Figure	3.1.	Example	of	adequately	orientated	section.	This	specimen	also	demonstrates	
moderate	enteropathy,	as	evidenced	by	reduced	villous	height	to	crypt	depth	ration	(<1.5:1),	
lymphocytosis,	and	a	fused	villus	on	the	left.	
Figure	3.2.	Example	of	computer-aided	morphometry.	An	automatically	generated	villus	
bounding	box	(to	measure	VH	and	VW)	is	shown	in	green.	VP	was	automatically	measured	
from	thresholded	villi	(outlined	in	red).	Lines	representing	crypt	depth	and	length	of	
underlying	mucosa	were	drawn	by	eye.	 	
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3.3 Confocal	laser	endomicroscopic	assessment	of	small	
intestinal	dysfunction	in	EE	
3.3.1 Introduction	
The	canonical	features	of	EE	include	increased	permeability,	mucosal	inflammation,	and	villous	atrophy.	Confocal	laser	endomicroscopy	(CLE)	is	a	relatively	novel	technique	which	potentially	allows	the	assessment	of	these	features	in	vivo	and	in	real	time.	Although	originally	envisaged	as	an	‘optical	biopsy’	method	for	the	detection	and	assessment	of	neoplasia	in	vivo,	more	recently	a	number	of	investigators	have	used	the	technique	to	assess	non-neoplastic	small	intestinal	dysfunction.	CLE	scoring	systems	have	been	devised	for	inflammatory	disorders	of	the	small	bowel	including	inflammatory	bowel	disease	and	coeliac	disease.	As	many	of	the	pathological	features	of	EE	are	shared	with	these	conditions,	elements	of	these	scoring	systems	may	be	applicable	to	the	study	of	EE.		
3.3.2 CLE	priniciples	
The	principle	of	confocal	microscopy	is	described	in	detail	elsewhere	(Tovey	et	al.,	2006).	Confocal	microscopy	allows	greater	vertical	and	horizontal	spatial	resolution	than	traditional	wide	field	microscopy	including	fluorescence	microscopy.	In	summary,	high	intensity	coherent	light	from	a	laser	source	is	focussed	on	the	desired	focal	plane	through	a	pinhole	aperture.	Emitted	light	from	excited	fluorophores	on	the	target	specimen	passes	back	through	a	pinhole	aperture	which	excludes	out-of-focus	light	arising	from	surrounding	areas	(i.e.	non-confocal	light).	Light	reaching	the	detector	through	this	confocal	aperture	is	therefore	in	sharp	focus,	but	collects	in-focus	light	from	a	single	point	at	a	single	depth.	In	order	to	create	a	2-dimensional	image	of	the	target	sample,	the	focal	point	scans	across	the	target	sample,	allowing	a	2-dimensional	image	to	be	reconstructed	(Figure	3.3).		
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Figure	3.3.	Confocal	microscopy	principle.	Taken	from	Tovey	et	al.,	2006.		In	the	confocal	laser	endomicroscope,	the	scanning	laser	light	source	and	confocal	aperture	are	integrated	into	the	endoscope,	with	2-dimensional	images	reconstructed	in	an	image	processing	unit	in	the	confocal	stack.	The	Pentax	CLE-enabled	gastroscope	(Pentax	EC-3870CLK,	Pentax	Corporation,	Tokyo,	Japan;	Figure	3.4)	combines	a	supra-high	definition	CMOS-based	digital	white	light	gastroscope	with	an	integrated	488nm	laser	and	confocal	detection	system.	The	sensor	detects	fluorescent	light	at	505-585nm.	Maximum	resolution	is	1024×1024	pixels	at	up	to	1.6	frames	per	second,	equivalent	to	a	field	of	view	of	475×475µm,	with	a	maximum	lateral	resolution	of	approximately	0.7µm.	Depth	of	scanning	(Z	axis)	and	imaging	can	be	adjusted	by	the	user	between	0	and	250µm	at	4μm	intervals.	
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Figure	3.4.	The	Pentax	integrated	CLE	system.	A,	distal	end	of	the	Pentax	EC-3870CLK	confocal	
laser	endomicroscope.	B,	an	integrated	laser	produces	coherent	light	at	488nm	which	can	be	
scanned	across	target	tissue	C	at	the	desired	focal	depth.	Emitted	fluorescence	passes	through	
the	integrated	confocal	aperture	in	the	endoscope	tip.	By	scanning	across	target	tissue,	2-
dimensional	images	can	be	reconstructed	in	various	user-controlled	planes	(D).	Taken	from	
Kiesslich	et	al.,	2007.		
3.3.3 Published	scoring	systems	to	assess	the	epithelial	barrier	
and	intestinal	inflammation	using	CLE	
3.3.3.1 Inflammatory	bowel	disease	
Watson	score	(Kiesslich	et	al.,	2012)	This	is	a	prospectively	validated	score	which	successfully	predicted	clinical	relapse	in	inflammatory	bowel	disease,	and	remains	the	only	published	prospectively	validated	scoring	system	of	intestinal	barrier	dysfunction	using	CLE.	It	is	calculated	by	combining	two	assessments	(Table	3.1):		1. Cell	shedding	events	(equivalent	to	epithelial	defects,	either	single	shed	cells	or	microerosions,	defined	as	an	exposed	lamina	propria	with	multiple	shed	cells)	2. Local	barrier	dysfunction,	characterised	luminal	fluorescein	leak	(defined	as	fluorescein	plumes,	or	luminal	fluorescein	rendering	the	lumen	as	bright	or	brighter	than	the	epithelium)	
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Table	3.1.	Watson	score	for	CLE	assessment	of	local	intestinal	barrier	dysfunction.	Taken	from	
Kiesslich	et	al.,	2012.		In	patients	in	clinical	remission,	a	Watson	score	of	II	or	III	is	associated	with	clinical	relapse	at	one	year	(Kiesslich	et	al.,	2012),	and	an	increased	density	of	epithelial	cell	defects	(microerosions)	is	associated	with	an	increased	risk	of	hospitalisation	or	surgery	(Turcotte	et	al.,	2012).	One	of	the	strengths	of	the	Watson	score	is	its	excellent	inter-observer	reproducibility	(Cohen	κ	0.87).		
Crohn’s	disease	endomicroscopic	activity	score	(CDEAS)	(Neumann	et	al.,	2012)	Using	CLE	in	54	patients	with	known	colonic	Crohn’s	disease	with	and	without	endoscopically	active	disease	as	assessed	by	the	Crohn’s	disease	endoscopic	index	of	severity	(Mary	and	Modigliani,	1989),	the	authors	created	a	semi-quantitative	score	which	correlated	with	CRP	(taken	as	a	marker	of	Crohn	disease	activity).	Prospective	validation	has	not	been	undertaken.	Of	the	six	endomicroscopic	features	studied,	microerosions,	hypervascularity	and	lamina	propria	cellular	infiltrates	are	potentially	applicable	to	small	intestinal	pathology.	Interobserver	agreement	for	these	abnormalities	was	κ	0.51	for	microerosions,	κ	0.75	for	vascularity	(intramucosal	fluorescein	leak)	and	κ	0.83	for	cellular	infiltrate.	On	the	other	hand,	colonic	crypt	tortuosity,	crypt	number	and	goblet	cell	number	are	likely	to	be	significantly	different	in	small	bowel	compared	to	colonic	disease.		 	
Grade	of	defect	 Cell	shedding	events	 Local	barrier	dysfunction	
I	(Normal)	 Cell	shedding	confined	to	single	cells	per	shedding	site		 None	
II	(Functional	defect)	 Cell	shedding	confined	to	single	cells	per	shedding	site	 Luminal	fluorescein	leak	or	fluorescein	plumes	
III	(Structural	defect)	 Microerosions	in	any	field	(lamina	propria	is	exposed	to	the	lumen	with	multiple	cells	being	shed	per	site)	
Luminal	fluorescein	leak	or	fluorescein	plumes	
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Terminal	ileal	microerosion	density	in	IBD	(Liu	et	al.,	2011)	The	authors	manually	counted	epithelial	‘gaps’	in	endoscopically	normal	terminal	ileum	in	both	Crohn’s	and	UC	patients,	equivalent	to	pathological	microerosions	rather	than	single	cell	shedding	events.	Gaps	per	thousand	enterocytes	in	side-on	villi	were	manually	counted	to	create	a	measure	of	epithelial	gap	density.	Gap	density	was	significantly	elevated	in	patients	with	IBD	compared	to	normal	controls,	although	this	was	not	related	to	the	presence	/	absence	of	clinical	disease.	Paradoxically,	a	lower	gap	density	was	associated	with	a	higher	risk	of	hospitalisation	in	the	preceding	year,	possibly	reflecting	deeper	remission	following	more	aggressive	treatment	in	this	group	of	patients.	Prospective	validation	is	awaited.	Interobserver	agreement	was	not	assessed.	Gap	(microerosion)	density	is	not	a	satisfactory	measure	of	intestinal	barrier	dysfunction	due	to	the	lack	of	prospective	validity,	lack	of	discriminatory	ability	between	inactive	and	active	disease	(when	there	is	known	to	be	impaired	intestinal	barrier	integrity),	unknown	interobserver	agreement,	as	well	as	being	extremely	time	consuming	to	assess.		
3.3.3.2 Irritable	bowel	syndrome	(IBS)	(Fritscher-Ravens	et	al.,	2014)	These	authors	observed	plumes,	fluorescein	leak,	microerosions,	intraepithelial	lymphocytosis	(>25/100	enterocytes)	and	widening	of	the	intervillous	space	in	response	to	direct	small	intestinal	administration	of	food	antigens	in	a	subset	of	patients	with	suspected	food	intolerance	/	IBS.	Excluding	the	food	antigens	which	provoked	a	positive	endomicroscopic	result	resulted	in	improved	symptom	scores,	compared	to	those	patients	and	controls	in	whom	no	changes	were	observed.		
3.3.3.3 Confocal	coeliac	score	(Leong	et	al.,	2008)	The	authors	describe	an	excellent	correlation	between	endomicroscopic	and	histological	villous	atrophy	and	crypt	hypertrophy	in	patients	with	suspected	/	confirmed	coeliac	disease.	Interobserver	agreement	in	the	endomicroscopic	diagnosis	of	villous	atrophy	and	crypt	hypertrophy	was	good	(κ	0.67	and	1.0	respectively).	Other	markers	of	enteropathy	were	not	assessed.	Although	CLE	was	
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confidently	able	to	diagnose	or	exclude	coeliac	disease,	it	is	not	designed	to	assess	severity	of	disease	and	is	thus	unsuitable	as	an	assessment	tool	in	EE.		
3.3.4 CLE	for	the	assessment	of	EE:	proof	of	concept	
In	summary,	discriminatory	features	of	the	CLE	scoring	systems	described	above	have	included	
• Vascularity	
• Intramucosal	leak	
• Luminal	leak	
• Distortion	
• Epithelial	defects	(particularly	microerosions).	Of	these,	only	epithelial	defects	and	luminal	leak	have	been	shown	to	be	reproducible	and	prognostic.	Intramucosal	leak	is	reproducible	and	may	be	a	marker	of	severity	of	mucosal	inflammation.		Similarly,	in	previous	work	in	this	population	we	demonstrated	that	there	was	strong	interobserver	agreement	for	fluorescein	leakage	(ρ	=	0.94;	P<0.0001)	and	plumes	(ρ	=	0.83;	P<0.0001),	but	weaker	for	epithelial	defects	such	as	single	cell	defects	(ρ	=0.41;	P	=	0.01)	or	micro-erosions	(ρ	=0.46;	P=0.004)	(Kelly	et	al.,	2016).	In	this	study	we	also	observed	that	the	incidence	of	pathological	fluorescein	leak	in	adults	with	environmental	enteropathy	was	extremely	high,	with	most	fields	demonstrating	large	amounts	of	intraluminal	or	intramucosal	fluorescein.	Furthermore,	we	have	demonstrated	that	pathological	leak	observed	with	CLE	is	associated	with	pathological	TJ	protein	expression	(specifically	claudin-4)	(Kelly	et	al.,	2016).		In	this	previous	study,	construction	of	a	‘Z-stack’	by	moving	the	plane	of	focus	and	recording	images	parallel	to	the	mucosa	(Kiesslich	et	al.,	2012)	demonstrated	high	levels	of	fluorescein	leak	at	all	observed	levels,	and	therefore	did	not	demonstrate	enhanced	discriminatory	ability	to	detect	abnormal	endomicroscopic	pathology.	In	other	words,	the	endomicroscopic	defects	were	so	florid	and	universal	that	it	was	possible	to	assess	for	the	presence	of	pathological	leak	in	a	single	plane.		
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A	modified	Watson	score	(including	intramucosal	fluorescein	leakage)	was	therefore	used	for	the	purposes	of	this	study.	The	most	superficial	plane	was	selected	for	assessment.		
3.3.5 CLE	examination	technique	
Participants	arrived	in	the	endoscopy	unit	following	an	overnight	fast	and	were	consented	for	the	procedure.	Participants	were	cannulated	and	positioned	semi-prone	in	the	left	lateral	position	with	pulse	oximetry	monitoring.	Participants	underwent	CLE	under	conscious	sedation	using	pethidine	(25-50mg)	plus	midazolam	(2.5-5mg)	or	diazepam	(2.5-10mg)	intravenously.	A	baseline	white	light	endoscopy	was	performed.	Endoscopic	technique	is	identical	to	standard	upper	GI	endoscopy	(Haycock	et	al.,	2014),	although	the	confocal	endomicroscope	has	reduced	manoeuvrability.	The	stomach	was	aspirated	to	dryness.	Up	to	2ml	of	gastric	secretions	for	pH	measurement	was	aspirated	through	the	biopsy	channel,	which	was	then	flushed	with	100mL	of	air.	The	endoscope	was	advanced	as	far	as	possible	into	the	duodenum,	and	once	in	a	stable	position,	duodenal	secretions	were	aspirated,	taking	care	not	to	damage	the	duodenal	mucosa	by	aspirating.	This	was	followed	by	instillation	of	the	carbohydrate	test	solution	(for	urinary	sugar	recovery	assay	of	intestinal	permeability),	which	was	flushed	through	with	50mL	of	water.	This	also	provided	a	uniform	intraluminal	osmotic	load,	as	luminal	leakage	(and	therefore	observable	fluorescein	fluorescence)	is	influenced	by	the	osmolarity	of	luminal	contents	(Kiesslich	et	al.,	2012).	Laser	settings	were	fixed	for	all	procedures	(gamma	1.74;	gain	0.5;	laser	power	300-400mW).	5-10mL	of	2%	fluorescein	was	then	administered	intravenously.	The	tip	of	the	endoscope	was	manoeuvred	in	a	helical	manner	around	the	duodenal	wall,	from	distal	to	proximal,	for	a	period	of	5	minutes,	recording	300-400	confocal	images,	in	order	to	obtain	a	luminal	survey	of	the	duodenal	mucosa.	Great	care	was	taken	to	avoid	areas	of	scope	trauma	and	any	macroscopically	evident	defects	(e.g.	duodenitis;	erosions;	ulcers).	
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	Recorded	images	were	reviewed	by	an	experienced	single	investigator	(JLA)	for	image	adequacy.	Duplicate	or	near-duplicate	images,	images	with	significant	image	artefact;	and	images	<50%	mucosa	were	discarded	(Figure	3.5).			
Figure	3.5.	Examples	of	inadequate	CLE	images	rejected	for	assessment.	Left,	inadequately	
visualised	mucosa.	Right,	excessive	movement	artefact.			The	remaining	images,	representing	unique	fields,	were	independently	scored	by	two	investigators	(PK	and	JLA).	The	proportion	of	fields	demonstrating	local	barrier	dysfunction	(Watson	score	II	or	III)	or	intramucosal	fluorescein	leak	was	recorded	(Figure	3.6	and	Table	3.1).		
 110 
Figure	3.6.	Use	of	CLE	to	assess	intestinal	barrier	dysfunction.	Examples	of	endomicroscopic	
findings	with	high	inter-observer	agreement	are	shown.	Top	left:	intact	barrier;	no	epithelial	
defects;	no	fluorescein	plumes;	intervillus	space	is	black	(Watson	grade	I).	Top	right:	single	
apoptotic	cell	and	defect	(arrowhead)	with	increased	background	fluorescein	leak	(arrow)	
(Watson	grade	II).	Middle	left:	marked	intraluminal	fluorescein	leak	(Watson	grade	III);	
intramucosal	fluorescein	leakage	is	also	evident	(arrows).	Middle	right:	microerosion	(arrow)	
with	background	fluorescein	leak	(Watson	grade	III).	Bottom	left:	multiple	plumes	and	
microerosions	without	background	fluorescein	leakage	(Watson	grade	II).	Bottom	right:	florid	
luminal	fluorescein	with	multiple	large	microerosions	(Watson	grade	III).	
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	CLE	could	provide	a	three	dimensional	image	of	in	real-time	of	abnormal	enteropathic	small	bowel	mucosa.	CLE	identified	some	of	the	grossly	distorted	architecture	observed	histologically	(Figure	3.7).		
Figure	3.7.	Examples	of	bizarre	enteropathic	mucosa	identified	by	CLE	in	vivo.	Mucosal	bridges	
and	villus	fusion	are	clearly	demonstrated.		
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3.4 Assessing	lamina	propria	T	cell	MTORC1	activity	by	
flow	cytometry	
3.4.1 Principle	
Flow	cytometry	allows	the	identification	and	quantification	of	antigens	of	interest	simultaneously	at	the	resolution	of	single	cells.	Most	commonly	this	is	used	to	immunophenotype	a	population	of	cells,	but	other	common	uses	include	monitoring	cell	signalling	pathways	in	response	to	stimulation	or	inhibition.	For	cellular	analyses,	a	solution	of	cells	is	prepared	with	antibodies	directed	against	antigens	of	interest.	Each	antibody	is	conjugated	directly	or	indirectly	to	a	fluorochrome	with	an	emission	spectrum	which	differs	from	every	other	fluorochrome	being	used.	Cells	then	pass	through	a	laser	array	in	single	file.	Bound	antibody-fluorochromes	on	each	cell	are	excited	by	a	laser	at	an	appropriate	excitation	wavelength	and	emit	light	at	their	known	spectra.	Sensors	detect	this	emitted	light,	with	each	emission	spectrum	corresponding	uniquely	to	one	antigen	of	interest,	so	that	the	intensity	of	emitted	light	which	is	detected	is	proportional	to	the	amount	of	antigen	present	in	each	cell.	In	practice,	however,	fluorochrome	emission	spectra	are	relatively	broad,	and	this	usually	results	in	‘spectral	overlap’	–	that	is,	light	emitted	by	one	fluorochrome	coincides	with	light	emitted	from	another	over	part	of	its	emission	spectrum.		If	unaccounted	for,	this	overlapping	light	emission	will	be	misinterpreted	as	a	positive	signal	from	a	second	fluorochrome,	when	in	fact	it	merely	represents	a	positive	signal	from	the	first.	This	is	corrected	by	compensation.	To	compensate	for	FITC	in	the	PE	channel	in	the	example	above,	a	sample	stained	with	FITC	alone	is	analysed.	The	proportion	of	emitted	light	in	the	grey	overlap	would	be	detected	in	the	PE	channel	(where	there	is	no	true	PE	signal).	This	‘false	positive’	signal	can	be	mathematically	neutralised,	so	that	after	compensation	the	signal	in	the	PE	channel	from	FITC	is	minimised	(Figure	3.8).	This	compensation	can	then	be	applied	to	samples	where	FITC	and	PE	(in	this	case)	are	used	together.		 	
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Figure	3.8.	Principle	of	compensation.	In	the	left	panel,	FITC-conjugated	compensation	beads	
(arrow)	are	incorrectly	detected	in	the	PE	channel	(x	axis)	due	to	spectral	overlap,	resulting	in	
a	false	positive	PE	signal.	After	compensation	(right	panel),	these	FITC-conjugated	beads	no	
longer	appear	positive	in	the	PE	channel	(mathematically,	the	median	fluorescence	intensity	
values	of	FITC	positive	and	negative	populations	in	the	PE	channel	have	been	equalised).		
3.4.2 Specific	considerations	in	the	flow	cytometric	analysis	of	
MTORC1	activity	
The	assessment	of	MTORC1	activity	by	flow	cytometry	in	mucosal	lymphocytes	presents	a	number	of	technical	challenges	in	addition	to	those	required	for	conventional	flow	cytometry.	Directly	conjugated	antibodies	to	phospho-4EBP1	(T36/T45)	–	the	initial	sites	of	phosphorylation	by	activated	MTORC1	(Gingras	et	al.,	1999)	–	are	commercially	available,	and	have	been	used	in	a	small	number	of	published	experiments	using	human	or	murine	PBMCs	or	cultured	cell	lines	(Hoerning	et	al.,	2015;	Syed	Alwi	et	al.,	2010;	Zeng	et	al.,	2013,	2012).	However,	the	assessment	of	MTORC1	activity	in	LPMCs	by	flow	cytometry	has	not	been	reported.		
3.4.2.1 Intracellular	antigen	localisation	MTORC1	and	its	targets	are	intracellular	proteins,	and	thus	require	cell	membrane	permeabilisation	to	become	accessible	to	antibodies.	All	published	and	
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manufacturer’s	protocols	use	methanol	(or	proprietary	methanol-containing	buffers)	as	the	permeabilising	agent,	at	concentrations	varying	from	50%	to	90%.	Methanol	also	has	a	fixative	effect	on	cellular	proteins;	methanol-permeabilised	cells	can	be	stored	at	–20°C	for	several	months.	However,	methanol	is	a	harsh	alcohol	and	has	significant	denaturing	effects.	This	is	particularly	relevant	in	flow	cytometry	where	exposure	of	antigens	to	methanol	can	destroy	the	reactive	epitope,	thus	reducing	the	staining	intensity,	and	therefore	brightness,	of	a	given	antigen.	This	effect	is	epitope-dependent,	and	therefore	some	clones	are	known	to	be	methanol	sensitive	or	insensitive	(for	example,	CD3	clone	UCH-T1	is	relatively	methanol	resistant,	whereas	clone	HIT-3A	is	methanol	sensitive).	The	methanol	sensitivity	of	many	antibody	clones	is	unknown.	On	the	other	hand,	intracellular	antigens	in	particular	may	benefit	from	more	aggressive	permeabilisation	in	order	to	increase	the	amount	of	antigen	available	for	antibody	binding.	In	preliminary	work	using	Ficoll-isolated	human	PBMCs,	permeabilisation	using	methanol	greater	than	50%	resulted	in	marked	loss	of	CD3	(clone	UCH-T1)	signal,	without	improving	phospho-4EBP1	signal	(Figure	3.9).	50%	methanol	was	therefore	selected	as	the	permeabilising	agent	for	the	study.	
Figure	3.9.	Effect	of	methanol	concentration	on	CD3	and	phospho-4EBP1	staining.	Staining	was	
performed	after	permeabilisation	with	50%	(left	panel)	or	70%	(right	panel)	methanol.	 	
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3.4.2.2 Phosphorylation	and	dephosphorylation	kinetics	MTORC1	activity	is	reflected	in	levels	of	phospho-4EBP1.	Phosphorylation	events	in	response	to	a	stimulus	are	in	general	transient	and	relatively	short-lived,	and	can	therefore	be	missed.	In	preliminary	work	using	Ficoll-isolated	human	PBMCs	from	a	healthy	adult	UK	resident,	the	phosphorylation	kinetics	of	4EBP1	in	freshly	isolated	CD3+	lymphocytes	were	studied	(Figure	3.10).	Phosphorylation	levels	did	not	increase	from	baseline	levels	despite	stimulation	with	a	variety	of	nutrient	rich	media,	reflecting	attenuation	and	accommodation	of	the	MTORC1	pathway	in	response	to	a	nutrient	stimulus.		
Figure	3.10.	4EBP1	phosphorylation	kinetics	in	freshly	isolated	CD3+PBMCs	stimulated	with	
DMEM	or	RPMI	media,	with	or	without	foetal	bovine	serum	(FBS).		In	a	second	experiment,	freshly	Ficoll-isolated	PBMCs	from	four	healthy	adult	UK	residents	were	cultured	in	a	nutrient	deplete	medium	(HBSS	with	4mM	glucose).	At	two	hours,	phospho-4EBP1	levels	were	approximately	50%	of	baseline,	and	little	further	dephosphorylation	occurred	up	to	four	hours	(Figure	3.11).	
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Figure	3.11.	Phospho-4EBP1	dephosphorylation	kinetics	in	freshly	isolated	CD3+PBMCs	
cultured	in	HBSS.	Data	from	four	healthy	adult	UK	residents.		Finally,	the	4EBP1	phosphorylation	kinetics	of	CD3+	PBMCs	from	basal	levels	were	assessed	by	stimulating	them	with	nutrient	rich	RPMI	complete	medium	following	a	two	hour	period	of	nutrient	deprivation	in	HBSS	with	4mM	glucose.	This	demonstrated	that	maximal	phosphorylation	occurs	between	one	and	two	hours,	with	near-maximal	phosphorylation	levels	sustained	for	at	least	four	hours	(Figure	3.12).	This	is	in	keeping	with	other	published	in	vitro	data	(Burnett	et	al.,	1998;	Von	Manteuffel	et	al.,	1996).		
Figure	3.12.	4EBP1	phosphorylation	kinetics	in	PBMCs	in	response	to	nutrient	stimulation	
following	two	hour	nutrient	deprivation.	 	
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On	the	basis	of	this,	lamina	propria	lymphocytes	were	deprived	of	nutrients	for	90	minutes	after	isolation	before	being	stimulated	in	nutrient-rich	complete	medium	for	90	minutes.		
3.4.2.3 Low	levels	of	phosphoprotein	expression	Under	normal	conditions,	cellular	kinases	are	constitutively	inactive,	with	kinase	activation	furthermore	being	generally	short	lived.	Protein	dephosphorylation	also	occurs	concurrently.	These	processes	usually	result	in	low	levels	of	phosphorylated	as	compared	to	the	dephosphorylated	proteins.	A	common	notable	exception	is	in	cancer,	where	mutations	commonly	result	in	constitutively	active	kinases	and	relatively	high	levels	of	target	phosphoproteins.	Since	the	magnitude	of	antibody-fluorochrome	signal	is	directly	related	to	the	level	of	target	antigen	present	(in	this	case	phosphoprotein),	phosphoprotein	signals	in	flow	cytometry	tend	to	be	‘dim’.	This	results	in	two	important	technical	considerations:	1. The	antibody	should	be	conjugated	to	the	brightest	fluorophore	possible	(a	phospho-4EBP1	–	PE	conjugate	was	therefore	chosen).	2. Care	should	be	taken	to	ensure	that	spectral	overlap	from	other	colours	in	the	panel	do	not	diminish	the	target	signal	(FITC	was	therefore	avoided).		
3.4.2.4 Determination	of	positivity	Many	antigens	(such	as	CD3	and	CD4	on	lymphocytes)	have	a	bimodal	expression	pattern,	with	very	few	cells	expressing	intermediate	levels.	This	results	in	clearly	defined	positive	and	negative	populations.	However,	many	antigens	are	expressed	at	variable	levels,	meaning	that	it	is	not	immediately	possible	to	divide	a	population	into	positive	and	negative.	In	addition,	phenomena	such	as	autofluorescence	and	non-specific	antibody	binding	mean	that	cells	that	do	not	express	an	antigen	of	interest	may	nonetheless	exhibit	detectable	fluorescence	which	may	be	incorrectly	be	interpreted	as	being	positive	for	the	target	antigen.	Determination	of	what	constitutes	a	‘positive’	for	an	antigen	with	a	non-bimodal	
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distribution	therefore	generally	requires	the	use	of	one	or	more	of	the	following	controls	(Maecker	and	Trotter,	2006).		
Biological	controls.	Particularly	when	assessing	response	to	stimulation,	the	most	relevant	control	is	usually	an	unstimulated/baseline/negative	control	sample,	which	will	simultaneously	control	for	non-specific	antibody	binding	and	fluorescence	spillover.	Any	fluorescence	above	that	observed	in	the	negative	sample	must	be	attributable	to	the	effects	of	stimulation.	A	biological	(unstimulated)	paired	control	for	the	p4eBP1	readout	was	therefore	used.	The	percentage	of	cells	responding	to	a	stimulus	(in	this	case	p4eBP1	positive	cells)	can	be	calculated	by	subtracting	the	unstimulated	/	control	histogram	(in	this	case,	nutrient	starved	cells)	from	the	stimulated	histogram	(in	this	case,	nutrient	stimulated	cells).	A	number	of	mathematical	algorithms	exist,	of	which	the	proprietary	Super-enhanced	DMax	(SED)	method	is	thought	to	be	most	accurate	(Bagwell,	1996).	The	biological	controls	for	phospho-4EBP1	expression	in	the	following	experiments	were	the	nutrient-deprived	lymphocytes.	
	
Isotype	controls.	Isotype	controls	are	non-specific	antibodies	of	the	same	isotype	class	as	the	test	antibody.	Use	of	isotypes	theoretically	allows	determination	of	non-specific	background	staining,	which	must	be	subtracted	from	the	staining	observed	with	the	specific	(target)	antibody,	to	give	the	amount	of	staining	attributable	to	specific	antibody	binding.	Most	isotype	controls	have	only	been	tested	and	validated	with	extracellular	antigens;	intracellular	staining	(following	permeabilisation)	may	be	significantly	greater,	and	in	fact	may	not	be	non-specific.	Furthermore,	to	be	truly	comparable,	the	antibody-fluorochrome	characteristics	of	the	isotype	(e.g.	fluorochrome	:	antibody	ratio)	must	match	the	target	antibody;	perfectly	matched	isotypes	are	rarely	possible.	In	the	following	experiments,	isotype	controls	for	HLA-DR	and	TBET	staining	were	used	as	suggested	and	validated	by	the	manufacturer.	 	
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Fluorescence-minus-one	(FMO)	controls.	In	multi-colour	experiments	with	variable	target	antigen	staining	intensity,	fluorescence	spillover	effects	may	be	complex.	This	can	be	controlled	by	the	use	of	FMOs.	FMOs	allow	the	measurement	of	total	background	fluorescence	in	a	given	channel	when	all	antibodies/fluorochromes	are	included	with	a	sample	except	the	antibody/	fluorochrome	in	that	channel	(i.e.	all	antibodies	minus	one).	Any	measured	fluorescence	in	this	channel	can	then	be	attributed	to	non-specific	background	fluorescence	(including	autofluorescence).	When	the	antibody	of	interest	in	added	(i.e.	the	full	panel),	any	fluorescence	above	this	value	must	be	due	solely	to	the	antibody	of	interest.	FMOs	cannot	provide	any	information	on	non-specific	antibody	staining	(which	is	ususally	provided	by	isotype	controls);	however	it	has	been	argued	that	with	modern,	high	quality	antibodies,	the	majority	of	background	/	non-specific	staining	is	due	to	spillover	effects,	rather	than	non-specific	antibody	binding.		
3.4.2.5 Effect	of	LPMC	isolation	on	phosphostatus	The	time	and	unphysiological	processes	involved	in	isolating	LPMCs	from	biopsy	tissue	(whether	enzymatically	or	by	biopsy	culture)	mean	that	the	isolated	cells	will	not	reflect	in	vivo	phospho-4EBP1	status.	It	is	therefore	more	appropriate	to	measure	the	phosphorylation	response	to	a	stimulus,	on	the	reasonable	assumption	that	the	isolated	cells	(particularly	if	isolation	occurs	soon	after	biopsy)	will	retain	much	of	the	phenotype	and	therefore	the	function	of	their	in	
vivo	counterparts.			
3.4.2.6 Limited	tissue	and	lamina	propria	lymphocyte	availability	LPMCs	were	isolated	from	up	to	four	endoscopic	duodenal	biopsies	per	participant.	In	preparatory	work,	mean	yield	following	fixation	and	methanol	permeabilisation	was	up	to	approximately	10000	lymphocytes	per	biopsy	at	most.	Less	aggressive	permeabilisation	(for	example	for	TBET	staining)	improved	lymphocyte	yield	by	a	factor	of	5-10.	This	relatively	small	number	of	lymphocytes	
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meant	that	examining	phospho-4EBP1	expression	had	to	be	limited	to	common	cell	populations.		
3.4.2.7 Effect	of	methanol	on	fluorochrome-conjugated	antibodies	Many	fluorophores	are	protein-based,	and	are	therefore	susceptible	to	degradation	by	methanol	in	the	permeabilisation	step.	Many	fluorophores	can	therefore	not	be	used	before	a	methanol	permeabilisation	step	(i.e.	in	a	stain-fix-perm	protocol).	Furthermore,	the	amide	linkages	in	tandem	dyes	are	also	susceptible	to	degradation.	This	would	result	in	a	false	positive	signal	in	the	‘donor’	channel	(e.g.	from	APC-Cy7	degrading	to	APC).	A	1-step	fix-perm-stain	protocol	was	utilised,	as	many	of	the	fluorochromes	used	were	methanol	sensitive.		
3.4.2.8 Choice	of	stimulus	for	MTORC1	pathway	Nutrients,	and	amino	acids	in	particular,	are	the	canonical	agonists	of	the	MTORC1	pathway.	Common	cell	culture	media	contain	relatively	high	levels	of	essential	and	non-essential	amino	acids,	and	thus	provide	an	easily	reproducible	stimulus.	Common	media	such	as	RPMI	and	DMEM	contain	2-fold	differences	in	amino	acid	concentrations,	but	preliminary	work	suggested	that	the	higher	concentrations	in	DMEM	did	not	significantly	enhance	MTORC1	activity	compared	to	RPMI.		
3.4.2.9 Resource	limitations	Access	to	technical	support	in	Zambia	is	limited,	with	online	support	and	servicing	being	provided	from	South	Africa,	approximately	1200km	away.	Furthermore	antibodies	and	reagents	had	to	be	imported	from	the	UK	by	freight.	Panels	and	experiments	were	therefore	designed	to	be	technically	robust.	For	example,	once	fixed	and	permeabilised,	cell	samples	could	be	stored	in	50%	methanol	at	–20°C	for	several	weeks	if	required	before	staining	and	analysis	without	significant	antigen	degradation.	The	2-laser	FACSVerse	cytometer	(BD	Biosciences,	UK)	
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available	in	Zambia	supported	a	maximum	of	six	colours	which	also	significantly	influenced	panel	design.		
3.4.3 Assay	principle	
The	responsiveness	of	lamina	propria	lymphocytes	to	nutrient	stimulation	can	be	assessed	in	vitro	by	measuring	the	percentage	of	cells	that	produce	phospho-4EBP1	in	response	to	nutrient	stimulation	compared	to	nutrient	deprivation.	These	results	can	determine	(1)	whether	the	mucosal	immune	compartment	response	to	nutrient	stimulation	differs	according	to	severity	of	EE;	and	(2)	whether	nutrient	supplementation	alters	the	responsiveness	of	the	MTORC1	pathway	to	nutrient	stimulation.	Furthermore,	basal	and	maximal	levels	of	MTORC1	activity	can	be	measured	simultaneously.		
3.4.4 Final	antibody	panel	
Taking	these	considerations	into	account,	the	following	antibody	panel	was	designed	(Table	3.2).	The	predicted	emission	spectra	are	shown	in	Figure	3.13,	demonstrating	that	the	phospho-4EBP1	antigen	conjugated	to	the	‘bright’	PE	fluorophore	is	minimally	affected	by	spillover	from	the	other	fluorophores	in	the	panel.		
	 Immunophenotype	 Conjugate	 Determination	of	positivity	
Activated	MTORC1	 p4EBP1(T36/T45)+	 PE	 Unstimulated	control	
Activated	cell	 HLA-DR+		 APC	 IgG2A	κ	isotype	control		
T	lymphocyte	 CD3+	 APC-Cy7	 Bimodal	
CD4+	lymphocyte	 CD3+	CD4+	 PerCP-Cy5.5	 Bimodal	
CD8+	lymphocyte	 CD3+	CD4– 	 –	 –	
Table	3.2.	Antibody	panel	for	the	MTORC1	activity	assay.		 	
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Figure	3.13.	Predicted	emission	spectra	for	the	panel,	with	lasers	at	488nm	&	635nm.	Created	
using	BD	Biosciences	spectra	viewer	(www.bdbiosciences.com/us/s/spectrumviewer)		
3.4.5 Assessment	of	lamina	propria	CD3+	lymphocyte	MTORC1	
activity	in	response	to	in	vitro	nutrient	deprivation	and	
stimulation:	method	
Lymphocyte	isolation	3-4	endoscopic	distal	duodenal	biopsies	were	taken	at	the	end	of	the	endoscopy	procedure	and	placed	in	1ml	of	RPMI	complete	medium	on	ice	for	up	to	4	hours,	until	ready	for	processing.	Mucus	and	debris	were	removed	by	gentle	agitation	with	5ml	plain	HBSS	in	a	Petri	dish.	The	biopsies	were	then	placed	in	10ml	pre-warmed	1mM	EDTA,	and	agitated	vigorously	on	a	heater/shaker	at	37°C	for	15	minutes	to	remove	the	epithelium.		Lamina	propria	mononuclear	cells	(LPMC)	were	then	enzymatically	liberated	from	the	remaining	lamina	propria	using	an	enzymatic	digestion	solution	made	up	immediately	before	use	consisting	of	1mg/mL	collagenase	D	(Roche	Diagnostics	GmBH,	Mannheim,	Germany)	and	20μg/mL	DNAse	I	(Roche	Diagnostics	GmBH,	Mannheim,	Germany)	in	pre-warmed	complete	RPMI.	The	remaining	lamina	propria	were	transferred	to	a	Petri	dish	with	250μl	of	enzymatic	digestion	solution,	to	prevent	desiccation.	The	tissue	was	rapidly	macerated	with	scalpels	to	create	a	finely	particulate	solution.	Tissue	retrieval	was	maximised	by	rinsing	the	scalpel	blades	with	enzymatic	digestion	solution,	and	by	rinsing	the	Petri	dish.	The	
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macerated	tissue	was	placed	into	a	total	of	10ml	of	pre-warmed	enzymatic	digestion	solution.	The	lamina	propria	/	digestion	solution	was	vigorously	agitated	for	40	minutes	on	a	heater/shaker	at	37°C.	
The	resulting	suspension	containing	LPMCs	was	filtered	through	a	100µm	cell	strainer,	with	the	digestion	vessel	rinsed	with	plain	HBSS,	to	give	a	total	volume	of	20ml.	The	cell	suspension	was	centrifuged	at	400g	for	5	minutes	and	the	supernatant	discarded.	The	cell	pellet	was	resuspended	in	4mL	complete	pre-warmed	RPMI	and	divided	into	2	aliquots.	Both	aliquots	were	centrifuged	once	more	at	400g	for	5	minutes	and	the	supernatant	discarded.		
MTORC1	inhibition	and	stimulation	Both	aliquots	were	resuspended	in	2ml	pre-warmed	HBSS	supplemented	with	1mM	L-Glutamine	and	incubated	for	90	minutes	at	37°C.	One	aliquot	(representing	the	nutrient	deprived	/	negative	control	/	basal	phospho-4EBP1	condition)	was	then	fixed	with	an	equal	volume	of	8%	PFA	(to	give	a	total	concentration	4%)	for	10	minutes	on	ice.	Fixed	cells	were	centrifuged	at	400g	for	5	minutes	and	the	supernatant	discarded.	The	cell	pellet	was	resuspended	in	3mL	FACS	buffer	(Biolegend	UK),	centrifuged	once	more	at	400g	for	5	minutes	and	the	supernatant	discarded.	The	pellet	was	resuspended	in	the	residual	FACS	buffer	by	vortexing	then	placed	on	ice	for	5	minutes.	Cells	were	fixed	with	50%	MeOH	at	–20°C	and	stored	at	least	overnight	at	–20°C	until	staining	and	analysis.	The	second	aliquot	(representing	the	nutrient	stimulated	/	maximal	phospho-4EBP1	condition)	was	resuspended	in	2ml	pre-warmed	complete	RPMI	supplemented	with	4mM	L-Glutamine,	and	incubated	for	a	further	90minutes	at	37°C	before	being	fixed	in	4%	PFA	and	permeabilised	in	ice	cold	50%	MeOH	as	above.		The	composition	of	the	nutrient	deprivation	/	nutrient	stimulating	solutions	is	given	in	Appendix	5,	p.221.		
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Staining,	acquisition,	and	analysis	Cells	were	washed	by	adding	FACS	buffer,	and	then	washed	two	further	times	in	FACS	buffer	and	resuspended	in	the	residual	at	each	step.	Antibodies	were	added	to	the	residual	according	to	Table	3.3	below	and	incubated	at	room	temperature	in	the	dark	for	one	hour.	The	staining	mixture	was	washed	with	FACS	buffer	once,	then	the	cells	were	acquired	immediately	in	300μl	FACS	buffer	on	a	FACSVerse	flow	cytometer	(BD	Biosciences	UK).		HLA-DR	positivity	was	determined	using	the	relevant	isotype	control.	Automated	compensation	was	performed	using	FACSuite	(BD	Biosciences).	Gating	and	analysis	was	performed	using	FlowJo	v.10.0.7	(FlowJo	LLC,	Ashland,	Oregon).	An	example	of	the	gating	strategy	used	is	given	in	Figure	3.14.	The	proportion	of	phospho-4EBP1	positive	cells	was	calculated	using	the	super-enhanced	Dmax	method	(Bagwell,	1996).		
	 Stimulated	 Nutrient	
deprived	/	
control	
Clone;	manufacturer;	cat.	#	
Phospho-4EBP1(T36/T45)	/	PE	 1μl	 1μl	 Cell	Signaling	Technology;	2855	
CD3	/	APC-Cy7	 2μl	 2μl	 SK7;	BD	Biosciences;	557832	
CD4	/	PerCP-Cy5.5	 1μl	 1μl	 RPA-T4;	BD	Biosciences;	560650	
HLA-DR	/	APC	 2μl	 –	 G46-6;	BD	Biosciences;	559866	
IgG2A	κ	isotype	/	APC	 –	 2μl	 G155-178;	BD	Biosciences;	555576	
Table	3.3.	Antibodies	used	for	MTORC1	assay.	 	
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Figure	3.14.	Gating	strategy	for	determining	phospho-4EBP1	positivity.	Top	left,	lymphocyte	
gate.	Top	right.	CD3+	CD4+	gate.	Bottom	left,	p4EBP1	in	unstimulated	(blue)	and	stimlulated	
(red)	conditions.	Bottom	right,	p4EBP1	in	unstimulated	(control,	blue)	and	stimulated	(red).		
3.5 Identification	and	quantification	of	lamina	propria	
TH1	cells	
3.5.1 Principle	
The	TBET	(‘T-Box	Expressed	in	T	cells’)	gene	encodes	the	TBET	protein	which	is	required	for	the	expression	of	the	canonical	TH1	cytokine	IFNγ.	Classical	TH1	cells	are	phenotypically	CD3+	CD4+	TBET+,	and	can	be	identified	using	antibodies	directed	against	these	antigens.	The	proportion	of	TH1	LP	cells	was	assessed	after	the	supplementation	period.	 	
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3.5.2 Method	
The	TBET	stain	was	incompatible	with	methanol	permeabilisation,	which	was	required	for	adequate	p4eBP1	staining	(Figure	3.15).	It	was	therefore	not	possible	to	assess	p4EBP1	and	TBET	status	in	the	same	panel.	A	separate	aliquot	of	isolated	LPMCs	was	therefore	used	for	assessing	TBET	status.	
Figure	3.15.	Incompatibility	of	TBET	(blue	histograms)	and	phospho-4EBP1	(red	histograms)	
fixation	/	permeabilisation	protocols.	Illustrative	experiment	from	human	PBMC	sample.	Left	
panel,	TBET	staining.	Right	panel,	phospho-4EBP1	staining.		In	practice	and	in	contrast	to	PBMCs,	LP	lymphocytes	did	not	demonstrate	a	bimodal	distribution	pattern	so	an	isotype	control	was	used	to	determine	positivity	(Figure	3.16).	LPMC	were	mechanically	and	enzymatically	isolated	as	for	MTORC1	analysis	(section	3.4.5,	p.	122).	After	filtration,	washing	and	resuspension,	samples	for	TBET	analysis	were	divided	into	two	further	aliquots,	centrifuged	at	400g	for	5	minutes	at	room	temperature	and	the	supernatant	discarded.	The	pellet	was	resuspended	in	0.5ml	Fix/Perm	solution	(eBioscience	UK),	vortexed	thoroughly,	and	incubated	at	room	temperature	for	45	minutes.	Without	washing,	1ml	of	Perm	Buffer	(eBioscience	UK)	was	added,	and	the	mixture	centrifuged	at	400g	for	5	
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minutes.	The	supernatant	and	residual	were	discarded	and	the	pellet	resuspended	in	100μl	Perm	Buffer	and	2.5μl	FBS.	The	antibody	panel	is	given	in	Table	3.4.	Antibodies	were	added	according	to	Table	3.5	and	incubated	at	room	temperature	in	the	dark	for	one	hour.	Cells	were	then	washed	twice	in	Perm	Buffer,	then	resuspended	in	300μl	FB	and	acquired	on	a	FACSVerse	cytometer.	
Figure	3.16.	Gating	strategy	to	identify	TH1	(CD3+	CD4+	TBET+)	lymphocytes.		
	 Immunophenotype	 Conjugate	 Determination	of	positivity	
TH1		 CD3+	CD4+	TBET+	 PE-Cy7	 IgG1	κ	isotype	control	
Activated	cell	 HLA-DR+		 APC	 IgG2A	κ	isotype	control	
T	lymphocyte	 CD3+		 APC-Cy7	 Bimodal	
CD4+	lymphocyte	 CD3+	CD4+	 PerCP-Cy5.5	 Bimodal	
Table	3.4.	Antibody	panel	for	TH1	assay.		
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	 TH1	assay	 Control	 Clone;	manufacturer;	cat.	#	
TBET	/	PE-Cy7	 1μl	 –	 4B10;	Biolegend,	644824	
IgG1	κ	isotype	/	PE-Cy7	 –	 1μl	 MOPC-21;	Biolegend;	400126	
CD3	/	APC-Cy7	 2μl	 2μl	 SK7;	BD	Biosciences;	557832	
CD4	/	PerCP-Cy5.5	 1μl	 1μl	 RPA-T4;	BD	Biosciences;	560650	
HLA-DR	/	APC	 2μl	 –	 G46-6;	BD	Biosciences;	559866	
IgG2A	κ	isotype	/	APC	 –	 2μl	 G155-178;	BD	Biosciences;	555576	
Table	3.5.	Antibodies	used	for	TH1	assay.		
3.6 Cell	viability	and	cell	permeabilisation	assay	
To	confirm	lymphocyte	viability	immediately	before	fixation,	a	cell	viability	assay	was	performed	on	26	LP	lymphocyte	samples;	adequacy	of	permeabilisation	was	also	assessed.	LPMC	were	mechanically	and	enzymatically	isolated	as	for	MTORC1	analysis	(section	3.4.5,	p.	122).	An	aliquot	of	cells	was	taken	from	both	the	nutrient	deprived	and	nutrient	stimulated	tubes	at	the	end	of	the	incubation	period	and	prior	to	fixation.		To	assess	viability	at	the	end	of	the	incubation	period,	cells	were	centrifuged	at	600g	for	5	minutes	at	room	temperature	and	the	supernatant	discarded.	Cells	were	resuspended	in	the	residual	by	vortexing.	Cells	were	stained	with	CD3	/	APC-Cy7	for	30	minutes	at	room	temperature,	washed	once	in	FACS	buffer,	and	resuspended	in	250μl	of	FACS	buffer.	Cells	were	then	stained	with	1μl	7-AAD	(BD	Biosciences	UK,	cat.	559925)	for	ten	minutes	and	acquired	immediately	(Figure	3.17).	
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The	remaining	cells	were	processed	and	analysed	for	TH1	or	MTORC1	activity	as	above.	To	assess	adequacy	of	permeabilisation,	surplus	cells	after	acquisition	were	stained	with	1μl	7-AAD	for	ten	minutes	at	room	temperature	and	acquired	immediately	(Figure	3.17).		
Figure	3.17.	Representative	experiment	of	7-AAD	staining	in	LP	CD3+	lymphocytes	before	and	
after	fixation	and	permeabilisation.	Cells	immediately	before	fixation	were	viable	on	the	basis	
of	7-AAD	exclusion	(blue	histogram).	After	fixation	and	permeabilisation,	only	a	minority	of	
cells	did	not	take	up	7-AAD	(red	histogram).		
3.7 Urinary	metabonomics	
3.7.1 Rationale	
Detailed	characterisation	of	the	microbiome	does	not	in	itself	provide	insights	into	disease	mechanisms.	The	vast	complexity	and	variability	of	the	microbiota	means	that	a	global	assessment	of	microbiota-host	interactions	is	required.	The	microbiota	interacts	with	the	host	primarily	through	metabolic	and	immunological	pathways.	Metabonomics	is	a	powerful	technique	which	provides	an	integrative,	functional,	global	evaluation	of	host	and	microbial	interactions	through	measuring	their	co-metabolites,	and	which	can	be	used	to	identify	disease,	response	to	therapy,	and	functional	changes	in	the	microbiota.	Metabonomics	has	been	used	to	
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study	severe	acute	malnutrition,	where	it	was	shown	that	nutritional	intervention	results	in	changes	in	the	metabonomic	profile	which	reflects	transferrable	alterations	in	the	microbiota	in	a	murine	model	(Smith	et	al.,	2013).	There	have	now	been	some	studies	investigating	the	urinary	metabonomic	profile	in	children	with	EE	(Farràs	et	al.,	2018;	Guerrant	et	al.,	2016;	Mayneris-Perxachs	and	Swann,	2018;	Mayneris-Perxachs	et	al.,	2016),	but	so	far	the	adult	metabonome	has	not	been	studied.			
3.7.2 Principle		
Metabonomics	is	defined	as	‘the	quantitative	measurement	of	the	dynamic	multiparametric	metabolic	response	of	living	systems	to	pathophysiological	stimuli	or	genetic	modifications’	(Nicholson	et	al.,	1999).	The	metabonome	consists	of	the	host’s	global	metabolite	profile,	and	is	influenced	by	the	host’s	microbiota	and	diet	&	other	lifestyle	factors,	as	well	as	host	&	microbiota	metabolic	pathways.	These	complex	metabolic	‘signatures’	reflect	processes	occurring	in	the	host	and	the	microbiota	across	multiple	functional	compartments	(Claus	and	Swann,	2013).	NMR	spectroscopy	is	the	most	commonly	used	technique	for	detecting	and	analysing	samples.	Urine	samples	have	the	advantage	of	being	safe	and	non-invasive,	and	reflect	host-microbiota	interactions	through	systemic	absorption	and	excretion	of	gut	products	(Claus	and	Swann,	2013).		
3.7.3 Method	
Urinary	1H	NMR	spectroscopic	metabonomic	analysis	was	performed	by	Dr	Jordi	Mayneris	and	Dr	Jonathan	Swann,	Department	of	Surgery	and	Cancer,	Imperial	College	London	(Figure	3.18).		 	
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Urine	samples	were	collected	prior	to	endoscopy	and	immediately	decanted	into	a	container	with	1	mL	0.5%	chlorhexidine.	Samples	were	stored	at	–80°C	until	transportation	to	London	on	dry	ice.	Urine	samples	(400μL)	were	combined	with	200μL	of	phosphate	buffer	(pH	7.4;	100%	D2O)	containing	1mM	of	3-trimethylsilyl-1-[2,2,3,3-2H4]	propionate	(TSP)	as	an	external	standard	and	2mM	sodium	azide	as	a	bactericide.	Samples	were	mixed	by	vortexing	and	centrifugated	at	10000g	for	10	minutes.	The	supernatant	(550μL)	was	transferred	to	a	5	mm	internal	diameter	NMR	tube.	Samples	were	analysed	by	1H	nuclear	magnetic	resonance	(NMR)	spectroscopy	using	a	700MHz	Bruker	NMR	spectrometer	operating	at	300K.	For	each	urine	sample	a	standard	noesy	experiment	was	performed	with	water-suppression	using	8	dummy	scans	followed	by	128	scans	collected	into	64K	data	points.	A	mixing	time	of	10ms	was	used	with	an	acquisition	time	of	3.8s	and	a	recycle	delay	of	3.0s.	1H	NMR	spectra	were	manually	corrected	for	phase	and	baseline	distortions.	Chemical	shifts	in	the	spectra	were	referenced	to	the	TSP	peak	at	δ	0.0ppm.	Spectra	were	digitized	using	an	in-house	Matlab	(version	R2012a,	The	Mathworks,	Inc.;	Natwick,	MA)	script.	Resonances	derived	from	water	were	removed	to	minimize	distortions	to	the	spectral	baseline.	Spectra	were	normalized	to	the	total	area.	
Figure	3.18.	Metabonomics	method.		
3.8 Quantification	of	plasma	CRP,	sCD14	&	GLP2	by	ELISA	
3.8.1 Introduction	
A	plasma	biomarker	panel	of	sCD14,	CRP	and	LPS	was	selected	as	an	adjunctive	assessment	of	microbial	translocation	and	immune	activation.	Furthermore,	levels	of	glucagon-like	peptide	2	(GLP2)	were	measured	to	assess	the	enterohumoral	axis,	in	particular	its	response	to	amino	acid	supplementation.	The	measurement	of	LPS	is	described	in	section	3.9,	p.133.		
3.8.2 Quantitative	sandwich	ELISA	principle	
Microplate	wells	are	coated	with	monoclonal	antibodies	specific	for	the	antigen	of	interest.	Samples	and	standards	are	incubated	in	the	wells,	so	that	antigen	is	bound	by	the	fixed	antigen-specific	antibody.	The	immobilised	antigen-antibody	complex	is	then	incubated	with	a	second	antigen-specific	antibody,	which	is	conjugated	to	an	enzyme	such	as	horseradish	peroxidase	(HRP).	
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A	substrate	solution	containing	hydrogen	peroxide	and	3,3’,5,5’-tetramethylbenzidine	(TMB)	is	then	added.	The	presence	of	HRP	catalyses	a	chromogenic	reaction	resulting	in	the	formation	of	TMB	diimine,	which	has	a	blue	colour.	The	reaction	is	stopped	with	the	addition	of	strong	acid,	resulting	in	a	yellow-green	colour	which	can	be	quantitatively	measured	by	colorimetry	using	a	spectrophotometer.	The	amount	of	TMB	diimine	present	(the	intensity	of	colour)	is	proportional	to	the	amount	of	antibody-antigen-antibody	conjugate	present.		
3.8.3 Sample	preparation	
Fresh	whole	blood	was	centrifuged	at	1000g	for	15	minutes	at	4°C.	The	plasma	was	then	aliquoted	and	stored	at	–20°C	until	required.	ELISAs	were	performed	according	to	the	manufacturer’s	instructions,	with	dilutions	where	required	as	stated	in	Table	3.6.	Samples,	standards	and	controls	were	plated	in	duplicate.	Optical	densities	were	determined	immediately	after	stopping	with	a	microplate	reader	measuring	absorbance	at	450nm,	with	the	correction	wavelength	set	at	540nm	for	CRP	and	sCD14	and	590nm	for	GLP2	(EL800,	BioTek	UK,	Swindon).		
Marker	 Manufacturer	 Cat.	#	 Dilution	 Standards	range	
CRP	 R&D	Systems	 DCRP00	 1/1000	 0-50ng/ml	
sCD14	 R&D	Systems	 DC140	 1/400	 0-16ng/ml	
GLP2	 EMD	Millipore	Corp.	 EZGLP2-37K	 N/A	 0-73ng/ml	
Table	3.6.	Experimental	details	for	ELISAs.		
3.8.4 Data	analysis	
A	standard	curve	was	constructed	using	the	Gen5	program	(BioTek	UK,	Swindon)	to	generate	a	4-parameter	logistic	curve	fit,	with	R2	>0.98.	Apparent	concentrations	were	multiplied	by	the	dilution	factor	to	provide	sample	concentrations.	Mean	values	with	a	coefficient	of	variation	(CV)	<20%	were	accepted.	
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3.9 Limulus	amoebocyte	assay	for	the	detection	of	
lipopolysaccharide	
3.9.1 Assay	principles	
Like	the	ELISA	assay,	the	Limulus	amoebocyte	lysate	(LAL)	assay	is	an	enzymatic	chromogenic	assay,	where	concentration	of	LPS	is	quantified	by	measuring	colour	intensity.	Innate	immune	blood	cells	(amoebocytes)	from	the	horsehoe	crab	Limulus	
polyphemus	react	to	LPS	in	vivo	by	promoting	the	blood	coagulation	cascade,	with	the	biological	effect	of	containing	LPS-containing	bacteria.	The	proteolytic	cascade	responsible	for	this	reaction	has	been	modified	so	that	a	purified	amoebocyte	lysate	results	in	the	cleavage	of	the	colourless	chromophore	para-nitroanilide	to	produce	para-nitroaniline	(pNA),	which	is	yellow	and	absorbs	at	405	nm,	when	the	lysate	is	activated	by	the	presence	of	LPS.	The	rate	of	pNA	production,	and	therefore	the	intensity	of	colour	produced,	is	related	to	the	amount	of	LPS	in	the	sample,	and	can	be	measured	by	comparing	to	a	standard	curve	of	known	concentrations.		
3.9.2 Method	
Fresh	whole	blood	was	centrifuged	at	1000g	for	15	minutes	at	4°C.	The	plasma	was	then	aliquoted	and	stored	at	–20°C	until	required.	LAL	assays	were	performed	using	a	Pyrochrome	®	kit	(Associates	of	Cape	Cod	International	Inc.,	Liverpool,	UK)	according	to	the	manufacturer’s	instructions.	Samples	were	diluted	with	LAL	reagent-grade	water	(Associates	of	Cape	Cod	International	Inc.,	Liverpool,	UK)	to	give	a	1000-fold	sample	dilution.	Controls	and	standards	were	prepared	using	2-fold	serial	dilutions	using	LAL	reagent-grade	water	to	provide	a	reference	range	between	0	and	5.12	EU/mL.	Samples,	standards	and	controls	were	plated	in	duplicate.	Optical	densities	were	determined	immediately	after	stopping	with	a	microplate	reader	measuring	absorbance	at	405nm	(EL800,	BioTek	UK,	Swindon).		
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3.9.3 Analysis	
A	standard	curve	was	constructed	by	plotting	optical	density	readings	against	standard	endotoxin	concentrations	using	Gen5	(BioTek	UK,	Swindon),	with	R2	>0.98.	Apparent	concentrations	were	multiplied	by	the	dilution	factor	to	provide	sample	concentrations.	Mean	values	with	a	coefficient	of	variation	(CV)	<20%	were	accepted.		
3.10 Assessment	of	nutritional	status	and	body	
composition	
A	number	of	assessments	of	body	composition	were	used	before	and	after	the	supplementation	period.		
3.10.1 BMI	
Height	and	weight	were	measured	in	the	community	research	clinic,	in	the	NuSTART	research	clinic,	and	by	air	displacement	plethysmography	(BodPod	®).	Correlation	between	the	three	measurements	was	excellent	(Table	3.7).	Of	these,	the	weight	measurements	used	for	BodPod	body	composition	analysis	were	the	most	accurate	and	were	therefore	used	for	analysis.			
		 ρ		 P	
Misisi	v.	NuSTART	 0.973	 	<0.001	
Misisi	v.	BodPod	 0.967	 	<0.001	
Nustart	v.	BodPod	 0.998	 	<0.001	
Table	3.7.	Spearman	rank	correlations	between	3	different	measurements	of	BMI.		
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3.10.2 Grip	strength	
Dynamometry	was	performed	before	the	endoscopy	procedure,	to	avoid	any	effect	of	sedation.	Non-dominant	grip	strength	was	measured	using	a	calibrated	dynamometer	(Takei	Scientific	Instruments,	Niigata,	Japan),	with	participants	in	a	standing	position	with	the	arm	by	their	side	and	elbow	extended.	The	‘best	attempt	of	three’	reading	was	recorded	by	one	of	two	study	nurses.			
3.10.3 Mid-upper	arm	circumference	(MUAC)	
Participants’	non-dominant	MUAC	was	measured	using	a	standardised	tape	measure	using	a	blinded	technique	by	a	single	trained	research	clinic	nurse.		
3.10.4 Bioelectrical	impedance	analysis	(BIA)	
3.10.4.1 Principle	(Ellis,	2000)	Impedance	has	both	resistive	and	reactive	(capacitative)	components,	with	resistance	deriving	from	intra-	and	extracellular	fluid	and	reactance	deriving	from	cell	membranes.	At	a	current	frequency	of	0	(i.e.	direct	current),	reactance	increases	so	that	impedance	(Z0)	is	equal	to	total	body	resistance	(R0)	which	reflects	passage	of	current	solely	through	the	extracellular	fluid	compartment.	Conversely,	at	infinite	frequency,	cell	membranes	will	behave	as	perfect	capacitors,	so	that	impedance	(Z∞)	will	be	equal	to	total	body	resistance	(R∞)	and	reflect	passage	of	current	through	both	extracellular	and	intracellular	fluid	compartments.	Because	these	extremes	are	theoretical,	measured	impedance	can	be	used	to	derive	R0	and	R∞	using	Cole-Cole	plots,	which	describe	reactance	against	resistance	when	frequency	and	impedance	are	known.		A	weak	alternating	current	at	50kHz	is	passed	through	the	body	through	electrodes	attached	to	the	subject’s	hands	and	feet,	and	impedance	is	measured.	Because	fat	has	an	extremely	high	impedance,	BIA	in	practice	measures	impedance	in	total	cellular	mass	and	extracellular	water	(i.e.	fat	free	tissue).	Incorporating	
 136 
empirically	derived	constants	to	correct	for	age,	sex,	weight	etc.	allows	fat	free	mass	to	be	estimated,	and	by	comparing	this	to	measured	weight,	fat	mass.		
3.10.4.2 Method	Bioelectrical	impedance	was	measured	using	a	Tanita	analyser	(Tanita	Corporation,	Tokyo,	Japan)	according	to	the	manufacturer’s	instructions.	All	measurements	were	performed	while	fasting	to	avoid	the	confounding	factor	of	fluid	intake	on	total	body	water	estimation.		
3.10.5 Air	displacement	plethysmography	
3.10.5.1 Principle	(Ellis,	2000)	These	models	all	rely	on	measurement	of	total	body	density.	Once	this	has	been	determined,	a	number	of	methods	exist	to	extrapolate	mean	(total)	body	density	to	various	body	compartments.	Two	compartment	models	divide	tissue	into	fat	mass	and	fat-free	mass	compartments,	using	experimentally	derived	formulae.	Cadaveric	body	density	assessment	is	viewed	as	the	gold	standard.	Allowance	must	be	made	for	race-related	differences	in	body	composition;	of	particular	note	is	the	increased	muscle,	bone	and	mineral	density	of	people	of	black	African	descent.	For	this	population	the	Ortiz	(for	women)	(Ortiz	et	al.,	1992)	and	Schutte	(for	men)	(Schutte	et	al.,	1984)	equations	provide	the	best	validated	estimates	of	lean	and	fat	mass.	ADP	measures	weight	using	a	highly	sensitive	and	atmospherically	isolated	balance.	Body	volume	is	calculated	by	measuring	air	pressure	within	an	atmospherically	sealed	capsule	of	known	volume:	by	altering	the	volume	by	a	known	amount	(by	use	of	a	diaphragm)	and	measuring	the	change	in	pressure,	body	volume	can	be	calculated	using	Boyle’s	law	(V2	=	[P1V1]/P2).	The	effect	of	thoracic	(air)	volume	must	also	be	considered.	Total	gas	volume	(TGV)	can	accurately	be	determined	using	exhalational	volumetry,	although	it	can	
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be	accurately	estimated	using	experimentally	derived	equations	incorporating	height,	age	and	gender	(McCrory	et	al.,	1998).		
3.10.5.2 Air	displacement	plethysmography	(‘BodPod’	®)	–	method	In	many	cases	participants	found	it	difficult	to	follow	the	multi-step	breathing	commands	which	were	required	to	accurately	assess	TGV	volumetrically,	so	predicted	TGV	was	used.	Air	displacement	plethysmography	was	conducted	using	BodPod	®	(Cosmed,	Rome,	Italy)	according	to	the	manufacturer’s	instructions	while	participants	were	fasted.	Participants	were	asked	to	change	into	slim	fitting	swimwear	and	a	swim	cap	to	minimise	artefactual	volume	due	to	clothing	and	hair.	
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4 	
CHAPTER	4	
RESULTS:	AMAZE	TRIAL	OVERVIEW,	PRIMARY	OUTCOMES,	
AND	SAFETY	
	
4.1 Study	participants	
The	trial	was	carried	out	between	October	2015	and	May	2016.	The	timing	of	recruitment	was	such	that	treatment	was	initiated	in	November	–	December	2015	(before	the	rainy	season),	and	the	final	assessments	after	treatment	were	made	in	March	–	April	2016	(after	the	rainy	season).	136	healthy	adult	volunteers	were	screened,	of	whom	102	met	all	inclusion	and	exclusion	criteria	and	were	recruited	and	randomised.	All	of	these	completed	the	baseline	study	assessments.	85	participants	completed	the	supplementation	period	and	underwent	assessments	at	the	end	of	the	supplementation	period.	One	participant	was	unable	to	tolerate	the	post-intervention	endoscopy	so	samples	and	data	from	84	participants	were	available	for	analysis.	The	CONSORT	trial	flowchart	(Schulz	et	al.,	2010)	is	given	in	Figure	4.1.	Baseline	characteristics	of	the	participants	by	treatment	group	at	randomisation	is	given	in	Table	4.2	(p.140),	and	in	the	per-protocol	group	in	Table	4.3	(p.141).	In	general,	participants	were	young	and	female.	Participants	were	significantly	stunted	(median	height	between	the	3rd	and	15th	centiles	for	men,	and	on	the	15th	centile	for	women	compared	to	WHO	reference	standards	(World	Health	Organization	and	Onis,	2006).	12.1%	of	men	and	43.5%	of	women	were	overweight	(BMI	>25),	whereas	no	men	and	17.4%	of	women	were	obese	(BMI	>	30).	In	terms	of	deprivation	markers,	only	45%	had	completed	primary	education,	30%	had	no	household	electricity,	and	only	24%	regularly	used	clean	(boiled	or	chlorinated)	water.	44/102	(43.1%)	of	randomised	participants	had	a	total	of	83	non-pathogenic	parasites	identified	on	stool	microscopy	(Table	4.1).		
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Figure	4.1.	CONSORT	flow	chart.	Total	numbers	of	participants	are	given	with	numbers	of	HIV	
positive	participants	in	brackets.		
Parasite	 Number	of	stool	samples	
Endolimax	nana	 28	
Entamoeba	coli	 27	
Blastocystis	hominis	 15	
Iodamoeba	bütschlii	 7	
Retortamonas	intestinalis	 5	
Entamoeba	hartmanni	 1	
Total	 83	
No	parasites	identified	
(%	of	participants)	
58	(56.9)	
One	or	more	parasites	identified	
(%	of	participants)	
44	(43.1)	
Table	4.1.	Non-pathogenic	parasites	on	stool	microscopy	in	randomised	participants.	
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Amino	acids	(n=52)	 Placebo	(n=50)	 Micronutrients	(n=52)	 Placebo	(n=50)	
Age,	years	 32	(22-45)	 39	(23-45)	 35	(24-45)	 34	(22-45)	
Sex,	M:F	 19:33	 14:36	 17:35	 16:34	
HIV	positive,	n	(%)	 15	(29)	 15	(30)	 16	(31)	 14	(28)	
	
Peripheral	CD4	count	 548	(305-613)	 554	(417-790)	 472	(327-697)	 582	(467-740)	
Height,	cm	 Male	 168	(165	–	174)	 168	(164	–	172)	 166	(165	–	174)	 171	(165	–	173)	
Female	 157	(153	–	161)	 158	(154	–	161)	 157	(153	–	161)	 157	(154	–	161)	
Body	mass	index,	kg.m-2		 Male	 19.9	(19.0	–	20.2)	 20.6	(19.6	–	25.7)	 20.1	(19.1	–	23.3)	 19.8	(19.1	–	20.5)	
Female	 24.6	(21.2	–	25.8)	 25.0	(20.7	–	29.0)	 23.5	(20.2	–	26.9)	 25.1	(20.5	–	28.3)	
Body	fat	by	ADP,	%	 Male	 16.9	(14.7	–	19.0)	 11.4	(7.8	–	25.8)	 14.3	(10.7	–	18.3)	 14.8	(11.0	–	17.7)	
Female	 33.7	(24.5	–	35.8)	 36.1	(27.6	–	44.1)	 34.0	(24.1	–	40.5)	 34.3	(27.7	–	39.3)	
Grip	strength,	kg	 Male	 39.5	(36.2	–	41.9)	 39.1	(36.1	–	42.2)	 40.8	(34.9	–	45.8)	 39.1	(36.2	–	41.6)	
Female	 27.2	(23.4	–	31.3)		 28.1	(25.9	–	33.0)	 28.6	(26.4	–	34.7)	 26.9	(24.2	–	32.2)	
Completed	primary	education,	%	 36	 54	 42	 48	
Household	Hygiene	Score	a,	(0-10)	 6	(5-7)	 6	(5-7)	 6	(5-7)	 6	(5-7)	
Household	electricity,	%	 71.2	 66	 69.2	 68	
Routinely	boil	water	b,	%	 7.6	 6	 5.7	 8	
Routinely	chlorinate	water	b,	%	 17.3	 30	 19.2	 28	
Non-pathogenic	stool	parasites,	%	 48.1	 38	 46.2	 40	
Table	4.2.	Baseline	characteristics	of	the	study	participants	at	randomisation	by	treatment	group.	Values	given	as	median	(IQR)	where	applicable.	ADP,	air	
displacement	plethysmography;	BMI,	body	mass	index.	a,	the	Household	Hygiene	Score	is	a	reproducible	objective	measure	of	the	living	conditions	of	each	
participant	and	ranges	from	0	(worst)	to	10	(best).	Trained	fieldworkers	score	up	to	2	points	in	each	of	five	categories	(overall	cleanliness;	water	storage	facilities;	
food	storage	facilities;	hand	washing	facilities	and	their	use;	sanitation	facilities).	b,	defined	as	most	or	all	days.	 	
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	 Amino	acids	(n=42)	 Placebo	(n=42)	 Micronutrients	(n=41)	 Placebo	(n=43)	
Age,	years	 35	(28-46)	 42	(24-51)	 40	(21-30)	 40	(30-46)	
Sex,	M:F	 16:26	 10:32	 11:30	 15:28	
HIV	seropositive,	n	(%)	 13	(31)	 14	(33)	 16	(38)	 11	(26)	
	 Peripheral	CD4	count	 510	(268	–	683)	 621	(422	–	800)	 472	(305	–	750)	 602	(387	–	827)	
Height,	cm	 Male	 169	(166	–	174)	 171	(165	–	172)	 166	(165	–	173)	 171	(166	–	174)	
Female	 157	(154	–	162)	 158	(154	–	161)	 157	(153	–	161)	 157	(154	–	161)	
Body	mass	index,	kg.m-2	 Male	 19.9	(19.0	–	20.2)	 20.6	(19.6	–	25.7)	 20.6	(20.0	–	25.4)	 19.7	(19.1	–	20.2)	
Female	 24.6	(21.2	–	25.8)	 25.0	(20.7	–	29.0)	 23.5	(20.1	–	27.4)	 25.1	(21.4	–	27.9)	
Body	fat	by	ADP,	%	 Male	 16.9	(14.7	–	19.0)	 11.4	(7.8	–	25.8)	 17.5	(11.6	–	24.1)	 15.8	(11.0	–	18.6)	
Female	 33.7	(24.5	–	35.8)	 36.1	(27.6	–	44.1)	 34.3	(23.9	–	40.2)	 34.5	(27.9	–	39.0)	
Grip	strength,	kg	 Male	 39.5	(36.2	–	41.9)	 39.1	(36.1	–	42.2)	 40.2	(35.7	–	46.6)	 39.2	(36.4	–	41.7)	
Female	 27.2	(23.4	–	31.3)	 28.1	(25.9	–	33.0)	 28.7	(26.5	–	34.0)	 26.7	(23.6	–	31.6)	
Completed	primary	education,	%	 35.7	 51.2	 40.5	 46.5	
Household	hygiene	score	a,	0-10	 6	(5	–	7)	 6	(5	–	6)	 6	(5	–	6.5)	 5	(5	–	8)	
Household	electricity,	%	 69.1	 65.1	 69.1	 65.1	
Routinely	boil	water	b,	%	 9.5	 4.7	 7.0	 7.1	
Routinely	chlorinate	water	b,	%	 14.3	 34.9	 19.1	 30.2	
Non-pathogenic	stool	parasites,	%	 47.6	 39.5	 42.9	 44.2	
Table	4.3.	Baseline	characteristics	in	per-protocol	participants.	See	Table	4.2	for	notes	and	explanations.		
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4.1.1 Compliance	
Compliance	as	assessed	by	monthly	supplement	counts	was	high:	median	(IQR)	percentage	of	amino	acid	supplement	packs	consumed	was	73	(60-86)%	and	of	micronutrient	capsules	taken	was	80	(67-88)%.	Adjustment	for	the	proportion	of	supplement	consumed	in	a	linear	regression	model	made	no	difference	to	the	results	presented	below.	The	correlation	between	MM	and	AA	consumption	was	high	(ρ	0.85,	P	<	0.001).	Reasons	for	supplement	discontinuation	and	study	withdrawal,	where	given,	are	provided	in	Table	4.4	and	Figure	4.1.		
	 Number	of	participants	
Lost	to	follow	up	(moved	out	of	area)	 5	
Supplement	not	tolerated	 2	
No	reason	given	 9	
Breastfeeding	 1	
Total	 17	
Table	4.4.	Reasons	for	withdrawal	from	the	study.		
4.2 Effect	of	AA	or	MM	supplementation	on	proximal	
small	intestinal	absorptive	area	
As	in	previous	studies	from	this	population,	participants	exhibited	histological	evidence	of	severe	enteropathy	at	baseline,	with	marked	villous	atrophy	(median	villus	height	200.2μm,	IQR	167.5μm	–	242.1μm)	and	dramatically	reduced	villus	height	to	crypt	depth	ratio	(median	1.3,	IQR	1.0	–	1.4)	(Figure	4.2).	
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Figure	4.2.	Marked	villus	atrophy	and	crypt	hypertrophy	at	baseline	in	study	participants.		
	 AA	(n=26)	 Placebo	
(n=23)	
MM	(n=26)	 Placebo	
(n=23)	
VH	(μm)	 185	(154-217)	 218	(201-250)	 202	(181-252)	 206	(170-235)	
CD	(μm)	 163	(141-196)	 163	(150-198)	 157	(135-194)	 174	(152-199)	
VW	(μm)	 230	(210-263)	 222	(197-268)	 221	(202-253)	 230	205-267)	
VP	(μm)	per	100μm	
muscularis	mucosae	
865	(702-1030)	 987	(868-1134)	 931	(788-1072)	 913	(772-1090)	
VA	(μm2)	per	100μm	
muscularis	mucosae	
30061	(23036-37178)	 32328	(27992-40093)	 31998	(23619-37642)	 31288	(24892-37200)	
Table	4.5.	Mean	baseline	morphometric	parameters	by	intervention	group.	VH,	villus	height;	
CD,	crypt	depth;	VW,	villus	width;	VP,	villus	perimeter;	VA,	villus	cross-sectional	area.		There	was	a	general	reduction	in	villus	and	crypt	measurements	between	the	first	and	second	biopsies	(Table	4.6	and	Table	4.7),	taken	before	and	at	the	end	of	the	rainy	season.	The	reduction	in	villus	height	and	villus	cross-sectional	area	was	negated	in	those	participants	receiving	amino	acid	supplementation	compared	to	placebo	(Table	4.6	and	Figure	4.3,	p.145).	Micronutrient	supplementation	had	no	effect	on	any	morphometric	measurement	(Table	4.7	and	Figure	4.4,	p.145).		 	
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Change	in:	 AA	(n=26)	 Placebo	(n=23)	 P	
Villus	Height	(μm)		 2.5	(59)	 -32.0	(57)	 0.04	
Crypt	Depth	(μm)	 -13.3	(39)	 -31.1	(45)	 0.2	
Villus	Width	(μm)	 -11.5	(60)	 -13.7	(138)	 0.9	
Villus	Perimeter	(μm)	per	100	μm	
muscularis	mucosae	
-1.9	(180)	 -89.5	(159)	 0.08	
Villus	Area	(μm2)	per	100	μm	
muscularis	mucosae	
715	(5632)	 -3220	(5694)	 0.02	
Villus	Surface	Area:Volume	Ratio	
(x10-4)	
-9	(7)	 3	(60)	 0.5	
Table	4.6.	Effect	of	AA	supplementation	on	change	in	morphometric	parameters	over	the	
supplementation	period.	Independent	samples	t	test;	values	given	as	mean	(SD).			
Change	in:	 MM	(n=26)	 Placebo	(n=23)	 P	
Villus	Height	(μm)		 -19.5	(62)	 -8.6	(60)	 0.5	
Crypt	Depth	(μm)	 -25.5	(43)	 -18.3	(43)	 0.6	
Villus	Width	(μm)	 -16.6	(72)	 -8.9	(126)	 0.8	
Villus	Perimeter	(μm)	per	100	μm	
muscularis	mucosae	
-64.1	(137)	 -24.4	(203)	 0.4	
Villus	Area	(μm2)	per	100	μm	
muscularis	mucosae	
-2469	(5061)	 51	(6494)	 0.1	
Villus	Surface	Area:Volume	Ratio	
(x10-4)	
-0.4	(60)	 -6	(60)	 0.8	
Table	4.7.	Effect	of	MM	supplementation	on	change	in	morphometric	parameters	over	the	
supplementation	period.	Independent	samples	t-test;	values	given	as	mean	(SD).		 	
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Figure	4.3.	Effect	of	AA	supplementation	on	change	in	morphometric	parameters	over	the	
supplementation	period.	Independent	samples	t-test.	
Figure	4.4.	Effect	of	MM	supplementation	on	change	in	morphometric	parameters	over	the	
supplementation	period.	Independent	samples	t-test.		Examining	for	main	effects	and	interactions	by	univariate	ANOVA	confirmed	a	significant	effect	of	amino	acid	supplementation	on	the	change	in	VH	and	VA,	such	that	participants	who	received	AA	were	protected	against	the	seasonal	decline	compared	to	those	who	received	placebo	(P	0.05	for	VH;	P	0.027	for	VA).	There	was	no	evidence	of	an	MM	supplementation	main	effect	(P	0.65	for	VH;	P	0.2	for	VA)	or	of	an	interaction	between	AA	and	MM	(P	0.7	for	VH;	P	0.9	for	VA).		 	
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4.3 Effect	of	amino	acid	or	multiple	micronutrient	
supplementation	on	small	intestinal	barrier	
dysfunction	as	assessed	by	CLE	
The	number	of	endomicroscopic	fields	demonstrating	pathological	barrier	dysfunction	(one	or	more	of	erosions;	fluorescein	plumes;	intraluminal	fluorescein;	intramucosal	fluorescein)	was	assessed	by	two	independent	blinded	observers.	Images	of	adequate	quality	were	available	in	81/85	patients	before	supplementation	and	77/84	after	supplementation.	The	median	(IQR)	number	of	fields	available	for	analysis	was	72	(49-98)	at	baseline	and	98	(78-117.5)	after	supplementation.	Images	were	rated	by	two	observers;	inter-observer	correlation	was	high	(ρ=0.94;	P<0.001;	Figure	4.5).		
Figure	4.5.	Interobserver	correlation	between	two	independent	blinded	assessors	of	
pathological	endomicroscopic	barrier	defects.	Levels	of	barrier	dysfunction	were	very	high	in	all	groups	at	baseline	(	Table	4.8;	Figure	4.6),	and	did	not	change	over	the	course	of	the	study.	71/81	(87.7%)	of	participants	at	baseline	and	65/77	(84.4%)	of	participants	post-intervention	demonstrated	barrier	dysfunction	in	more	than	30%	of	fields.	
	Table	4.8.	Endomicroscopic	barrier	dysfunction	at	baseline.	 	
	 AA	 Placebo	 MM	 Placebo	
Median	(IQR)	fields	
with	dysfunction,	%	
79.1	(57.2-88.5)	 85.8	(75.9-91.6)	 80.5	(57.2-91.1)	 86.0	(75.0-91.6)	
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Figure	4.6.	Baseline	endomicroscopic	barrier	dysfunction	by	treatment	group.	Left,	AA	v.	
placebo.	Right,	MM	v.	placebo.		Neither	intervention	altered	levels	of	leak	observed	(Figure	4.7).	Examining	for	main	effects	and	interactions	by	univariate	ANOVA	confirmed	there	was	no	evidence	of	a	main	effect	of	AA	or	MM	supplementation	on	change	in	endomicroscopic	leak	(P	0.35	for	AA;	P	0.31	for	MM).	However,	there	was	evidence	of	a	significant	interaction	(P	0.004)	with	a	crossover	effect:	a	significant	reduction	in	endomicroscopic	leak	was	observed	in	participants	who	received	both	AA	and	MM	supplements	(Figure	4.8).		
Figure	4.7.	Change	in	endomicroscopic	barrier	dysfunction	by	intervention	group.	 	
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Figure	4.8.	Interaction	effect	of	supplements	on	change	in	endomicroscopic	barrier	
dysfunction.	P		=	0.023	across	all	groups	(one-way	ANOVA).		
4.4 Effect	of	AA	or	MM	supplementation	on	mucosal	T	
lymphocyte	MTORC1	activity	
The	responsiveness	of	lamina	propria	T	lymphocytes	was	assessed	by	measuring	the	proportion	of	phospho-4EBP1	positive	cells	following	in	vitro	nutrient	stimulation.	Approximately	50%	of	lamina	propria	CD4+	T	cells	were	nutrient	responsive	(phospho-4EBP1	positive)	at	baseline	(Table	4.9).	CD4+	basal	MTORC1	activity	(measured	as	phospho-4EBP1	MFI	after	nutrient	deprivation)	and	maximal	MTORC1	activity	(phospho-4EBP1	MFI	after	nutrient	stimulation)	declined	over	the	supplementation	period	in	all	four	arms	(Figure	4.9,	p.150).	The	proportion	of	nutrient	responsive	(phospho-4EBP1	positive)	CD4+	T	cells	was	unchanged	in	all	arms	apart	from	participants	who	received	MM,	where	the	proportion	of	responsive	cells	declined	(Figure	4.9).	Neither	intervention	altered	nutrient	responsiveness	or	basal	or	maximal	MTORC1	activity	compared	to	placebo	(Table	4.10	and	Figure	4.10,	p.151).	
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	 AA	(n=14)	 Placebo	(n=23)	 MM	(n=18)	 Placebo	(n=19)	
%	p4EBP1	positive	 47.9	(41.1	–	58.3)	 60.0	(44.6	–	67.0)	 58.1		(46.8	–	65.1)	 48.3		(32.9	–	61.9)	
Table	4.9.	Proportion	of	CD3+	CD4+	lamina	propria	lymphocytes	responding	to	in	vitro	nutrient	
stimulation	at	baseline.		
Change	in:	 AA	 Placebo	 P		 MM	 Placebo	 P		
Basal	p4EBP1	MFI	 -152	(56)	 -125	(85)	 1.0	 -121	(67)	 -150	(81)	 0.3	
Max.	p4EBP1	MFI	 -288	(128)	 -276	(126)	 0.8	 -281	(114)	 -282	(138)	 0.9	
%	p4EBP1	positive	 -9.0	(18.5)	 -10.2	(19.1)	 0.9	 -15.0	(13.5)	 -4.8	(21.5)	 0.2	
Table	4.10.	Change	in	lamina	propria	CD4+	MTORC1	signalling	according	to	intervention.			Examining	for	main	effects	and	interactions	by	univariate	ANOVA	confirmed	there	were	no	main	or	interaction	effects	for	the	interventions	on	the	change	in	phospho-4EBP1	positivity	(P	0.6	for	AA;	P	0.14	for	MM;	P	0.5	for	interaction),	basal	MTORC1	activation	(P	0.3	for	AA;	P	0.3	for	MM;	P	0.5	for	interaction),	or	maximal	MTORC1	activation	(P	0.8	for	AA;	P	0.9	for	MM;	P	0.4	for	interaction).	The	Shapiro-Wilk	test	confirmed	normality	for	these	outcomes.	The	proportion	of	MTORC1	responsive	cells	was	correlated	with	maximal	MTORC1	activity,	but	not	with	basal	activity.	Basal	and	maximal	MTORC1	activity	was	positively	correlated	(Table	4.11).	These	correlations	were	stronger	and	more	significant	across	all	treatment	groups	as	a	whole	after	the	intervention	period	(Table	4.11;	overall	correlations	across	treatment	groups	shown).		
	 Pre-supplementation	 Post-supplementation	
	 ρ		 P		 ρ		 P		
%	responsive	v.	basal	activity	 -0.2	 0.3	 0.1	 0.6	
%	responsive	v.	max.	activity	 0.4	 0.01	 0.5	 0.001	
Basal	v.	max.	activity	 0.6	 0.001	 0.9	 <0.001	
Table	4.11.	Correlations	between	three	different	measurements	of	MTORC1	activity.		
	 150	Figure	4.9.	LP	CD4+	MTORC1	activity	before	&	after	the	supplementation	period,	showing	basal,	maximal	&	%	responsive.	Top,	AA	v.	placebo;	bottom,	MM	v	placebo.	
	 151	Figure	4.10.	Effect	of	supplementation	on	change	in	LP	CD4+	MTORC1	activity.	Top,	AA	v.	placebo.	Bottom,	MM	v.	placebo.	
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Although	MTORC1	responsiveness	was	not	affected	by	treatment	allocation,	it	was	correlated	with	post-treatment	VH	in	both	AA	and	MM	groups	(ρ	=	0.56;	P	=	0.04	and	ρ	=	0.53;	P	=	0.01	respectively;	Figure	4.11),	but	not	their	corresponding	placebos	(ρ	=	0.4;	P	=	0.2	and	ρ	=	0.4;	P	=	0.1	for	AA	placebo	and	MM	placebo,	respectively).	However	there	was	no	correlation	at	baseline,	and	the	change	in	VH	was	not	correlated	to	baseline	MTORC1	activity	(data	not	shown).	
Figure	4.11.	Correlation	between	MTORC1	responsiveness	and	villus	height	after	the	
supplementation	period	in	active	treatment	groups.		
4.5 Effect	of	HIV	status	
4.5.1.1 Baseline	characteristics	in	per-protocol	population	The	HIV	seropositivity	prevalence	at	randomisation	was	29.4%	(30/102	participants),	reflecting	the	known	HIV	prevalence	of	30%	in	this	population.	5/30	were	new	diagnoses.	20/25	of	established	diagnoses	were	on	HAART,	with	a	median	duration	of	therapy	of	7	years	(IQR	2.75	–	9	years).	Peripheral	CD4+	counts	were	robust	(median	550,	IQR	372-720,	range	129	–	999),	and	only	2	participants	had	a	CD4+	count	of	<200.	HIV	positive	men	were	under-represented	in	the	per-protocol	population.	HIV	positive	participants	were	also	older.	Interestingly,	non-pathogenic	stool	parasites	were	less	prevalent	in	HIV	positive	participants	(Table	4.12).	
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	 HIV	negative	(n=57)	 HIV	positive	(n=27)	 P		
Age	 34.4	(22.0	–	47.0)	 41.0	(35.0	–	50.0)	 0.02	
Sex,	M:F	 22:35	 4:23	 0.02	a	
Height,	cm	 Male	 167	(165	–	172)	 173	(171	–	174)	 0.08	
Female	 156	(153	–	161)	 159	(156	–	162)	 0.09	
Body	mass	index,	kg.m-2	 Male	 20.1	(19.2	–	21.2)	 19.9	(19.3	–	24.4)	 0.8	
Female	 25.0	(22.2	–	28.4)	 23.3	(20.0	–	27.6)	 0.08	
Fat	%	by	ADP	 Male	 15.9	(11.0	–	18.0)	 20.0	(14.5	–	30.0)	 0.2	
Female	 34.2	(27.7	–	41.1)	 34.3	(24.3	–	38.8)	 0.3	
Grip	strength,	kg	 Male	 39.4	(36.2	–	42.7)	 38.0	(34.8	–	41.3)	 0.5	
Female	 27.6	(24.2	–	33.2)	 28.3	(24.2	–	30.5)	 0.9	
Completed	primary	education,	%	 44.8	 40.7	 0.7	a	
Household	hygiene	score,	0-10	 6	(5	–	7)	 6	(5	–	6)	 0.15	
Household	electricity,	%	 72.4	 55.6	 0.1	b	
Routinely	boil	water	 2/57	 4/27	 0.08	a	
Routinely	chlorinate	water	 14/57	 7/27	 1	a	
Non-pathogenic	stool	parasites,	%	 53.4	 22.2	 0.007	b	
Table	4.12.	Baseline	characteristics	in	HIV	positive	and	negative	participants	Values	are	given	as	median	(IQR)	unless	otherwise	stated.	For	explanatory	notes	see	
Table	4.2	(p.	140).	P	values	derived	using	Mann-Whitney	U	test	unless	otherwise	stated.	a	Fisher’s	exact	test.	b	χ2	test.	
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4.5.1.2 Effect	of	HIV	on	primary	outcomes	There	were	no	differences	in	baseline	parameters	between	HIV	positive	and	negative	participants	(Table	4.13).		
	 HIV	negative	n	 HIV	positive	n	 P	
VH,	μm	 42	 200	(168	–	242)	 19	 212	(190	–	249)	 0.5	
CD,	μm	 42	 166	(139	–	197)	 19	 163	(152	–	199)	 0.9	
VW,	μm	 42	 229	(204	–	256)	 19	 223	(199	–	289)	 1	
VA	per	unit	MM	 42	 17900	(13600	–	21200)	 19	 18300	(15400	–	21300)	 0.9	
VP	per	unit	MM	 42	 511	(423	–	676)	 19	 512	(457	–	590)	 1	
%	CD4+	p4EBP1+	 33	 49.5	(39.7	–	65.0)	 11	 57.1	(48.6	–	77.4)	 0.4	
Basal	p4EBP1	MFI	 33	 265	(239	–	318)	 11	 300	(261	–	349)	 0.4	
Max.	p4EBP1	MFI	 33	 502	(434	–	563)	 11	 510	(394	–	597)	 1	
%	fields	with	leak	 54	 83.2	(56.7	–	91.3)	 27	 83.3	(62.8	–	91.7)	 0.9	
Table	4.13.	Baseline	parameters	in	HIV	positive	and	negative	participants.		No	significant	differences	between	HIV	seropositive	and	seronegative	participants	were	observed	on	the	primary	outcomes	when	analysed	by	treatment	group;	however	in	many	cases	too	few	paired	samples	were	available	for	HIV	positive	participants	to	draw	meaningful	conclusions.	Furthermore,	no	main	or	interaction	effects	were	observed	between	HIV	status	and	either	or	both	of	the	interventions,	and	a	regression	model	(section	4.6)	also	confirmed	that	HIV	was	not	contributing.	Although	the	proportion	of	nutrient	responsive	CD4+	T	cells	was	similar	at	baseline	between	HIV	positive	and	negative	participants,	HIV	positive	participants	who	received	AA	supplementation	had	a	significantly	higher	proportion	of	MTORC-responsive	CD4+	T	cells	compared	to	placebo	(Figure	4.12).	Due	to	the	small	numbers	of	participants	with	available	paired	samples,	it	could	not	be	shown	that	AA	supplementation	affected	a	change	in	phospho-4EBP1	positivity	or	activity	in	HIV	positive	participants.	
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Figure	4.12.	Effect	of	AA	supplementation	on	lamina	propria	CD4+	T	cell	nutrient	
responsiveness	post-intervention.		
4.6 Correlation	between	small	intestinal	structure,	
function	and	lamina	propria	lymphocyte	nutrient	
responsiveness	
There	was	no	correlation	between	baseline	morphometry,	MTORC1	activity,	and	endomicroscopic	barrier	dysfunction	(Table	4.14).	Furthermore,	no	correlations	were	observed	between	any	of	the	primary	outcomes.	In	particular,	the	change	in	VH,	fluorescein	leak,	and	CD4+	T	cell	MTORC1	activity	were	not	associated	with	each	other,	either	over	all	or	by	treatment	group	(Table	4.15;	overall	correlations	shown).	In	a	multivariate	linear	regression	model	examining	the	effect	of	supplement	type,	HIV	status,	lean	body	mass	percentage	at	baseline	(as	a	global	marker	of	health)	and	endomicroscopic	leak	at	baseline	on	change	in	villus	height,	only	AA	supplementation	emerged	as	a	statistically	significant	predictor	(P	0.04),	although	the	model	had	poor	predictive	value	(adjusted	R2	0.04).		Similarly,	post-supplementation	MTORC1	activity	was	correlated	with	post-supplementation	VH,	and	a	multivariate	linear	regression	model	examining	the	
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effect	of	HIV	status,	treatment	group,	post-supplementation	endomicroscopic	leak,	post-supplementation	lean	body	mass	percentage,	and	post-supplementation	proportion	of	phospho-4EBP1	positive	CD4+	T	cells,	only	MTORC1	responsiveness	was	a	significant	predictor	(P	0.046),	although	again	the	model	explained	only	a	tiny	fraction	of	the	variance	observed	(adjusted	R2	0.01).		
	 ρ		 P		
VH	v.	leak	 -0.1	 0.6	
VH	v.	MTORC1	 0.1	 0.4	
Leak	v.	MTORC1	 -0.2	 0.3	
Table	4.14.	Correlations	between	baseline	parameters.		
	 ρ		 P		
Change	in	VH	v.	change	in	leak	 -0.1	 0.5	
Change	in	VH	v.	change	in	MTORC1	 0.1	 0.9	
Change	in	leak	v.	change	in	MTORC1	 -0.3	 0.2	
Table	4.15.	Correlations	between	primary	outcomes.		
4.7 Safety	and	adverse	events	
All	supplements	were	well	tolerated.	The	most	frequent	adverse	events	were	feeling	hungry,	cough,	diarrhoea,	nausea,	vomiting,	and	dizziness.	There	were	no	serious	adverse	events	and	no	deaths	occurred.	Adverse	experiences	were	not	more	frequent	in	the	amino	acid	or	micronutrient	groups	(Table	4.16).	
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Table	4.16.	Adverse	events.	*Diarrhoea	classed	as	severe	if	required	time	off	work	/	usual	
activities,	lasted	3	or	more	days,	was	bloody,	or	required	medical	attention.	None	of	the	cases	
classed	as	severe	were	because	of	dysentery	or	requiring	medical	attention.	**	There	were	no	
confirmed	cases	of	malaria.	***Reversal	agents	not	required.	
Adverse	event	 Placebo	 AA	 Placebo	 MM	
Abdominal	fullness	
	 1	 1	 	
Abdominal	pain	 8	 3	 4	 7	
Accidental	ingestion	of	sachet	
	 1	 1	 	
Anorexia	
	 2	 1	 1	
Backache	 5	 4	 5	 4	
Body	pains	 3	 1	 2	 2	
Body	weakness	
	 3	 	 3	
Chest	pain	 1	 	 	 1	
Cough	 4	 1	 2	 3	
Cough	requiring	oral	antibiotics	 6	 6	 4	 8	
Diarrhoea	(severe)*	 5	 2	 2	 5	
Diarrhoea	(uncomplicated)	 5	 8	 9	 4	
Dizziness	 5	 2	 3	 4	
Dysmenorrhoea	
	 1	 	 1	
Febrile	illness	requiring	oral	antibiotics	 1	 1	 	 2	
Feet	swelling	 1	 	 1	 	
Fever	 1	 1	 1	 1	
Headache	 10	 13	 8	 15	
Heart	palpitations	 2	 	 1	 1	
Herpes	zoster	
	 1	 	 1	
Hunger	 6	 15	 8	 13	
Incomplete	spontaneous	abortion	 1	 	 1	 	
Joint	pains	 4	 3	 4	 3	
Malaise	 1	 	 	 1	
Malaria	(self-diagnosed)	
	 1	 1	 	
Malarial	illness**	 3	 6	 5	 4	
Nausea	 5	 10	 6	 9	
Odynophagia	
	 1	 1	 	
Oversedation	at	endoscopy***	 1	 	 1	 	
Painful	legs	 2	 3	 3	 2	
Phlebitis	at	sedative	injection	site	 2	 1	 1	 2	
Prolonged	menstrual	bleeding	 1	 	 1	 	
Rash	 1	 	 	 1	
Reduced	mobility	 1	 	 	 1	
Sleepiness	
	 2	 	 2	
Sneezing	 2	 4	 2	 4	
Sore	mouth	 1	 	 1	 	
Sore	throat	 1	 	 	 1	
Sore	throat	requiring	oral	antibiotics	 1	 1	 1	 1	
Toothache	
	 1	 1	 	
Toothache	requiring	oral	antibiotics	 1	 	 	 1	
Borborygmi	
	 1	 1	 	
Vomiting	 6	 6	 5	 7	
Weakness	 1	 1	 1	 1	
Weight	loss	
	 1	 	 1	
TOTAL	 98	 108	 89	 117	
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5 	
CHAPTER	5	
RESULTS:	SECONDARY	OUTCOMES	
6 AND	EXPLORATORY	ANALYSES	
5.1 Lamina	propria	TH1	cells	and	the	role	of	MTORC1	
signalling	
The	proportion	of	lamina	propria	TH1	(CD3+	CD4+	TBET+)	cells	was	assessed	after	the	supplementation	period	and	compared	across	treatment	groups.	There	was	a	high	proportion	of	lamina	propria	TH1	lymphocytes	(median	(IQR)%	81.9	[73.5-76.5]).	29.9	(1-38.4)%	of	TH1	cells	had	an	activated	phenotype	(HLA-DR+).	Although	in	HIV	positive	participants	the	absolute	number	of	CD4+	LP	lymphocytes	was	reduced	(section	5.4,	p.162),	the	proportion	of	TH1	cells	(of	total	LP	CD4+	lymphocytes)	was	not	significantly	affected	by	HIV	status.	The	proportion	of	TH1	cells	that	was	activated	was	also	unaffected	by	HIV	status	(data	not	shown).	In	HIV	negative	but	not	HIV	positive	participants	there	was	a	moderate	overall	correlation	between	post-supplementation	MTORC1	activity	and	the	proportion	of	LP	TH1	cells	(ρ	0.58,	P	0.001	for	basal	activity,	ρ	0.52,	P	0.002	for	maximal	activity;	ρ	0.3,	P	0.09	for	the	proportion	of	phospho-4EBP1	positive	cells;	Figure	5.1).	However,	none	of	the	interventions	resulted	in	a	change	in	the	proportion	of	CD4+	HLA-DR+	cells	(29.4%	placebo	v.	29.8%	AA,	P	0.8;	32.2%	placebo	v.	29.2%	MM,	
P	0.9).	The	change	in	MTORC1	activity	over	the	supplementation	period	was	not	correlated	with	the	proportion	of	TH1	cells	after	supplementation	(ρ	0.1,	P	0.7	for	proportion	of	phospho-4EBP1	positive	cells;	ρ	0.1,	P	0.6	for	maximal	activity;	ρ	0.4,	
P	0.1	for	basal	activity).		 	
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Figure	5.1.	Correlation	between	LP	CD4+	lymphocyte	MTORC1	responsiveness	and	the	
proportion	of	LP	CD4+	TH1	lymphocytes	(of	all	CD4+	lymphocytes)	in	HIV	negative	participants.		
5.2 Correlation	between	T	cell	type	and	activation	status	
on	MTORC1	activity	
MTORC1	activity	in	lamina	propria	T	lymphocytes	was	assessed	by	flow	cytometry	using	three	measures:	basal	activity	(phospho-4EBP1	MFI	after	nutrient	deprivation);	maximal	activity	(phospho-4EBP1	MFI	after	nutrient	stimulation);	and	percentage	phospho-4EBP1	positive.	Basal	MTORC1	activity	was	greater	in	CD8+	cells	compared	to	CD4+	cells	(Table	5.1).	Maximal	phospho-4EBP1	activity	and	the	proportion	of	phospho-4EBP1	positive	cells	was	similar	in	CD4+	and	CD8+	cells.	There	were	no	significant	differences	between	HIV	positive	and	negative	participants	Table	5.2.		
	 CD4+		 CD8+		 P	
Basal	p4EBP1	MFI	 281	(241	–	318)	 290	(241	–	343)	 0.011	
Max.	p4EBP1	MFI	 502	(424	–	571)	 550	(408	–	630)	 0.2	
%	p4EBP1	positive	 51.2	(41.6	–	64.8)	 46.9	(39.0	–	61.0)	 0.2	
Table	5.1.	MTORC1	activity	according	to	T	lymphocyte	type.		
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Table	5.2.	MTORC1	activity	markers	in	CD4+	compared	to	CD8+	cells,	according	to	HIV	status.		Activated	(HLA-DR+)	CD4+	lymphocytes	had	greater	maximal	MTORC1	activity	compared	to	resting	(HLA-DR–)	cells	(Table	5.3).	There	were	no	significant	differences	in	CD8+	cells	overall.	However,	when	analysed	by	HIV	status,	maximal	phospho-4EBP1	levels	were	higher	in	activated	compared	to	resting	CD4+	and	CD8+	T	cells	in	HIV	negative	participants,	and	in	CD4+	but	not	CD8+	T	cells	in	HIV	positive	participants	(Table	5.4).	There	were	no	significant	differences	between	HIV	positive	and	negative	participants	(data	not	shown).		
	 HLA-DR+		 HLA-DR–		 P		
CD4+	p4EBP1	MFI	 528	(442	–	615)	 467	(401	–	529)	 <0.001	
CD8+	p4EBP1	MFI	 546	(420	–	629)	 536	(396	–	635)	 0.3	
Table	5.3.	Maximal	MTORC1	activity	according	to	activation	status.		
	 HLA-DR+		 HLA-DR–		 P		
CD4+	p4EBP1	MFI	
(HIV	negative)	
528	(456	–	603)	 467	(415	–	529)	 <0.001	
CD8+	p4EBP1	MFI	
(HIV	negative)	
567	(447	–	628)	 528	(394	–	608)	 0.005	
CD4+	p4EBP1	MFI	
(HIV	positive)	
528	(405	–	674)	 436	(297	–	518)	 0.004	
CD8+	p4EBP1	MFI	
(HIV	positive)	
459	(370	–	635)	 548	(393	–	646)	 0.1	
Table	5.4.	HIV	negative:	maximal	phospho-4EBP1.	
	 HIV	negative	 HIV	positive	 P	
Basal	CD4+	p4EBP1	MFI	 265	(239	–	318)	 300	(261	–	349)	 0.4	
Basal	CD8+	p4EBP1	MFI	 298	(242	–	364)	 273	(228	–	325)	 0.5	
Max.	CD4+	p4EBP1	MFI	 502	(434	–	563)	 510	(394	–	597)	 0.9	
Max.	CD8+	p4EBP1	MFI	 559	(421	–	617)	 491	(385	–	648)	 0.4	
CD4+	p4EBP1+	%	 49.5	(39.7	–	65.0)	 57.1	(48.6	–	64.8)	 0.4	
CD8+	p4EBP1+	%	 49.9	(39.5	–	61.2)	 45.0	(36.7	–	56.9)	 0.5	
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There	was	a	good	correlation	between	CD4+	and	CD8+	MTORC1	activity	(ρ	0.66,	
P	<0.001	for	phospho-4EBP1	positive	proportion;	ρ	0.71,	P	<0.001	for	basal	phospho-4EBP1;	ρ	0.66,	P	<0.001	for	maximal	phospho-4EBP1).		
5.3 Impaired	MTORC1	signalling	response	to	in	vitro	
nutrient	stimulation	in	a	subset	of	lamina	propria	
CD3+	lymphocytes	
Nutrient	stimulation	produced	a	bimodal	p4E	expression	pattern	in	both	CD4+	and	CD8+	lymphocytes	in	many	participants,	with	a	significant	proportion	of	cells	not	demonstrating	any	MTORC1	activity	after	nutrient	stimulation	(Figure	5.2).	7-AAD	staining	before	and	after	fixation	and	permeabilisation	in	a	subset	of	participants	demonstrated	that	these	cells	were	both	viable	up	to	the	point	of	fixation,	and	subsequently	fully	permeabilised	to	allow	nuclear	staining	with	the	phospho-4EBP1	antibody	(representative	experiment	shown	in	Figure	5.3).	A	bimodal	distribution	was	present	in	40/70	(57.1%)	of	participants	at	baseline,	and	was	not	associated	with	HIV	status	(P	0.29,	χ2).	The	percentage	of	‘anorexic’	lymphocytes	was	20.9	(15.4	–	28.4)	for	CD4+	cells	and	17.8	(12.1	–	30.5)	for	CD8+	cells	(P	0.27).	
Figure	5.2.	Bimodal	phospho-4EBP1	pattern	in	lamina	propria	CD4+	lymphocytes	in	response	
to	nutrient	stimulation	in	vitro.	
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Figure	5.3.	7-AAD	staining	demonstrating	that	all	LP	CD4+	cells	were	viable	before	fixation	(red	
histogram)	and	fully	permeabilised	after	fixation	&	permeabilisation	(blue	histogram).		
5.4 Effect	of	HIV	status	on	lamina	propria	CD4+	T	
lymphocyte	population	
The	mean	number	of	lamina	propria	CD3+	lymphocytes	harvested	from	biopsies	in	HIV	negative	and	positive	participants	was	similar	(1778	v.	1747	cells,	P	0.66).	However,	the	mean	number	of	CD3+	CD4+	cells	was	greatly	reduced	in	HIV	positive	participants	(741	v.	303,	P	0.02).	In	HIV	positive	participants,	the	peripheral	CD4+	count	was	strongly	correlated	with	the	proportion	of	lamina	propria	CD4+	lymphocytes	(ρ	0.81,	P	<0.001;	Figure	5.4).	
Figure	5.4.	Correlation	between	peripheral	CD4+	count	and	the	proportion	of	CD4+	lamina	
propria	T	lymphocytes	in	HIV	positive	participants.	
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	The	proportion	of	CD4+	lamina	propria	lymphocytes	was	greatly	reduced	in	HIV	positive	individuals	(38.2	(27.9	–	54.2)%	in	HIV	negative	v.	11.6	(4.7	–	33.1)%	in	HIV	positive;	P	<0.001;	Figure	5.5);	however	the	proportion	of	activated	(HLA-DR+)	lymphoctyes	and	the	proportion	of	CD4+	TH1	cells	was	not	affected	by	HIV	status	(sections	5.1	and	5.5.2).	
Figure	5.5.	Proportion	of	CD4+	lamina	propria	T	cells	according	to	HIV	status.		
5.5 Characteristics	of	the	lamina	propria	immune	
compartment	in	adults	with	EE	
5.5.1 CD8+:CD4+	ratio	
Lamina	propria	CD3+	T	lymphocytes	were	predominantly	CD8+	in	all	participants.	The	CD8+:	CD4+	ratio	at	baseline	was	1.6	(0.85	–	2.5)	in	HIV	negative	individuals	and	7.6	(2.15	–	18.75)	in	HIV	positive	individuals	(P	<0.001).	There	was	no	correlation	between	CD8+:CD4+	ratio	and	severity	of	enteropathy	as	assessed	by	morphometry,	CLE,	or	serum	markers	(data	not	shown).		
P <0.001 
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5.5.2 T	cell	activation	
The	proportion	of	CD4+	and	CD8+	HLA-DR+	cells	declined	significantly	over	the	supplementation	period	(Table	5.5),	although	no	significant	changes	were	observed	when	analysing	by	HIV	status	(data	not	shown).		
	 Baseline		 Post		 P		
%	HLA-DR+	(CD4+)	 57.1	(42.7	–	72.4)	 46.0	(35.8	–	56.2)	 0.036	
%	HLA-DR+	(CD8+)	 54.8	(42.0	–	73.0)	 42.6	(30.6	–	56.9)	 0.001	
Table	5.5.	Proportion	of	activated	lymphocytes	before	and	after	supplementation.		None	of	the	interventions	resulted	in	significant	changes	in	the	proportion	of	HLA-DR+	T	cells	(CD4+:	P	0.5	for	AA	v	placebo,	P	0.8	for	MM	v	placebo;	CD8+:	P	0.9	for	AA	v	placebo;	P	1.0	for	MM	v	placebo).	None	of	the	markers	of	MTORC1	activity	(proportion	of	phospho-4EBP1	positive	cells;	basal	phospho-4EBP1	MFI;	maximal	phospho-4EBP1	MFI)	were	correlated	with	the	proportion	of	CD4+	or	CD8+	HLA-DR+	cells	(data	not	shown).		
5.6 Serum	markers	of	intestinal	barrier	function	
5.6.1 Effect	of	supplementation	on	serum	markers	of	
translocation	and	immune	activation		
A	summary	of	baseline	levels	of	serum	CRP,	sCD14	and	LPS	is	given	in	Table	5.6.	Levels	were	largely	unchanged	over	the	supplementation	period	in	all	groups.	74/74	of	participants	had	detectable	LPS	at	baseline,	compared	to	64/68	(94.1%)	after	supplementation.	Although	median	levels	of	CRP	and	sCD14	were	within	the	normal	range,	22/85	(25.9%)	of	participants	at	baseline	and	25/82	(30.5%)	after	supplementation	had	raised	serum	CRP	levels.	Similarly,	3/85	(3.5%)	of	
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participants	at	baseline	and	9/84	(10.7%)	after	supplementation	had	raised	serum	sCD14	levels.		
	 Normal	 AA	placebo	 AA	 MM	placebo	 MM	
sCD14	/	mg.ml-1	 <4	 2.0	(1.5-2.5)	 1.8	(1.4-2.4)	 1.7	(1.4-2.2)	 2.0	(1.5-2.6)	
LPS	/	EU.ml-1	 <1	 173	(88-232)	 177	(104-264)	 161	(79-262)	 184	(107-262)	
CRP	/	mg.ml-1	 <5	 3.9	(1.1-9.7)	 1.8	(0.7-3.4)	 2.0	(0.9-8.5)	 2.0	(0.7-7.9)	
Table	5.6.	Serum	levels	of	sCD14,	LPS	and	CRP	at	baseline.	EU,	endotoxin	units.	
	None	of	the	interventions	had	any	effect	on	these	markers	(Table	5.7).	HIV	status	did	not	influence	the	response	to	supplementation	(data	not	shown).	CRP	was	weakly	correlated	with	sCD14	at	baseline	(ρ	0.26,	P	=	0.017)	and	in	all	intervention	groups	post-intervention	(ρ	0.31,	P	0.004	across	intervention	groups)	but	neither	were	correlated	with	LPS.		
Change	in	 AA	 Placebo	 P	 MM	 Placebo	 P	
LPS	(EU/ml)	 -36	(-136-86)	 -24	(-91-58)	 0.64	 -55	(-165-15)	 5	(-91-86)	 0.11	
CRP	(mg/l)	 0.05	(-0.8-1.7)	 -0.3	(-2.9-2.0)	 0.26	 0.06	(-0.8-2.5)	 -0.2	(-1.5-0.8)	 0.19	
sCD14	(mg/l)	 0.3	(-0.07-0.9)	 0.1	(-0.3-0.7)	 0.28	 0.1	(-0.3-0.7)	 0.4	(-0.2-0.8)	 0.37	
Table	5.7.	Change	in	LPS,	sCD14	and	CRP	levels	over	time	and	effect	of	supplementation.		
5.6.2 Correlations	between	serum	markers	and	morphometry	&	
endomicroscopic	leak	
There	was	a	modest	correlation	between	serum	LPS	levels	and	VH	(ρ	0.28,	P	0.038)	and	VA	per	unit	mucosal	length	(ρ	0.31,	P	0.022)	at	baseline	only	(Figure	5.6).	There	was	no	correlation	between	the	serum	markers	and	in	vivo	mucosal	leak	as	assessed	by	CLE	(v.	LPS:	ρ	0.07,	P	0.5	;	v.	sCD14:	ρ	–0.05,	P	0.7;	v.	CRP:	ρ	–0.14,	
P	0.2).	
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Figure	5.6.	Correlation	between	serum	LPS	and	morphometry	at	baseline.		
5.6.3 Effect	of	HIV	status	on	translocation	and	activation	markers	
LPS	and	CRP	levels	at	baseline	were	unaffected	by	HIV	status.	sCD14	levels	were	significantly	higher	in	HIV	seropositive	participants	at	both	timepoints	(Table	5.8	and	Figure	5.7).	Neither	HIV	positive	nor	HIV	negative	participants	responded	to	any	of	the	interventions	(data	not	shown).		
	 HIV	negative	 HIV	positive	 P	
sCD14	/	ng.ml-1	 1.7	(1.4-2.0)	 2.5	(2.1-3.1)	 <0.001	
LPS	/	EU.ml-1	 175	(97-262)	 161	(91-266)	 0.9	
CRP	/	mg.ml-1	 1.9	(0.6-8.4)	 4.1	(1.2-7.7)	 0.1	
Table	5.8.	Serum	levels	of	sCD14,	LPS	and	CRP	according	to	HIV	status	at	baseline.	EU,	
endotoxin	units.		 	
	 167	
Figure	5.7.	Serum	levels	of	sCD14	according	to	HIV	status. 	
5.7 Metabonomics	
Metabonomic	analysis	was	performed	by	Dr	Jonathan	Swann	and	Dr	Jordi	Mayneris,	Imperial	College	London.	Significant	OPLS-DA	models	were	obtained	for	the	three	active	groups	(MM	with	‘AA’	placebo;	AA	with	‘MM’	placebo;	and	both)	post-supplementation	compared	to	placebo,	and	also	for	differences	over	time	within	each	treatment	group.	Significantly	differentially	excreted	urinary	metabolites	are	shown	in	Table	5.9	and	Table	5.10,	with	OPLS-DA	loadings	plots	in	Figure	5.8	(p.169).	
Changes	by	group	after	supplementation	
	 Increased	with	intervention	 Reduced	with	intervention	 Q2Y	 P	for	
model	
MM	v	placebo	 Panthothenate,	HMB,	PAGn,	4CS	 NMNA,	3HPHPA	 0.35	 0.01	
AA	v	placebo	 BAIBA,	PAGn,	4CS,	citrate	 No	significant	changes	 0.35	 0.01	
MM+AA	v	placebo	 Pantothenate,	succinate,	HMB,	PAGn,	fumarate,	2PY		 No	significant	changes	 0.36	 0.01	
Table	5.9.	Significant	metabonomic	changes	in	three	active	treatment	groups	compared	to	
placebo.	2PY	=	N-methyl-2-pyridone-5-carboxamide;	3HPHPA	=	3-(3-hydroxyphenyl)-3-
hydroxy-propionic	acid;	4CS	=	4-cresyl	sulphate;	BAIBA	=	β-amino-isobutyric	acid;	HMB	=	
β-hydroxy-β-methylbutyrate;	NMNA	=	N-methylnicotinic	acid;	PAGn	=	phenylacetylglutamine	 	
	 168	
Changes	within	group	over	time	
	 Increased	over	time	 Reduced	over	time	 	 Q2Y	 P	for	
model	
MM	pre	v	post	 Pantothenate,	HMB,	succinate,	2PY,	NMND	 BAIBA,	4HH,	3IS	 0.54	 0.01	
AA	pre	v	post	 Citrate,	myo-inositol,	formate	 Taurine,	glycolate,	trans-aconitate	 0.55	 0.01	
MM+AA	pre	v	post	 Pantothenate,	HMB,	succinate,	2PY,	PAGn,	citrate,	NMND,	unknown	 BAIBA,	2HIB,	choline,	acetylcholine,	taurine,	hippurate	 0.79	 0.01	
Placebo	pre	v	post	 No	significant	changes	 No	significant	changes	 N/A	 N/A	
Table	5.10.	Significant	metabonomic	changes	in	treatment	groups	over	time.	2HIB	=	2-
hydroxyisobutyrate;	2PY	=	N-methyl-2-pyridone-5-carboxamide;	3IS	=	3-indoxyl	sulphate;	4HH	
=	4-hydroxyhippurate;	BAIBA	=	β-amino-isobutyric	acid;	HMB	=	β-hydroxy-β-methylbutyrate;	
NMND	=	N-methylnicotinamide;	PAGn	=	phenylacetylglutamine		To	explore	drivers	of	our	primary	endpoints,	OPLS	models	were	constructed	to	identify	metabolic	features	associated	with	post-treatment	villus	height	and	post-treatment	MTORC1	activation	(as	measured	by	the	proportion	of	phospho-4EBP1	positive	CD4+	T	cells).	Significantly	differentially	excreted	urinary	metabolites	are	shown	in	Table	5.11,	with	a	representative	OPLS-DA	loadings	plot	(for	the	MTORC1	model)	in	Figure	5.9	(p.170).	Putative	roles	of	these	metabolites	are	given	in	Table	5.12	(p.172).		
Outcome	 Positively	correlated	 Negatively	correlated	 P	for	model	
VH	 HMB,	DMG,	creatine,	creatinine,	GAA,	taurine,	2PY,	formate	 No	significant	changes	 0.01	
MTORC1	 HMB,	2HIB,	2PY,	pseudouridine	 4CS,	Hippurate,	PAGn	 0.01	
Table	5.11.	Differentially	excreted	urinary	metabolites	correlated	with	post-treatment	villus	
height	and	post-treatment	MTORC1	responsiveness.	2HIB	=	2-hydroxyisobutyrate;	2PY	=	N-
methyl-2-pyridone-5-carboxamide;	4CS	=	4-cresyl	sulphate;	DMG	=	dimethylglycine;	GAA	=	
guanidinoacetic	acid;	HMB	=	β-hydroxy-β-methylbutyrate;	PAGn	=	phenylacetylglutamine		
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Figure	5.8.	OPLS-DA	loadings	plots	showing	metabolites	associated	with	supplementation	
versus	corresponding	placebo.	Top,	MM	v.	placebo.	Middle,	AA	v.	placebo.	Bottom,	AA+MM	v.	
placebo.	Metabolites	with	significant	correlations	are	highlighted.	1,	NMNA;	2,	PAGn;	3,	
3HPHPA;4,	4CS;	5,	HMB;	6,	Pantothenate;	7,	Citrate;	8,	BAIBA;	9	2PY;	10	Succinate.	For	
abbreviations	and	further	information	see		Table	5.12	.	
	 170	
	
	
Figure	5.9.	OPLS-DA	loadings	plots	showing	metabolites	associated	with	MTORC1	activity.	
Metabolites	with	significant	correlations	are	highlighted.	1,	2PY;	2,	Hippurate;	3,	
Pseudouridine;	4,	PAGn;	5,	4CS;	6,	HMB.	For	abbreviations	and	further	information	see	Table	
5.12.		
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Metabolite	 	 Pathway	 Origin	 Possible	roles	in	enteropathy,	stunting	or	
nutrition	
References	
β-hydroxy-β-
methylbutyrate	
HMB	 Leu	 Host	 Minor	physiological	leucine	metabolite.	Some	evidence	for	promoting	lean	muscle	mass.	Positively	correlated	with	VH	in	childhood	EE.	MTORC1	agonist.	
(Borack	and	Volpi,	2016;	Farràs	et	al.,	2018)	
Phenylacetyl-
glutamine	
PAGn	 Phe	 Co-metabolite	 Produced	by	hepatic	conjugation	of	L-Gln	with	microbially	derived	phenylacetic	acid.	Correlated	with	VH	in	childhood	EE.	 (Aronov	et	al.,	2011;	Farràs	et	al.,	2018)	
N-methylnicotinic	
acid	
NMNA	 B3	/	Trp	/	IDO	 Host	 L-Trp	/	Niacin	(B3)	metabolite.	Reduced	levels	observed	in	rat	model	of	malnutrition.	Correlated	with	childhood	wasting	and	underweight.	
(Mayneris-Perxachs	et	al.,	2016;	Wu	et	al.,	2010)	
3-(3-hydroxy-
phenyl)-3-hydroxy-
propionic	acid	
HPHPA	 Phe	 Co-metabolite	 Microbially	derived	L-Phe	metabolite	–	particularly	Clostridia.	Possibly	implicated	in	neuropsychiatric	disorders.	 (Shaw,	2010;	Xiong	et	al.,	2016)	
β-amino-isobutyric	
acid	
BAIBA	 Val	 Host	 Lower	levels	associated	with	enhanced	catch-up	growth	in	childhood	undernutrition.	Anti-inflammatory	and	protective	against	oxidative	stress	and	insulin	resistance.	Thermogenic.	
(Mayneris-Perxachs	et	al.,	2016)	
N-methyl-2-
pyridone-5-
carboxamide	
2PY	 Trp	 Host	 Correlated	with	childhood	stunting.	 (Mayneris-Perxachs	et	al.,	2016)	
N-methyl-
nicotinamide	
NMND	 B3	/	Trp		/	IDO	 Host	 L-Trp	/	Niacin	(B3)	derivative.	Hgher	levels	associated	with	enhanced	catch-up	growth	in	childhood	undernutrition.	 (Mayneris-Perxachs	et	al.,	2016)	
2-hydroxy-
isobutyrate	
2HIB	 	 Co-metabolite	 Correlated	with	childhood	stunting	and	VH	in	childhood	EE.	 (Farràs	et	al.,	2018;	Mayneris-Perxachs	et	al.,	2016)	
Pantothenate	 	 B5	 Host	 Required	for	lipid	biosynthesis.	Correlated	with	childhood	stunting.	 (Mayneris-Perxachs	et	al.,	2016)	
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Taurine	 	 Cys	 Co-metabolite	 Low	levels	associated	with	childhood	stunting.	 (Semba	et	al.,	2016)	
4-cresyl	sulphate	 4CS	 Tyr	 Co-metabolite	 Correlated	with	childhood	stunting.	 (Mayneris-Perxachs	et	al.,	2016)	
Citrate	 	 TCA	 Host	 Negatively	correlated	with	childhood	stunting.	 (Mayneris-Perxachs	et	al.,	2016)	
Succinate	 	 TCA	 Host	 Correlated	with	VH	in	childhood	EE.	 (Farràs	et	al.,	2018)	
Fumarate	 	 TCA	 Host	 Unknown	 	
Myo-inositol	 	 PL	 Host	 Enhances	insulin	sensitivity.	Precursor	to	membrane	phospholipids.	 	
Formate	 	 	 Co-metabolite	 Byproduct	of	acetate	metabolism.	 	
Hippurate	 	 	 Co-metabolite	 Correlated	with	childhood	wasting	and	underweight.	 (Mayneris-Perxachs	et	al.,	2016)	
4-hydroxyhippurate	 	 	 Co-metabolite	 Correlated	with	VH	in	childhood	EE.	 (Farràs	et	al.,	2018)	
Glycolate	 	 	 	 Unknown	 	
Trans-aconitate	 	 TCA	 	 Unknown	 	
3-indoxyl	sulphate	 3IS	 Trp	 Co-metabolite	 Correlated	with	childhood	stunting	and	VH	in	childhood	EE.	 (Farràs	et	al.,	2018;	Mayneris-Perxachs	et	al.,	2016)	
Choline	 	 	 	 Required	for	lipid	membrane	stability	and	lipid	metabolism.	 	
Acetylcholine	 	 TCA	 	 Unknown	 	
Guanidinoacetic	
acid	
GAA	 	 	 Creatine	precursor;	livestock	muscle	enhancer	supplement	 (Ostojic,	2015)	
Table	5.12.	Significant	metabolites	identified	through	metabonomic	analysis:	putative	biological	roles.	B3,	niacin;	B5,	pantothenate;	IDO,	indolamine	2,3-
dioxygenase;	TCA,	tricyclic	acid	cycle;	PL,	phospholipid	synthesis.	
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5.8 Enterohumoral	trophic	signalling	assessed	by	plasma	
GLP2	levels	
Serum	GLP2	levels	were	similar	across	all	treatment	groups,	and	did	not	change	significantly	over	the	supplementation	period.	GLP2	levels	were	not	altered	by	any	of	the	interventions	(Table	5.13).	GLP2	levels	were	suppressed	in	HIV	positive	individuals	(Table	5.14	and	Figure	5.10),	although	HIV	status	had	no	effect	on	response	to	supplementation	(data	not	shown).	
	 AA	 Placebo	 P	 MM	 Placebo	 P	
Baseline	GLP2	
(ng/mL)*	
0.76		(0.0	–	1.4)	 0.92		(0.49	–	1.4)	 0.44	 0.75		(0.0	–	1.5)	 0.88		(0.51	–	1.4)	 0.86	
Δ	GLP2	
(ng/mL)	
0.21		(-0.57	–	0.63)	 0.34	(0.0	–	0.52)	 0.44	 0.25		(-0.27	–	0.57)	 0.25		(-0.05	–	0.59)	 0.66	
Table	5.13.	Effect	of	AA	or	MM	supplementation	on	fasting	serum	GLP2	concentrations.	
*Normal	range	not	established.	
Figure	5.10.	Serum	GLP2	concentrations	according	to	HIV	status.			
	 HIV	negative	 HIV	positive	 P	
GLP2	/	ng.ml-1	 1.2	(0.5	–	1.5)	 0.6	(0.0	–	1.3)	 0.047	
Table	5.14.	Baseline	GLP2	levels	by	HIV	status.	
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Furthermore	there	was	a	moderate	negative	correlation	between	morphometry	and	GLP2	levels	in	HIV	positive	individuals	only.	Although	small	intestinal	absorptive	area	as	measured	by	morphometry	was	not	correlated	with	GLP2	levels	in	the	study	population	as	a	whole,	there	was	a	moderate	negative	correlation	with	both	VH	(ρ	-0.53,	P	0.02)	and	CD	(ρ	-0.46,	P	0.046)	in	HIV	positive	individuals	at	baseline.		
5.9 Global	nutritional	status	and	body	composition	
5.9.1 Effect	of	interventions	on	body	composition	
Baseline	anthropometric	and	nutritional	markers	are	given	in	Table	5.15.	None	of	the	interventions	influenced	any	of	these	nutritional	outcomes	(Table	5.16).	
	 AA	 Placebo	 MM	 Placebo	
MUAC	 27.3		(25.3	–	30.2)	 28.5		(25.8	–	32.0)	 28.3		(25.4	–	31.3)	 27.9		(25.4	–	31.3)	
Grip	strength	 31.8		(24.7	–	39.2)	 29.2		(27.1	–	36.9)	 30.7		(27.5	–	36.9)	 31.2		(25.7	–	37.9)	
Body	fat	%	 24.5		(17.2	–	34.4)	 30.9		(19.3	–	40.6)	 30.3		(17.6	–	38.1)	 28.5		(17.3	–	36.1)	
BMI	 22.5		(19.7	–	25.0)	 22.4		(20.5	–	27.6)	 23.0		(20.0	–	26.4)	 21.5		(19.8	–	25.8)	
Table	5.15.	Baseline	anthropometric	characteristics	by	intervention	group.		
Change	in:	 AA	 Placebo	 P		 MM	 Placebo	 P		
MUAC	 0.3		(-0.8	–	1.2)	 0.2		(-1.0	–	1.4)	 0.86	 0.1		(-0.8	–	1.4)	 0.3		(-1.0	–	1.0)	 0.79	
Grip	strength	 0.0		(-2.8	–	1.6)	 -0.9		(-3.8	–	1.1)	 0.25	 -0.9		(-3.8	–	1.3)	 -0.6		(-2.4	–	0.9)	 0.64	
Body	fat	%	 -1.2		(-3.4	–	0.7)	 -0.8		(-3.7	–	1.3)	 0.69	 -1.1		(-3.6	–	1.5)	 -0.9		(-3.5	–	0.6)	 0.89	
BMI	 -0.4		(-0.7	–	0.4)	 0.0		(-0.7	–	0.3)	 0.95	 -0.4		(-0.8	–	0.2)	 -0.0		(-0.5	–	0.5)	 0.13	
Table	5.16.	Effect	of	intervention	on	body	composition.	
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5.9.2 Effect	of	HIV	
Despite	similar	lean	mass	percentage	and	other	anthropometric	markers,	HIV	positive	individuals	had	lower	grip	strength	at	baseline	only	(Table	5.17).		
	 HIV	negative	 HIV	positive	 P		
MUAC	 28.0	(25.7	–	31.0)	 27.9	(25.1	–	32.0)	 0.90	
Grip	strength	 34.4	(27.0	–	39.1)	 28.7	(25.7	–	33.0)	 0.04	
Body	fat	%	 27.7	(16.9	–	36.2)	 31.7	(21.6	–	38.6)	 0.31	
BMI	 22.6	(20.0	–	26.0)	 21.4	(19.8	–	26.0)	 0.51	
Table	5.17.	Baseline	nutritional	characteristics	by	HIV	status.	
	Body	fat	percentage	moderately	correlated	with	CRP	in	HIV	negative	participants	only	(ρ	0.46,	P	<0.001;	Figure	5.11),	but	not	other	markers	of	enteropathy	or	leak	including	morphometry	and	endomicroscopy	(data	not	shown).	
 
Figure	5.11.	Correlation	between	serum	CRP	and	body	fat	percentage	at	baseline	in	HIV	
negative	participants.	
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6 	
CHAPTER	6	
DISCUSSION	
	
6.1 Overview	
Environmental	enteropathy	is	a	sub-clinical	alteration	in	small	intestinal	mucosal	architecture	and	function,	widely	prevalent	in	the	tropics	and	in	disadvantaged	communities.	A	randomised,	double	blind,	placebo-controlled	trial	was	completed	in	a	particularly	disadvantaged	sub-Saharan	urban	community	with	little	food	security	or	access	to	sanitation,	clean	water	or	health	facilities.	The	trial	explored	several	factors	thought	to	influence	enteropathy:	nutrition	and	the	mucosal	immune	response	to	nutrients;	gut	permeability;	systemic	and	mucosal	immune	inflammation;	dysbiosis;	and	trophic	enterohumeral	signalling.	This	was	a	complex	interventional	phase	II	trial	undertaken	in	a	low	income	country.	The	trial	was	successfully	completed	as	planned	according	to	the	trial	protocol.	This	is	the	largest	clinical	study	of	confocal	laser	endomicroscopy	ever	undertaken,	with	in	vivo	CLE	examinations	completed	in	84	participants	at	two	timepoints.	It	is	also	the	first	time	that	the	mucosal	immune	compartment	in	EE	has	been	studied	by	flow	cytometry,	and	the	first	study	of	nutrient	and	MTORC1	signalling	in	human	intestinal	immune	cells.	Participants	were	representative	of	the	adult	population	from	which	they	were	drawn,	and	were	predominantly	young	and	female.	Importantly,	the	proportion	of	HIV	positive	participants	was	similar	to	the	population	prevalence	(30%).	Although	the	study	was	conducted	in	healthy	adults,	the	participants	had	clear	evidence	of	stunting	and	of	significant	asymptomatic	small	bowel	enteropathy.	In	addition	to	lifestyle	markers	of	deprivation	(lack	of	access	to	chlorinated	/	boiled	water;	low	levels	of	education;	low	levels	of	household	hygiene	and	sanitation),	the	high	prevalence	of	non-pathogenic	intestinal	parasites	(as	well	as	helminths	and	Giardia	in	excluded	participants)	reflects	the	unsanitary	conditions	in	this	community.	
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Despite	widespread	undernutrition	in	this	population,	a	significant	proportion	of	the	study	population	were	overweight	or	obese	(occasionally	morbidly	so)	despite	harbouring	significant	enteropathy.	This	likely	reflects	one	sequela	of	the	‘impoverished	gut’	hypothesis	(Guerrant	et	al.,	2013),	where	impaired	gut	barrier	function	results	in	a	chronic	systemic	pro-inflammatory	response	and	the	metabolic	syndrome.	Women	were	disproportionately	overweight,	which	is	opposite	to	the	pattern	observed	in	Western	populations	(although	the	overall	prevalence	of	overweight	is	significantly	lower	in	Zambia).	In	the	UK,	for	example,	male	and	female	levels	of	overweight	are	68%	and	58%	respectively	(Health	and	Social	Care	Information	Centre,	2016).	This	has	concerning	implications	at	a	population	health	level,	given	that	both	stunting	and	the	metabolic	syndrome	are	inheritable	phenomena,	and	the	increased	perinatal	and	maternal	morbidity	and	mortality	associated	with	maternal	overweight.	The	supplements	were	well	tolerated	and	compliance	appeared	to	be	high.	This	was	assessed	using	supplement	counts	every	four	weeks;	although	directly	observed	therapy	is	the	gold	standard	for	confirming	compliance,	this	was	not	feasible	in	an	interventional	study	of	this	size	and	nature.	Some	of	the	significant	metabolites	in	the	AA	and	MM	groups	(pantothenate	in	MM	supplemented;	PAGn	–	a	glutamine	co-metabolite	–	in	AA	supplemented)	may	be	indirect	evidence	of	good	compliance.		
6.2 Summary	of	findings	
Although	there	was	evidence	for	an	effect	of	the	interventions	on	villus	morphology	and	barrier	dysfunction	as	hypothesised,	the	supplements	did	not	modify	mucosal	lymphocyte	MTORC1	nutrient	sensing.	The	novel	findings	arising	from	this	study	include:	
• Amino	acid	supplementation	compared	to	placebo	increased	villous	height	and	villous	cross-sectional	area,	but	this	change	was	not	correlated	with	changes	in	serological	or	endomicroscopic	signs	of	intestinal	barrier	dysfunction.	
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• The	combination	of	amino	acids	and	micronutrients,	taken	together	but	not	separately,	did	appear	to	reduce	gut	permeability	assessed	by	confocal	endomicroscopy.	
• Although	mucosal	T	lymphocyte	MTORC1	activity	was	not	influenced	by	either	intervention,	post-supplementation	lamina	propria	CD4+	MTORC1	activity	was	correlated	with	villous	height	and	cross-sectional	area.	
• Serological	measures	of	immune	activation	and	microbial	translocation	(CRP;	sCD14;	LPS)	did	not	change	with	any	of	the	interventions.	LPS	was	correlated	with	VH	at	baseline	only.	
• Although	MTORC1	activity	was	not	altered	by	supplementation,	CD4+	T	cell	nutrient	responsiveness	was	correlated	with	TBET	expression	in	CD4+	T	cells	(TH1	phenotype).	There	was	a	high	proportion	of	LP	TH1	cells.	
• Levels	of	GLP2,	a	trophic	enterohumoral	peptide,	were	generally	paradoxically	depressed	and	were	not	influenced	by	supplementation,	including	with	amino	acids.	
• The	lamina	propria	CD8+:CD4+	ratio	was	reversed,	with	a	CD8+	dominant	population	compared	to	normal.	
• There	appears	to	be	a	seasonal	effect	on	MTORC1	responsiveness	in	LP	lymphocytes,	although	there	was	no	correlation	with	morphometry	which	also	exhibited	a	seasonal	variation.	
• A	number	of	metabolites	were	identified	which	correlated	with	VH	and	MTORC1	activity;	of	these,	the	tryptophan	metabolite	2PY	and	the	leucine	metabolite	HMB	were	also	affected	by	supplementation	(although	not	by	amino	acid	supplementation	alone).	
• In	contrast	to	effects	on	morphometry,	some	of	these	results	were	affected	by	HIV	status.	
• No	effects	were	observed	on	body	composition	assessed	using	a	number	of	methods.	Taken	together,	these	findings	provide	further	insight	into	the	immunological,	microbiological	and	functional	abnormalities	characterising	EE.	Although	AA	supplementation	improved	VH	and	VA,	and	supplementation	with	both	AA	and	MM	improved	endomicroscopic	barrier	dysfunction,	there	were	few	correlations	between	the	histological	severity	of	enteropathy	or	endomicroscopic	severity	of	
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barrier	dysfunction	and	any	other	markers	of	enteropathy.	There	was	an	intriguing	correlation	between	villus	height	(and	small	intestinal	histology)	and	CD4+	lymphocyte	nutrient	responsiveness.		
6.3 Enteropathy	characteristics	in	the	study	population	
6.3.1 Severity	of	enteropathy	at	baseline	
Morphometry,	confocal	endomicroscopy,	and	serological	markers	were	consistent	with	a	moderate	to	severe	enteropathy,	despite	no	evidence	of	loss	of	epithelial	integrity	under	white	light	endoscopy.	Morphometry	confirmed	marked	villus	atrophy	and	crypt	hypertrophy.	The	villus-to-crypt	ratio	was	in	several	cases	<1,	and	was	normal	(≥	3)	in	none.	Severe	and	almost	universal	intestinal	dysfunction	was	observed	by	confocal	endomicroscopy.	Pathological	barrier	dysfunction	has	been	noted	in	other	small	bowel	diseases	including	quiescent	Crohn’s	disease,	coeliac	disease,	and	irritable	bowel	syndrome	(Fritscher-Ravens	et	al.,	2014;	Kiesslich	et	al.,	2012;	Leong	et	al.,	2008;	Neumann	et	al.,	2012),	but	the	gross	abnormalities	observed	here	are	remarkable	by	their	severity	and	universality.	For	example,	quiescent	Crohn’s	is	characterised	by	pathological	endomicroscopic	findings	in	up	to	30%	of	fields	in	individual	patients,	in	comparison	to	the	great	majority	of	involved	fields	in	this	study.		
6.3.2 Microbial	translocation	and	immune	activation	
Serum	markers	of	bacterial	translocation	such	as	LPS	and	immune	activation	such	as	sCD14	and	CRP	have	been	used	indirectly	to	assess	the	level	of	translocation	in	
vitro.	These	markers	were	elevated	in	a	significant	proportion	of	healthy	asymptomatic	individuals	in	this	study,	but	were	unaffected	by	the	study	interventions.	LPS	was	almost	universally	detectable;	over	a	quarter	of	participants	had	elevated	levels	of	CRP;	and	up	to	10%	of	participants	had	elevated	levels	of	sCD14.	Interestingly,	sCD14	levels	were	significantly	higher	in	HIV	
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positive	participants	despite	other	markers	of	enteropathy	being	similar,	suggesting	that	other	subtle	abnormalities	are	at	work	in	HIV	infection.	The	importance	of	low	grade	chronic	inflammation	has	been	implicated	in	the	metabolic	syndrome.	In	stunted	infants,	elevated	inflammatory	markers	are	correlated	with	serum	markers	of	intestinal	damage	and	with	suppressed	growth	factor	secretion,	providing	a	mechanism	which	links	immune	activation	due	to	intestinal	damage	to	impaired	growth	in	children	(Prendergast	et	al.,	2014).		The	relevance	of	these	markers	in	adults	with	enteropathy	is	not	fully	understood,	but	in	western	populations	has	been	implicated	in	the	metabolic	syndrome.	The	‘impoverished	gut’	hypothesis	extrapolates	this	to	impoverished	communities,	where	chronic	immune	activation	in	combination	with	early	life	epigenetic	imprinting	predisposes	these	individuals	to	obesity	and	metabolic	disorders	including	diabetes	which	is	increasingly	observed	in	these	populations	despite	the	lack	of	classical	risk	factors	for	these	conditions	(Guerrant	et	al.,	2013).		
6.3.3 The	lamina	propria	immune	compartment	
6.3.3.1 CD8+	predominance	in	the	CD3+	compartment	The	investigation	of	the	mucosal	immune	compartment	in	EE	by	flow	cytometry	has	not	previously	reported.	The	lamina	propria	was	heavily	skewed	towards	CD8+	(CD3+	CD4–) T	cells,	with	CD8+	cells	outnumbering	CD4+	cells	1.6:1	in	HIV	negative	individuals	and	7.6:1	in	HIV	positive	individuals,	in	contrast	to	normal	lamina	propria	where	CD4+	predominate.	In	the	only	previous	study	to	assess	the	lamina	propria	in	EE	(in	Gambian	children),	LP	T	lymphocyte	density	was	assessed	using	immunohistochemistry	(Campbell	et	al.,	2003a).	CD3+	cells	were	dramatically	increased	compared	to	UK	controls,	and	the	numbers	of	CD4+	and	CD8+	cells	were	estimated	to	be	similar.	Although	the	ratio	is	skewed	further	in	this	current	study,	both	studies	strikingly	demonstrate	the	reverse	of	‘healthy’	lamina	propria,	where	CD4+	cells	predominate.	It	is	interesting	to	speculate	that	the	proportion	of	CD8+	cells	may	increase	over	time	in	appropriately	exposed	environments.	This	may	reflect	the	excessive	T	cell	mediated	cytotoxic	tissue	response	resulting	in	the	disordered	mucosal	architecture	observed	in	EE;	however,	there	was	no	
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correlation	between	CD8+:CD4+	ratio	and	morphometric,	endomicroscopic,	or	serological	measures	of	enteropathy.	It	is	interesting	to	contrast	these	studies	in	individuals	with	EE	with	patients	with	coeliac	disease,	a	histologically	similar	enteropathy,	where	80%	of	lamina	propria	T	cells	are	CD4+	(Jöhrens	et	al.,	2010).	Both	are	characterised	by	lamina	propria	T	cell	infiltration	and	a	cytotoxic	T	cell	inflammatory	response.	It	is	likely	that	both	LP	CD4+	and	CD8+	lymphocytes	are	increased	in	EE	(with	proportionately	greater	CD8+	cells,	explaining	the	inverse	ratio	observed),	whereas	in	coeliac	disease	the	increased	infiltrate	is	due	predominantly	to	CD4+	recruitment.	The	lamina	propria	CD8+	dominance	has	not	been	described	in	other	conditions,	and	the	drivers	and	consequences	of	this	require	further	study.		
6.3.3.2 Activated	lymphocytes	In	this	study,	approximately	half	of	LP	CD4+	and	CD8+	T	lymphocytes	were	activated	(HLA-DR+).	There	are	little	data	on	LP	lymphocyte	activation	in	the	proximal	small	bowel,	and	no	recent	studies	using	flow	cytometry.	However,	a	study	investigating	the	proportion	of	duodenal	/	proximal	jejunal	lamina	propria	CD4+	HLA-DR+	lymphocytes	by	immunohistochemistry	found	only	33%	and	8%	of	CD4+	and	CD8+	lymphocytes	(respectively)	were	activated	in	adults	with	untreated	coeliac	disease,	compared	to	20%	and	12.5%	in	controls	(Griffiths	et	al.,	1988).	On	the	other	hand,	a	previous	study	of	adults	with	EE	in	this	population,	where	HLA-DR	status	was	also	assessed	immunohistochemically,	found	that	87%	of	LP	CD3+	cells	were	HLA-DR+	(Veitch	et	al.,	2001).	Interestingly	the	proportion	of	CD3+	HLA-DR+	cells	observed	in	relatively	affluent	South	Africans	in	the	same	study	is	comparable	to	the	that	seen	in	the	current	study.	It	is	possible	that	improved	living	standards	over	the	last	fifteen	years	has	resulted	in	a	reduction	in	immunological	stimulation.	However,	EE	is	convincingly	characterised	by	an	activated	lamina	propria	T	cell	immune	response	in	addition	to	a	highly	activated	epithelial	immune	compartment;	and	this	is	markedly	more	pronounced	than	the	lamina	propria	activation	observed	in	coeliac	disease,	a	histologically	similar	enteropathy.	Mucosal	lymphocytes	are	traditionally	seen	as	controlling	and	influencing	the	mucosa.	It	is	interesting	to	note	that	the	severity	of	enteropathy	(as	assessed	
	 182	
histologically)	was	not	correlated	with	lamina	propria	TH1	or	CD8+	activation	(as	assessed	by	HLA-DR	positivity),	and	similarly	that	changes	in	morphology	were	not	correlated	to	HLA-DR	positivity.	It	would	be	interesting	to	compare	and	contrast	these	findings	with	coeliac	disease;	to	my	knowledge	this	has	not	been	investigated	previously.		
6.3.3.3 TH1	predominance	in	the	CD4+	compartment	The	LP	CD4+	population	was	predominantly	of	a	TH1	phenotype,	as	observed	in	normal	lamina	propria	and	in	coeliac	disease	(Jöhrens	et	al.,	2010).	This	is	in	keeping	with	previous	observations	that	EE	is	characterised	by	TH1-mediated	T	cell	cytotoxicity	(Campbell	et	al.,	2003a;	Veitch	et	al.,	2001).	Counterintuitively,	however,	these	TH1	cells	had	a	predominantly	resting	phenotype	(HLA-DR–).	Possible	explanations	for	this	include	immunological	senescence	following	chronic	over-stimulation,	or	suppression	in	a	tolerogenic	environment.	Given	that	overall	CD4+	activation	was	approximately	50%,	by	definition	non-TH1	CD4+	cells	will	be	highly	activated	and	it	is	interesting	to	speculate	that	this	may	reflect	a	highly	activated	Treg	population.		
6.3.3.4 ‘Anorexic’	lymphocytes	A	majority	of	participants	had	lamina	propria	T	cells	which	exhibited	a	bimodal	response	to	nutrient	stimulation.	This	could	most	easily	be	explained	by	non-viable	cells	(which	would	not	respond	to	nutrient	stimulation)	or	by	failure	of	the	permeabilisation	step	(so	that	the	target	phospho-4EBP1	antigen	was	not	accessible	for	staining).	However	both	of	these	possibilities	were	excluded	with	the	use	of	a	viability	dye,	which	confirmed	that	these	cells	were	viable	before	fixation	and	adequately	permeabilised	before	staining.	This	subset	of	lymphocytes	could	not	be	characterised	further;	they	may	represent	senile,	anergic	or	pre-apoptotic	cells,	which	are	metabolically	inactive.	This	phenomenon	was	not	observed	in	peripheral	T	cells	from	healthy	UK	donors,	and	further	work	is	required	to	determine	if	this	phenomenon	is	specific	to	environmental	enteropathy,	lamina	propria	T	cells,	or	both.	There	was	no	correlation	to	any	other	
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flow	cytometric	findings	such	as	T	cell	activation,	the	proportion	of	TH1	cells,	or	CD8+:CD4+	ratio.		
6.3.4 Seasonal	variability	
Seasonal	variation	in	mucosal	structure	and	/	or	intestinal	permeability	and	microbial	translocation	in	this	population	has	previously	been	demonstrated	(Kelly	et	al.,	2004).	A	reduction	in	small	bowel	absorptive	area	over	the	rainy	season	(which	coincided	with	the	supplementation	period)	was	again	observed.	This	has	anecdotally	been	attributed	to	increased	pathogen	load	resulting	in	increased	mucosal	inflammation,	secondary	to	deteriorating	water	and	sanitation	in	the	rainy	season.	In	this	study	no	functional	changes	in	gut	function	were	observed	–	LPS,	sCD14,	CRP	and	endomicroscopic	leak	were	unchanged	over	the	supplementation	period,	somewhat	arguing	against	this.	However,	a	reduction	in	dietary	quality	and	quantity	during	this	time	(colloquially	known	as	the	‘hungry	season’)	may	also	be	relevant,	particularly	with	regards	to	nutrient	sensing	pathways.		
6.4 Impact	of	supplementation	on	the	intestinal	barrier	
in	EE	
6.4.1 Effects	of	amino	acid	supplementation	
AA	supplementation	prevented	a	seasonal	deterioration	in	villous	height	and	cross-sectional	area.	Crucially,	the	observed	effect	on	mucosal	histology	was	not	associated	with	in	any	changes	in	gut	barrier	function.	Microbial	translocation	(measuring	LPS)	and	systemic	immune	activation	(measuring	serum	CRP	and	sCD14)	were	all	unaffected	by	the	interventions,	and	were	not	correlated	with	the	histological	severity	of	enteropathy.	An	interaction	effect	was	observed	on	barrier	permeability	as	assessed	by	CLE:	barrier	leak	reduced	in	participants	who	received	both	active	supplements.	The	reduction	in	permeability	observed	does	not	appear	to	be	functionally	relevant,	as	there	was	no	correlation	with	other	markers	of	
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barrier	dysfunction	such	as	LPS,	sCD14,	and	CRP;	this	suggests	that	greater	improvements	in	permeability	than	those	observed	are	required	to	reduce	microbial	translocation.	These	findings	can	be	explained	by	hypothesising	that	different	pathophysiological	mechanisms	are	driving	villus	atrophy	and	intestinal	permeability.	Villus	height	in	the	proximal	small	bowel	(determined	by	enterocyte	replication,	migration	and	apoptosis)	might	be	rate-limited	by	MTORC1	signalling	and	the	enteral	availability	of	nutrients	such	as	glutamine,	leucine	and	tryptophan.	Conversely,	pathological	permeability	may	be	predominantly	driven	by	dysbiosis	and	inflammation.	If	improvements	in	histology	and	barrier	function	are	limited	to	the	proximal	small	bowel	(the	major	site	of	nutrient	absorption),	then	residual	gut	dysfunction	present	in	the	distal	small	bowel	and	colon	may	be	enough	to	negate	any	benefits	in	the	proximal	bowel.	This	hypothesis	will	be	difficult	to	test	until	less	invasive,	but	still	reliable,	methods	of	evaluating	the	whole	small	intestinal	mucosa	are	available.		
6.4.2 Effects	of	multiple	micronutrient	supplementation	
In	the	current	study,	no	effects	of	MM	supplementation	on	the	villus	unit	were	identified.	This	is	in	contrast	to	a	post	hoc	analysis	of	a	trial	of	vaccine	immunogenicity	in	healthy	adults	with	EE	in	this	population,	which	suggested	that	high	dose	multiple	micronutrient	supplementation	improved	villus	height	(Louis-Auguste	et	al.,	2014).	The	findings	from	this	study	are	likely	to	be	more	reliable	as	this	morphometry	was	a	primary	outcome	in	this	study,	as	opposed	to	a	secondary	retrospective	analysis.	Furthermore,	our	previous	study	used	histological	samples	taken	at	a	single	timepoint	during	the	Zambian	dry	season,	whereas	the	current	study	looked	for	changes	on	a	background	of	a	seasonal	deterioration	in	morphometry.	It	is	possible	that	the	severity	of	the	enteropathy	in	the	rainy	season	would	have	negated	any	beneficial	effects	of	the	micronutrient	supplement.		
	 185	
6.4.3 Relationship	between	barrier	dysfunction	and	
morphometry	
Little	is	known	about	the	correlation	between	small	intestinal	histology	and	intestinal	permeability,	as	the	great	majority	of	work	has	been	conducted	in	children	with	non-invasive	tests.	In	this	study,	permeability	in	healthy	but	stunted	adults	was	measured	in	two	complementary	ways:	directly	by	endomicroscopy	and	indirectly	by	levels	of	serum	markers.	A	positive	correlation	between	serum	LPS	and	small	intestinal	absorptive	area	at	baseline	(reflected	in	VH	and	VA	per	unit	mucosal	length)	was	observed,	without	any	correlations	with	other	serum	and	confocal	markers	of	barrier	dysfunction	(although	numbers	were	relatively	small).	This	suggests	that,	at	least	up	to	a	certain	extent,	a	reduced	surface	area	may	in	fact	be	protective	against	microbial	translocation:	individuals	with	blunted	villi	have	less	area	for	translocation	to	occur,	resulting	in	lower	levels	of	microbial	translocation.	A	relatively	mild	reduction	in	absorptive	capacity	is	sacrificed	in	order	to	reduce	the	degree	of	systemic	immune	activation	and	chronic	inflammation.	The	lack	of	other	correlations	may	be	explained	by	hypothesising	that	the	physiological	improvements	from	a	relatively	unaffected	proximal	small	bowel	may	be	completely	negated	by	a	dysfunctional	distal	bowel,	as	discussed	above.	Furthermore,	subtle	changes	in	permeability	would	not	necessarily	be	detectable	by	endomicroscopy,	as	high	levels	of	fluorescein	leak	would	still	be	observed.	In	a	previous	study	in	this	population,	the	histological	severity	of	enteropathy	was	inversely	correlated	with	intestinal	permeability	as	assessed	by	urinary	lactulose	recovery	(Kelly	et	al.,	2004).	In	a	recent	study	we	identified	a	weak	correlation	between	serum	LPS	and	endomicroscopic	barrier	defects	/	leak,	as	well	as	a	U-shaped	correlation	between	serum	LPS	and	morphometry	(Kelly	et	al.,	2016).	The	positive	correlation	between	VH	and	serum	LPS	seen	here	would	be	consistent	with	the	upstroke	of	this	correlation.	Although	sCD14	and	CRP	levels	were	correlated	with	each	other,	neither	were	correlated	with	levels	of	LPS.	Of	these	markers,	LPS	is	direct	measure	of	bacterial	translocation,	whereas	sCD14	and	CRP	are	host-related	factors;	it	is	possible	that	immune	dysregulation	/	tachyphylaxis	in	individuals	with	EE	means	that	levels	of	
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these	inflammatory	markers	/	mediators	are	paradoxically	suppressed	and	may	not	be	correlated	with	translocation	in	a	linear	manner.	Over	all,	the	correlation	between	VH	and	serum	LPS	needs	to	be	taken	with	caution	as	the	strength	of	the	correlation	was	modest	(ρ	0.31),	no	effect	was	observed	post-supplementation	(although	any	correlation	may	have	been	obscured	by	the	positive	effect	of	AA	supplementation	on	VH),	and	there	was	no	association	with	the	other	markers	used.	However,	this	is	some	further	evidence	for	a	‘protective’	role	of	mucosal	atrophy	in	EE,	and	represents	a	conceptual	shift	in	the	pathogenesis	of	EE.		
6.5 Potential	role	of	MTORC1	signalling	
The	role	of	MTORC1	signalling	in	lymphocytes	of	the	mucosal	immune	compartment	has	not	previously	been	investigated.	These	first	results	in	humans	support	a	role	of	MTORC1	signalling	promoting	villus	growth.	Amino	acid	but	not	micronutrient	supplementation	improved	VH	compared	to	placebo,	without	influencing	mucosal	T	lymphocyte	MTORC1	activity.	However	the	correlation	between	post-supplementation	VH	and	CD4+	MTORC1	activity	in	participants	receiving	amino	acids	suggests	that	immune	cell	MTORC1	signalling	may	indirectly	influence	the	epithelial	compartment.	Interestingly,	a	similar	positive	correlation	was	also	observed	in	post-supplementation	VH	and	CD4+	MTORC1	activity	in	the	MM	supplement	group.	This	may	suggest	that	amino	acid	or	micronutrient	supplementation	may	prime	the	villus	compartment	for	growth,	in	response	to	permissive	nutrient-replete	signals	from	the	immune	compartment.		The	trophic	effect	of	AA	supplementation	on	the	intestinal	epithelium	may	be	mediated	trough	enterocyte	/	intestinal	stem	cell	MTORC1	signalling.	For	example,	Glutamine	is	a	well	known	enterotrophic	amino	acid	but	its	mechanism	of	action	is	unknown.	Intriguingly,	however,	a	number	of	in	vitro	and	animal	models	have	suggested	that	MTORC1	inhibition	(by	dietary	or	pharmacological	means)	results	in	mucosal	atrophy	(Dias	et	al.,	1998;	Nakamura	et	al.,	2012;	Yi	et	al.,	2015).	Furthermore,	animal	and	in	vitro	models	suggest	a	role	for	intestinal	epithelial	MTORC1	signalling	in	protecting	against	apoptosis	and	LPS-induced	cell	death.	
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These	findings	are	of	obvious	relevance	for	EE,	and	may	explain	the	protective	effect	on	VH	observed	in	AA	supplementation.		Preliminary	work	for	this	study	attempted	to	investigate	epithelial	MTORC1	signalling	using	immunohistochemistry.	In	surgically	resected	small	intestinal	tissue,	phospho-rS6	(an	alternative	marker	of	MTORC1	activity)	was	diffusely	and	indiscriminately	expressed	in	the	epithelial	barrier,	in	contrast	to	previous	work	in	mice	where	activity	is	predominantly	limited	to	the	crypts	(Nakamura	et	al.,	2012;	Yilmaz	et	al.,	2012).	We	hope	to	conduct	further	work	to	examine	the	role	of	MTORC1	signalling	in	the	villous	unit	in	future	work.		
6.5.1 Lamina	propria	lymphocyte	MTORC1	signalling	and	TH1	
differentiation	
This	is	thought	to	be	the	first	investigation	of	MTORC1	signalling	in	intestinal	lymphocytes.	MTORC1	signalling	has	critical	roles	in	innate	and	adaptive	immune	cell	(particularly	CD4+	T	lymphocyte)	differentiation	and	response.	In	peripheral	CD4+	lymphocytes,	MTORC1	activity	promotes	a	TH1	(effector)	phenotype,	whereas	MTORC1	inhibition	results	in	a	Treg	(anti-inflammatory)	phenotype	(Powell	et	al.,	2012).	T	cell	activation	also	requires	MTORC1	activity	which	can	only	occur	in	a	nutrient-rich	environment.	It	was	postulated	that	amino	acid	supplementation	would	augment	lymphocyte	MTORC1	signalling	and	therefore	promote	TBET	expression	/	TH1	differentiation.	However	amino	acid	supplementation	had	no	effect	had	MTORC1	signalling	or	TBET	expression.	The	amino	acid	dosages	are	likely	to	have	ensured	adequate	delivery	to	the	proximal	small	bowel.	It	is	possible	that	the	lack	of	response	observed	is	a	phenomenon	secondary	to	the	chronic	immune	stimulation	in	EE	(e.g.	anergy	or	senescence).	Alternatively,	isolated	nutrient	stimulation	may	be	an	insufficient	stimulus	for	MTORC1	activation	in	this	immune	cell	population	in	individuals	with	EE.	On	the	other	hand,	the	proportion	of	nutrient-responsive	LP	lymphocytes	correlated	with	the	proportion	of	CD4+	TBET+	T	cells,	consistent	with	a	role	for	MTORC1	signalling	in	effector	cell	differentiation.	TBET	is	the	canonical	TH1	
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transcription	factor	and	is	necessary	and	required	for	TH1	differentiation	and	function	(i.e.	IFNγ	production).	The	mucosal	immune	compartment	is	predominantly	inhabited	by	experienced	(differentiated)	immune	cells;	however	these	cells	exhibit	plasticity	under	appropriate	stimuli	and	immune	signalling	conditions.	Therefore	the	population	of	TBET+	cells	observed	may	include	non-classical	‘mixed’	immune	cells	expressing	TBET,	in	addition	to	classical	TH1	cells.	In	other	systems,	these	cells	have	TH1-like	effector	functions	including	IFNγ	production.	Further	work	is	required	to	establish	the	precise	immunophenotype,	function	and	relevance	of	these	TBET+	cells,	but	this	work	suggests	that	MTORC1	signalling	promotes	a	TH1	or	TH1-like	phenotype	in	mucosal	lymphocytes.		
6.5.2 MTORC1	signalling	by	T	cell	subtype	
Basal	MTORC1	activity	was	higher	in	CD8+	compared	to	CD4+	cells	in	HIV	negative	participants	only.	Although	the	proportion	of	nutrient-responsive	lymphocytes	was	not	affected	by	activation	status,	activated	lymphocytes	(HLA-DR+)	had	higher	maximal	phospho-4EBP1	levels	compared	to	resting	(HLA-DR–)	cells.	This	implies	that	activation	augments	MTORC1	synergistically	with	nutrient	stimulation.	The	higher	MTORC1	activity	observed	would	promote	a	transcriptional	and	metabolic	program	to	support	effector	functions.	Due	to	experimental	design,	basal	phospho-4EBP1	levels	according	to	activation	status	and	phospho-4EBP1	levels	in	TBET+	cells	could	not	be	measured.	Although	the	proportion	of	responsive	cells	was	similar	at	both	study	timepoints,	basal	and	maximal	MTORC1	levels	(assessed	by	p4E	MFI)	declined	significantly	over	the	supplementation	period.	Interestingly	the	proportion	of	activated	CD4+	and	CD8+	cells	also	declined	over	the	supplementation	period.	The	biological	significance	of	this	finding	is	unclear.		Due	to	LP	CD4+	depletion	in	HIV	positive	participants,	there	were	insufficient	CD4+	cells	for	analysis	in	many	cases	and	the	sample	size	was	small.	Conclusions	regarding	MTORC1	activity	cannot	be	confidently	drawn	from	this	group	of	individuals;	however,	AA	supplementation	appeared	to	enhance	CD4+	MTORC1	
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responsiveness	in	HIV	positive	individuals.	These	findings	need	to	be	replicated	in	the	first	instance.		
6.6 Effect	of	HIV	on	the	mucosal	immune	compartment	
Lamina	propria	CD4+	depletion	is	an	early	and	durable	consequence	of	HIV	infection.	In	this	current	study	population,	as	has	previously	been	observed,	overall	LP	T	cell	numbers	were	similar	but	the	proportion	and	number	of	CD4+	cells	was	dramatically	reduced	in	HIV	positive	individuals,	even	when	peripheral	CD4+	counts	were	robust.		Studies	in	Western	cohorts	suggest	that	early	HAART	initiation	as	the	most	important	determinant	of	mucosal	CD4+	reconstitution	(Allers	et	al.,	2016;	Guadalupe	et	al.,	2003);	furthermore	peripheral	reconstitution	in	these	studies	does	not	predict	mucosal	reconstitution.	Zambian	treatment	guidelines	at	the	time	of	the	study	advised	initiating	treatment	for	all	asymptomatic	adults	once	peripheral	CD4+	count	was	≤500	(Zambia	Ministry	of	Health,	2014),	based	on	WHO	guidelines	(World	Health	Organization,	2013).	Most	HIV	positive	participants	in	the	study	were	established	on	HAART.	Although	information	of	CD4+	count	and	WHO	HIV	stage	at	diagnosis	/	initiation	of	treatment	was	not	available,	it	is	likely	that	many	patients	were	diagnosed	later	than	would	be	the	case	in	Western	populations.	It	is	therefore	surprising	that	the	proportion	of	mucosal	CD4+	cells	was	strongly	correlated	with	the	peripheral	CD4+	count.	It	therefore	appears	that	the	predictors	(and	therefore	pathophysiology)	of	mucosal	CD4+	T	cell	reconstitution	in	this	population	is	different;	it	is	possible	that	the	additional	mucosal	and	systemic	immune	stimulation	resulting	from	EE	may	be	contributing.	The	correlation	between	peripheral	and	mucosal	CD4+	counts	has	not	previously	been	described	in	a	population	with	a	high	prevalence	of	EE	and	may	have	important	implications	in	treatment	of	HIV	in	impoverished	communities.		HIV	viral	load	was	not	measured	as	this	was	not	an	aim	of	the	study.	Although	the	HIV	virus	may	have	a	directly	cytopathic	effect	on	the	intestinal	epithelium	(Epple	et	al.,	2010),	its	effects	on	the	mucosal	immune	system	is	likely	to	be	predominantly	due	to	its	role	in	manipulating	the	CD4+	compartment.	
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6.6.1 Effect	of	HIV	on	intestinal	barrier	structure	and	function	
Importantly,	despite	its	effect	on	the	mucosal	immune	system,	HIV	status	did	not	affect	any	of	the	outcomes	measured,	and	neither	peripheral	nor	mucosal	CD4+	counts	correlated	with	any	of	the	outcomes.	However,	there	were	some	subtle	differences	at	baseline	between	HIV	positive	and	negative	participants.	No	histological	or	endomicroscopic	differences	between	HIV	positive	and	negative	participants	were	observed.	The	lack	of	effect	of	HIV	on	histology	and	on	barrier	permeability	may	seem	surprising.	However,	the	data	presented	here	are	entirely	consistent	with	earlier	work	(Kelly	et	al.,	2004)	which	showed	that	only	in	advanced	AIDS	did	villus	height	fall	below	the	range	consistent	with	environmental	enteropathy,	whereas	crypt	depth	was	increased	earlier	in	HIV	infection.	It	is	likely	that	in	industrialised	countries	HIV	may	impact	on	villus	morphology,	but	that	in	LMICs	any	such	subtle	effect	is	undetectable	alongside	the	environmental	enteropathy	which	is	virtually	ubiquitous.	Although	the	number	of	HIV	positive	participants	was	small,	this	suggests	that	HIV	infection	(when	well	controlled	as	defined	by	peripheral	CD4+	count,	and	irrespective	of	viral	load)	is	not	a	primary	determinant	of	enteropathy	severity	in	HIV	positive	individuals,	despite	its	effects	on	the	mucosal	immune	compartment.	Serum	sCD14	concentrations,	but	not	other	markers	of	translocation	and	immune	activation,	were	significantly	higher	in	HIV	positive	individuals	compared	to	HIV	negative	ones.	sCD14	is	released	by	activated	monocytes,	for	example	in	response	to	LPS.	The	elevated	levels	observed	here	may	reflect	a	mucosal	barrier	dysfunction	which	is	subtly	more	pronounced	in	HIV	positive	individuals,	and	/	or	subtle	over-activation	of	systemic	innate	immune	signalling.	Of	note,	elevated	sCD14	levels	are	correlated	with	excess	morbidity	and	mortality	in	HIV	positive	patients	in	Western	populations	(Hunt	et	al.,	2014;	Sandler	et	al.,	2011).	The	excessive	mortality	of	some	HIV	patients	with	EE	initiating	HAART	in	impoverished	populations	may	be	partially	explained	by	a	dysregulated	innate	immune	response;	sCD14	may	provide	a	useful	biomarker	for	risk	stratification.		
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6.7 Insights	into	host-microbial	interactions	
Metabonomic	analysis	revealed	a	number	of	insights	which	may	merit	further	investigation.	A	number	of	host-	and	microbiota-derived	metabolites	were	significantly	correlated	with	VH	and/or	CD4+	T	lymphocyte	MTORC1	activity.	Metabonomics	has	only	recently	been	applied	to	EE	/	undernutrition	and	this	is	the	first	study	to	investigate	the	metabonomic	profile	of	adults.	There	has	been	one	previous	study	investigating	the	urinary	metabonome	with	small	intestinal	histology	in	severely	malnourished	and	stunted	Zambian	children	(Farràs	et	al.,	2018),	one	non-invasive	study	investigating	correlations	with	stunting	and	growth	in	Brazilian	children	(Mayneris-Perxachs	et	al.,	2016),	and	one	non-invasive	study	investigating	responses	before	and	after	treatment	for	severe	acute	malnutrition	in	Malawian	infants	(Giovanni	et	al.,	2016).	Intriguingly,	many	of	the	significantly	correlated	metabolites	observed	in	the	current	study	have	previously	been	identified	as	markers	of	enteropathy	and	/	or	gut	dysfunction	and	/	or	stunting	in	one	or	more	of	these	studies.			
6.7.1 Markers	of	muscle	mass	and	metabolism	
β-hydroxy-β-methylbutyrate	(HMB)	is	of	particular	interest.	HMB	was	positively	correlated	with	both	MTORC1	activity	and	VH.	HMB	is	a	physiological	leucine	metabolite,	with	some	studies	supporting	a	role	for	HMB	in	enhancing	lean	muscle	mass	and	strength	(Borack	and	Volpi,	2016).	Intriguingly,	it	is	a	potent	MTORC1	agonist.	However,	despite	the	presence	of	leucine	in	the	supplement,	HMB	levels	were	not	augmented	by	amino	acid	supplementation	alone,	although	it	was	paradoxically	increased	by	MM	(with	and	without	AA)	supplementation.	These	results	corroborate	a	recent	study	in	Zambian	children,	where	a	positive	correlation	between	HMB	and	VH	was	also	noted	(Farràs	et	al.,	2018).	The	correlation	between	creatinine	and	creatine	and	VH	is	intriguing,	as	both	are	markers	of	lean	body	mass,	and	may	be	more	sensitive	markers	of	lean	body	mass	than	global	body	composition	analysis.	The	positive	correlation	may	suggest	a	correlation	between	epithelial	health	and	a	shift	towards	anabolism	in	a	reduced	inflammatory	state.	Of	note,	a	positive	correlation	between	creatinine	and	VH	was	
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also	observed	in	a	Zambian	paediatric	population	(Farràs	et	al.,	2018),	and	creatinine	was	negatively	correlated	with	stunting	in	a	Brazilian	paediatric	population	(Mayneris-Perxachs	et	al.,	2016).	Similarly,	guanidinoacetic	acid	(GAA)	is	a	creatine	precursor,	and	was	positively	correlated	with	VH.		
6.7.2 Tryptophan	and	its	metabolites	
Physiologically	and	microbially	derived	metabolites	of	tryptophan	include	N-methylnicotinamide	(NMND),	N-methylnicotinic	acid	(NMNA),	3-indoxyl	sulphate	(3IS),	and	N-methyl-2-pyridone-5-carboxamide	(2PY).	Tryptophan-derived	metabolites	were	correlated	with	MM	supplementation	(with	or	without	AA	supplementation),	but	not	with	AA	supplementation	alone.	These	included	2PY	and	NMND	which	increased	with	supplementation,	and	NMNA	which	reduced	with	supplementation.	3IS	was	reduced	in	the	MM	+	placebo	group	only.	It	therefore	appears	that	micronutrient	supplementation	modifies	host	and	/or	microbial	tryptophan	pathways,	and	that	the	amount	of	tryptophan	in	the	amino	acid	supplement	was	insufficient	to	alter	host	/	microbial	metabolic	pathways.	In	this	study,	2PY	was	correlated	with	both	VH	and	MTORC1	activity.	In	the	Brazilian	study,	2PY	was	correlated	with	stunting,	but	was	also	a	predictor	of	good	catch-up	growth.	Although	the	histological	severity	of	enteropathy	was	unknown	in	the	Brazilian	study,	good	catch-up	growth	must	reflect	low	systemic	inflammation	and	a	pro-anabolic	environment,	which	would	be	consistent	with	a	lesser	degree	of	villus	atrophy.	The	association	with	MTORC1	activity	may	reflect	MTORC1	activation	by	tryptophan-related	metabolites.	Although	no	correlations	with	VH	were	observed,	NMND	levels	increased	and	NMNA	levels	reduced	with	intervention.	This	may	have	subtle	beneficial	effects,	as	in	the	Brazilian	study	NMND	was	positively	correlated	with	catch-up	growth,	whereas	NMNA	was	negatively	correlated.	The	tryptophan	/	indoleamine	2,3-dioxygenase	(IDO)	/	kyneurine	immunometabolic	axis	is	currently	a	subject	of	great	interest.	Tryptophan	is	partly	metabolised	through	host	IDO	1	and	2	to	produce	kynurenines,	and	this	pathway	may	be	subverted	by	microbial	tryptophan	uptake	and	metabolism	(McGaha	et	al.,	
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2012;	Murray,	2016).	High	levels	of	IDO	activity	promote	regulatory	immune	responses	and	Treg	differentiation	and	inhibit	Teff	differentiation,	mediated	through	kynurenine	and	related	tryptophan	metabolite	production	(Yan	et	al.,	2010),	activation	of	GCN2	via	tryptophan	depletion	(Munn	et	al.,	2005),	and	inhibition	of	MTORC1	(Metz	et	al.,	2012).	In	stunted	children	with	EE,	plasma	tryptophan	levels	are	correlated	with	growth	(Semba	et	al.,	2016),	and	the	kynurenine	to	tryptophan	ratio	(KTR,	with	high	ratios	indicative	of	high	IDO	activity)	is	correlated	with	systemic	markers	of	inflammation	and	inversely	correlated	to	growth	(i.e.	high	KTR	and	presumed	greater	IDO	activity	associated	with	greater	stunting)	(Kosek	et	al.,	2016),	suggesting	that	microbial	manipulation	of	tryptophan	signalling	and	inhibition	of	kynurenine	production	may	be	relevant	in	the	pathophysiology	of	EE.	The	differences	observed	in	this	study	also	suggest	a	possible	role	for	tryptophan	signalling	in	modulating	the	villus	compartment	and	immune	cell	nutrient	sensing.		
6.7.3 Other	metabolites	
Dimethylglycine	(DMG)	is	a	marker	of	choline	flux.	In	this	study	it	was	positively	correlated	with	VH.	This	is	consistent	with	the	Brazilian	study	where	it	was	negatively	correlated	with	stunting	(Mayneris-Perxachs	et	al.,	2016).	A	number	of	other	metabolites	correlated	with	VH,	MTORC1	activity,	or	the	interventions	were	identified.	These	can	be	broadly	classed	as	amino	acid-derived	(e.g.	taurine;	4-cresyl	sulphate;	phenylacetylglutamine),	TCA	cycle	intermediaries	(e.g.	succinate;	formate),	or	microbial	co-products	(e.g.	pseudouridine;	hippurate).	Although	some	of	these	have	been	identified	in	undernourished	/	stunted	populations	previously,	the	significance	of	these	findings	in	this	study	is	unclear.		
6.8 Enterohumoral	signalling	in	EE:	role	of	GLP2	
GLP2	is	physiologically	secreted	in	L	cells	in	the	distal	small	bowel	in	response	to	luminal	amino	acid	delivery.	GLP2	stimulates	villus	growth	which	increases	small	
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intestinal	absorptive	area	and	thus	nutrient	(including	amino	acid)	absorption.	AA	supplementation	however	did	not	augment	GLP2	levels.	This	could	be	because,	despite	the	presence	of	enteropathy	and	reduced	absorptive	area,	all	of	the	amino	acid	load	would	have	been	absorbed	before	reaching	the	site	of	amino	acid	sensing	and	GLP2	secretion	in	the	distal	ileum.		Fasting	GLP2	levels	measured	here	were	an	order	of	magnitude	lower	than	published	values	obtained	from	normal	volunteers	(Hartmann	et	al.,	2000;	Russo	et	al.,	2012).	Although	some	of	this	variability	may	be	explained	by	different	kits,	the	lowest	results	observed	in	normal	adults	(5ng/ml)	was	obtained	using	the	same	ELISA	kit	as	used	in	the	current	study	(Russo	et	al.,	2012).	These	values	are	still	several	times	larger	than	the	median	results	observed	in	this	study.	GLP2	levels	are	also	paradoxically	suppressed	in	children	with	severe	acute	malnutrition	with	severely	reduced	small	bowel	absorptive	areas	(Amadi	et	al.,	2017)	and	have	also	been	noted	to	be	low	in	adults	with	EE	in	this	population	(Kelly	et	al.,	2016),	providing	strong	evidence	that	the	GLP2	axis	is	dysregulated	in	EE.	The	suppressed	levels	suggest	that	there	is	a	failure	of	normal	sensing	/	secreting	mechanisms	rather	that	end-organ	resistance.	However,	the	lack	of	trophic	signalling	may	have	a	protective	role,	by	reducing	the	amount	of	permeable	mucosa	available	for	microbial	translocation.	GLP2	levels	were	significantly	lower	in	HIV	positive	individuals	compared	to	HIV	negative	individuals.	Villus	height	and	crypt	depth	were	also	inversely	correlated	to	serum	GLP2	levels	in	HIV	positive	participants	only.	As	the	severity	of	enteropathy	(as	assessed	by	morphometry)	was	similar	in	HIV	positive	and	negative	participants,	it	is	unlikely	that	this	reflects	a	difference	in	absorptive	area;	rather	this	may	reflect	a	difference	in	how	nutrient	signals	to	the	distal	small	bowel	are	regulated	in	HIV.		
6.9 Anthropometry	
Baseline	anthropometrics	in	this	community	encapsulate	the	burgeoning	concern	of	the	‘impoverished	gut’	–	despite	the	relative	food	insecurity	in	this	impoverished	population,	there	is	a	high	prevalence	of	overweight	and	obesity.	It	is	postulated	
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that	the	abnormal	microbial	translocation	and	systemic	immune	activation	observed	in	EE	results	in	a	disordered	(pro-inflammatory)	metabolic	phenotype,	comparable	to	the	dysregulation	observed	in	the	metabolic	syndrome.	Of	all	the	measures	of	intestinal	barrier	dysfunction	used	in	this	study,	only	CRP	correlated	with	body	composition,	and	then	only	in	HIV	negative	participants.	CRP	is	a	non-specific	marker	of	immune	activation	from	whatever	cause,	and	this	correlation	may	therefore	reflect	the	degree	of	global	immune	activation	observed	in	EE,	as	a	sum	of	the	sub-clinical	contributions	of	a	number	of	pro-inflammatory	pathways	(reflected,	for	example,	in	LPS	or	sCD14).	The	AA	supplement	contained	the	leucine	and	tryptophan	equivalent	of	150g	of	beef	(US	Department	of	Agriculture,	2018),	and	is	likely	to	have	provided	a	significant	increase	in	daily	essential	amino	acid	intake.	The	lack	of	response	on	lean	body	mass	may	reflect	pathological	diversion	of	nutritional	resources	in	EE	in	a	catabolic	state.		
6.10 Study	strengths	
This	study	was	conducted	in	the	context	of	a	double	blind,	randomised,	placebo-controlled	trial,	and	the	differences	observed	between	treatment	groups	can	therefore	be	attributed	solely	to	those	treatments.	Compliance	was	good	and	there	were	no	problems	with	the	administration	of	the	study	which	would	limit	its	reliability	or	cast	doubt	on	its	conclusions.	To	my	knowledge,	this	is	the	largest	clinical	study	of	confocal	laser	endomicroscopy	ever	undertaken,	with	in	vivo	CLE	examinations	completed	in	84	participants	at	two	timepoints.		One	of	the	strengths	of	this	study	was	the	histological	samples	that	were	obtained	for	analysis.	This	study	obtained	a	number	of	tissue	types	from	well	characterised	healthy	adults,	including	small	intestinal	biopsies.	The	vast	majority	of	studies	investigating	EE	rely	on	indirect	/	non-invasive	measures	of	barrier	dysfunction,	most	usually	sugar	absorption	/	permeability	studies.	This	study	builds	on	our	
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previous	studies	which	have	investigated	the	links	between	the	histological	and	functional	abnormalities	observed	in	EE.		Interventional	studies	in	LMICs	should	ideally	investigate	interventions	which,	if	shown	to	be	useful,	can	be	relatively	easily	scaled	up	to	phase	III	trials	or	population-level	introduction	within	the	logistical	and	resource	limited	environment.	This	trial	investigated	the	effects	of	supplementation	in	a	representative	sample	taken	from	a	community	which	mirrors	the	problems	of	poverty	and	poor	sanitation	present	throughout	sub-Saharan	Africa	and	beyond	in	populations	with	EE.	The	interventions	themselves	were	simple,	safe,	well	tolerated,	easily	administered	and	cheap.		
6.11 Study	weaknesses	
6.11.1 Carbohydrate	and	micronutrient	absorption	assays	
The	standard	assay	of	epithelial	barrier	function	in	studies	of	EE	is	the	sugar	absorption	/	permeability	assay.	In	particular,	xylose	absorption	is	most	relevant	to	the	assessment	of	global	small	intestinal	absorptive	function.	Although	imperfect,	it	remains	in	use	because	it	is	safe	and	non-invasive.	However,	analysis	is	not	widely	available	and	there	are	technical	limitations.	This	study	aimed	to	explore	the	use	of	novel	and	alternative	methods	of	assessing	the	small	intestinal	barrier,	in	particular	using	CLE	as	in	in	vivo	method.	In	order	to	assess	the	validity	of	CLE	in	the	study	of	EE,	and	in	particular	to	assess	absorptive	function,	a	solution	containing	D-xylose	(absorbable),	L-rhamnose	(non-absorbable),	lactulose	(non-absorbable),	and	inulin	(non-absorbable)	was	administered	at	the	time	of	endoscopy,	and	baseline	and	interval	urine	samples	were	obtained	and	stored	at	–80°C.	Furthermore,	plasma	samples	to	assay	zinc	and	selenium	uptake	following	instillation	of	a	second	test	solution	were	also	obtained.	Unfortunately	due	to	insurmountable	technical	and	servicing	problems	with	the	optical	emission	spectrophotometer	in	Zambia	(for	the	zinc	and	selenium	uptake	assays)	and	HPLC	in	the	UK	(for	the	urinary	sugar	recovery	assays)	it	was	not	possible	to	complete	these	assays	in	the	timescale	of	this	work.	Although	assessment	of	zinc	and	selenium	levels	in	the	context	of	this	trial	would	be	interesting,	the	sugar	
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permeability	/	absorption	studies	are	important	to	place	the	results	of	intervention	in	context	with	other	studies	of	enteropathy,	and	with	the	utility	of	CLE	in	this	condition.	It	is	hoped	that	these	samples	will	be	analysed	and	results	will	become	available	in	2019	to	enable	a	more	complete	picture	of	the	effects	of	the	interventions.		
6.11.2 Sample	size	and	power	
The	morphometry	assessments	used	established	techniques	and	protocols,	and	sample	size	was	calculated	using	preliminary	data	from	a	previous	study	(Louis-Auguste	et	al.,	2014).	This	assumed	a	power	to	detect	15%	difference	in	morphometry	with	the	interventions	when	n=28	in	each	group	(active	treatment	v.	placebo).	The	sample	size	required	to	detect	differences	in	CLE	and	MTORC1	signalling	was	unknown,	and	the	required	sample	size	was	assumed	to	be	similar	to	the	morphometry.	In	effect	it	would	have	been	extremely	difficult	to	increase	the	trial	size	much	further	given	the	constraints	of	the	invasive	and	resource-intensive	nature	of	interventional	trials	involving	advanced	endoscopy.	Sample	size	was	adversely	affected	by	inadequately	orientated	histological	sections	and	by	low	rates	of	viable	mucosal	lymphocyte	recovery	to	the	point	of	flow	cytometric	acquisition	due	to	the	destructive	effect	of	methanol	permeabilisation	and	relative	paucity	of	tissue.	The	interventions	did	not	result	in	any	changes	in	any	of	the	secondary	outcomes	measured,	although	the	study	was	not	powered	for	these	outcomes.		
6.11.3 Poor	discriminatory	ability	of	CLE	
CLE	was	a	promising	technique	to	examine	epithelial	barrier	defects	in	real	time,	and	has	shown	reproducibility	and	prognostic	validity	in	conditions	including	IBD	and	IBS.	This	study	for	the	first	time	used	CLE	to	look	for	differences	in	barrier	function	following	an	intervention.	The	data	from	this	data	show	that	functional	mucosal	barrier	defects	are	almost	universal;	significant	fluorescein	leak	was	seen	in	the	majority	of	duodenal	fields	assessed	in	most	participants.	This	is	in	stark	contrast	to	previous	work	by	others	in	other	inflammatory	conditions;	in	clinically	
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and	endoscopically	quiescent	IBD,	for	example,	small	intestinal	endomicroscopic	leak	was	observed	in	up	to	30%	of	fields	and	in	only	5%	of	normal	controls	(Kiesslich	et	al.,	2012).	The	almost	universal	presence	of	high	levels	fluorescein	leak	encountered	in	individuals	with	EE	means	that	the	CLE	scoring	system	used	had	a	low	ability	to	discriminate	between	individuals	or	over	time.		
6.11.4 Lack	of	assessment	of	epithelial	MTORC1	activity	
The	mechanisms	by	which	nutrition	influences	the	intestinal	mucosa	is	largely	unknown.	This	study	investigated	the	role	of	nutrient	sensing	by	MTORC1	in	mucosal	T	lymphocytes.	No	effect	of	supplementation	was	observed	in	the	T	lymphocytes	but	was	seen	in	the	epithelial	compartment	(assessed	by	morphometry),	and	this	was	correlated	with	T	lymphocyte	MTORC1	responsiveness.	However	epithelial	MTORC1	signalling	could	not	be	assessed	due	to	the	difficulties	with	developing	an	assay	that	was	sufficiently	sensitive	and	discriminatory	to	detect	subtle	differences	in	MTORC1	activity	within	the	intestinal	epithelium.	This	could	probably	only	be	done	with	IHC,	as	epithelial	cells	are	not	amenable	to	flow	cytometric	analysis.	However,	in	preparatory	work,	staining	with	the	available	MTORC1	pathway	antibody	(directed	against	phospho-rS6)	was	present	diffusely	throughout	the	epithelium	and	therefore	could	not	provide	a	semi-quantitative	assessment	of	epithelial	MTORC1	activity.	Furthermore,	satisfactory	co-staining	with	lymphocyte	markers	was	not	possible	with	several	antigen	retrieval	protocols.	This	technique	was	therefore	not	pursued	further.		
6.12 Methodological	comments	
6.12.1 Morphometry	reproducibility	
Unfortunately,	in	contrast	to	previous	studies	in	this	population	it	was	not	possible	to	obtain	well	orientated	histology	sections	for	several	participants,	reducing	the	sample	size	available	for	morphometric	analysis.	However,	the	baseline	
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morphometric	measurements	of	the	small	intestinal	epithelial	compartment	in	this	study	and	in	a	previous	study	in	the	same	population	(Louis-Auguste	et	al.,	2014)	are	strikingly	similar,	suggesting	that	the	morphometry	methodology	is	valid.			
6.12.2 CLE	as	a	method	to	assess	gut	permeability	
In	this	study	CLE	was	used	as	an	in	vivo	method	to	assess	intestinal	barrier	dysfunction.	The	barrier	dysfunction	noted	on	CLE	was	significantly	greater	than	that	observed	in	other	classical	enteropathies	(Kiesslich	et	al.,	2012;	Leong	et	al.,	2008;	Neumann	et	al.,	2012).	The	scoring	system	used	here	was	easy	to	use	and	had	excellent	inter-observer	agreement.	However,	the	gross	fluorescein	leak	observed	may	have	obscured	more	subtle	abnormalities	which	might	provide	better	discriminatory	ability.	For	the	first	time	in	adults,	CLE	provided	direct,	in	
vivo	evidence	of	the	bizarre	and	highly	abnormal	mucosa	which	until	now	has	only	been	observed	histologically,	but	it	was	not	possible	to	quantify	this	reproducibly.		
6.12.3 Assessment	of	MTORC1	activity	
MTORC1	activity	in	lamina	propria	T	cells	was	measured	by	quantifying	levels	of	phospho-4EBP1	by	flow	cytometry.	Three	measures	of	MTORC1	activity	were	measured:	basal	activity	(phospho-4EBP1	MFI	after	a	period	of	nutrient	deprivation	in	vitro);	maximal	activity	(phospho-4EBP1	MFI	after	a	period	of	nutrient	stimulation	in	vitro);	and	the	proportion	of	nutrient-responsive	cells	(the	proportion	of	phospho-4EBP1	positive	cells	following	a	period	of	nutrient	stimulation	in	vitro,	compared	to	the	unstimulated	/	nutrient	deprived	control).	All	three	of	these	measures	are	potentially	biologically	relevant;	for	example	T	cells	with	high	basal	levels	of	MTORC1	activity	may	be	primed	to	perform	effector	functions	when	stimulated,	and	cells	with	high	maximal	levels	of	MTORC1	activation	in	response	to	nutrient	stimulation	may	provide	a	greater	amplitude	response	to	stimulation.	The	proportion	of	cells	responding	to	nutrient	stimulation	likely	reflects	the	population	of	cells	that	are	available	to	divide	/	differentiate	/	respond	to	an	immune	stimulus.	
	 200	
In	vitro,	LP	immune	cells	exhibited	a	clear	response	to	nutrient	stimulation.	However	no	change	in	response	was	seen	following	in	vivo	supplementation.	The	doses	chosen	ensured	high	delivery	to	the	proximal	small	bowel,	and	the	delivery	of	amino	acids	and	micronutrients	to	the	lamina	propria	immune	compartment	is	likely	to	have	been	sufficient.	This	suggests	that	chronic	stimulation	of	the	lamina	propria	T	cell	MTORC1	system	with	exogenous	(dietary)	nutrients	does	not	upregulate	MTORC1	signalling.		
6.12.4 Identification	of	T	lymphocyte	subsets	
A	number	of	methodological	considerations	meant	that	not	all	T	cell	subsets	could	be	positively	identified.	
• CD3+	CD4–	lymphocytes	were	assumed	to	represent	CD3+	CD8+	lymphocytes.	This	is	likely	to	be	valid	as	CD3+	CD4–	CD8–	cells	(which	would	have	an	identical	appearance	in	these	experiments)	are	a	rare	population	in	the	lamina	propria.	
• CD3+	CD4+	TBET+	cells	were	assumed	to	be	TH1	cells,	although	CD4+	lymphocytes	with	mixed	functions	(e.g.	TH1	–	Th17	hybrids)	would	appear	identical.	However,	studies	of	lymphocyte	plasticity	suggest	that	hybrid	cells	expressing	TBET	exhibit	TH1-like	properties;	similarly,	TBET	positive	cells	were	assumed	to	be	functional	(i.e.	effector	cytokine	production	such	as	IFNγ	in	response	to	appropriate	immunological	stimuli.	
• HLA-DR	alone	was	used	as	an	activation	marker.	
• No	functional	assays	were	performed.		
6.12.5 Methods	for	assessing	intestinal	permeability	
It	was	intended	to	measure	intestinal	permeability	by	urinary	lactulose	recovery.	Due	to	technical	reasons	it	has	not	yet	been	possible	to	undertake	this,	although	appropriate	samples	were	taken	and	stored	during	the	study.	The	results	of	this	assay	will	allow	us	to	determine	which	method	of	assessing	gut	permeability	is	most	relevant,	but	all	three	permeability	assays	(endomicroscopy;	serum	
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biomarkers;	urinary	sugar	recovery)	may	have	pathophysiological	relevance	and	are	likely	to	give	complementary	information.		Abnormal	sugar	permeability	is	correlated	both	with	bacterial	translocation	and	growth	faltering	in	children	(Campbell	et	al.,	2003b);	however	this	has	not	been	demonstrated	in	adults	(although	there	is	no	obvious	reason	to	suspect	this	does	not	occur).	Mechanistically,	sugar	uptake	studies	measure	the	paracellular	uptake	of	normally	non-absorbable	simple	carbohydrate	molecules;	the	relevance	of	this	to	the	passage	of	much	larger	and	more	complex	molecules	such	as	LPS	has	not	been	demonstrated	and	may	not	be	directly	linked.		On	the	other	hand,	CLE	has	been	studied	exclusively	in	adults,	and	pathological	fluorescein	leak	into	the	gut	lumen	has	been	shown	to	imply	inward	leakage	of	large	molecules	(at	least	up	to	MW	10,000kDa)	(Kiesslich	et	al.,	2012).	Furthermore,	in	a	prospective	study	of	quiescent,	endoscopically	normal	terminal	ileal	Crohn’s	disease	(another	condition	characterised	by	endoscopically	normal	mucosa),	the	presence	of	endomicroscopic	leak	was	clinically	relevant	and	predicted	risk	of	clinical	overt	relapse	(Kiesslich	et	al.,	2012).		
6.13 Conclusions	and	future	directions	
In	this	double-blinded	placebo-controlled	randomised	controlled	trial,	supplementation	with	AA	but	not	MM	increased	villus	height	and	villus	area	compared	to	placebo	on	a	background	of	a	seasonal	deterioration	in	small	intestinal	architecture.	AA	in	combination	with	MM	also	reduced	the	pathological	intestinal	barrier	permeability	observed	in	vivo	by	CLE.	The	pronounced	correlation	between	post-treatment	phospho-4EBP1	expression	in	lamina	propria	CD4+	cells	and	villus	height	suggests	that	nutrient	sensing	by	the	MTORC1	pathway	in	the	mucosal	immune	compartment	plays	a	part	in	determining	villus	morphology,	but	we	could	not	detect	evidence	that	this	determines	the	response	to	amino	acid	supplementation.	Baseline	and	post-supplementation	assessments	demonstrate	that	the	enteropathy	in	this	population	is	significant,	and	is	characterised	by	a	number	of	
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immunological,	histological,	metabonomic,	and	enterohumoral	abnormalities.	The	study	has	suggested	novel	mechanisms	in	which	nutrient	status	can	influence	the	mucosal	immune	compartment,	for	example	by	influencing	TBET	expression	/	TH1	differentiation.	Furthermore,	for	the	first	time	in	humans,	it	has	provided	insights	into	nutrient	sensing	in	lamina	propria	T	lymphocytes,	by	demonstrating	differential	responsiveness	to	nutrient	stimuli	depending	on	activation	status	and	T	cell	type,	for	example.	Despite	previous	in	vitro	evidence	of	a	role	for	nutrient	supplementation	in	determining	T	cell	fate,	in	vivo	supplementation	with	amino	acids	did	not	alter	T	cell	fate	or	MTORC1	signalling.	Metabonomic	profiling	identified	potentially	physiologically	relevant	metabolites	that	were	altered	by	the	interventions	studied,	and	metabolites	that	were	associated	with	intestinal	epithelial	morphology	and	MTORC1	nutrient	sensing.	One	of	these	in	particular,	HMB,	was	upregulated	by	the	supplements	and	was	positively	correlated	with	villus	height	and	MTORC1	signalling,	and	has	previously	been	identified	as	being	of	particular	interest	for	its	role	in	promoting	lean	muscle	mass.	Changes	were	identified	in	numerous	host-microbial	metabolic	pathways,	many	of	which	have	previously	been	identified	as	being	implicated	in	EE.	Future	work	will	need	to	identify	the	pathophysiological	relevance	of	these	perturbations.	Furthermore,	although	this	study	summarises	some	of	the	functional	consequences	of	the	presumed	dysbiosis	in	EE,	it	will	be	important	to	complete	the	assessment	of	the	microbiota	with	other	“omic”	methodologies	using	stool	specimens	taken	in	the	course	of	the	study.	Although	there	was	no	correlation	between	serum	and	in	vivo	endomicroscopic	measures	of	barrier	dysfunction,	both	methodologies	are	potentially	relevant	and	require	further	investigation	to	determine	method	is	most	relevant	for	quantifying	gut	barrier	dysfunction.	The	methods	are	conceptually	different	and	are	likely	to	provide	complementary	information	about	the	abnormalities	observed.	Assessments	of	micronutrient	(zinc	and	selenium)	absorption	and	macronutrient	(carbohydrate)	absorptive	capacity	will	hopefully	complete	the	assessment	of	gut	barrier	function	in	the	coming	months.	The	AMAZE	study	has	shown	that	a	combination	of	selected	amino	acid	and	micronutrient	supplementation	can	result	in	some	histological	and	functional	changes	in	adults	with	EE.	This	is	believed	to	be	the	first	time	that	a	therapy	for	EE	
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has	been	demonstrated	to	have	positive	effects	on	its	histological	features	in	the	context	of	a	randomised	controlled	trial.	It	has	recently	been	proposed	that	the	assessment	of	environmental	enteropathy	should	be	considered	in	several	domains	–	villus	morphology,	permeability,	microbial	translocation,	mucosal	inflammation,	systemic	inflammation,	malabsorption,	and	dysbiosis	(Keusch	et	al.,	2014;	Owino	et	al.,	2016).	These	data	suggest	that	therapies	for	EE	may	have	an	impact	on	one	or	two	of	these	domains	(in	this	case,	villus	atrophy	and	in	vivo	barrier	permeability)	without	necessarily	affecting	others;	furthermore,	it	is	unknown	which	of	these	pathophysiological	domain(s)	is	/	are	most	relevant	to	growth	in	children,	and	to	controlling	systemic	inflammation	and	reducing	intergenerational	deficits	in	adults.	Future	work	involving	long-term	follow	up	will	need	to	address	this.		Due	to	the	superadded	problems	of	under-resourced	healthcare	systems	and	healthcare	infrastructure	in	the	developing	world,	successful	therapeutic	interventions	for	EE	must	be	both	pathophysiologically	effective	and	simple	to	implement.	The	interventions	used	in	the	AMAZE	study	were	safe,	well	tolerated,	and	cheap,	and	may	therefore	be	suitable	for	further	study	as	a	clinical	intervention.	This	work	has	also	provided	further	insights	into	the	complexity	of	the	relationship	between	nutrition,	mucosal	immune	function,	and	intestinal	health.	For	as	long	as	this	relationship	remains	poorly	understood,	it	will	continue	to	present	fascinating	opportunities	for	further	study.	
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Amino acids and / or multiple Micronutrients in Adult Zambians with environmental Enteropathy: effects on intestinal 
structure & function and host-microbiome interactions. A randomised placebo controlled trial (AMAZE) 
 
We would like to invite you to be part of this research project. You should only agree to take part if you want to, it is entirely up to 
you. If you choose not to take part there won’t be any disadvantages for you and you will hear no more about it. Choosing not to 
take part will not affect your access to treatment or services in any way, now or in the future. 
 
Please read or listen to the following information carefully before you decide to take part; this will tell you why the research is 
being done and what you will be asked to do if you take part. Please ask if there is anything that is not clear or if you would like 
more information.  
 
If you decide to take part you will be asked to sign a consent form to say that you agree. You are still free to withdraw at any time 
and without giving a reason. 
 
Why we are doing this research 
Almost all children and adults who live in Misisi, like millions of other people in Africa and around the world who do not have 
easy access to clean water or toilets, often have problems with bowel inflammation. Although this inflammation doesn't cause any 
symptoms or make you feel unwell, we now think that it causes significant problems with growth and development. 
 
Over the last twenty years, we have done several research projects into this problem in Misisi, and we have learned a lot about this 
condition. Unfortunately, there is still a lot that is unknown, and there are still no treatments for the inflammation. 
 
Why we are doing this new research study 
One of our previous studies suggested that giving people some extra vitamins every day may help with some of the signs of the 
inflammation. It is also possible that the inflammation can be reduced by giving people some simple proteins to take. We would 
like to investigate the effects that these simple proteins and vitamins have on bowel inflammation in more detail. If the results are 
promising, then future trials will see if people should be given these supplements routinely. 
 
What the study involves 
You will be asked to take two supplements every day – either a vitamin pill or inactive pill, and either a simple protein powder or 
energy powder. You will take the same supplements every day for four months. You will not be able to tell which pill contains the 
vitamins, or which powder contains the proteins. Most people (three out of every four) will receive either the vitamins or the 
protein powder or both, but some people (one out of every four) will get the energy powder and inactive capsule. This is so that 
we can be sure that any benefits are truly due to the vitamins and / or proteins, rather than chance. Whether you get vitamins, 
protein, energy powder or inactive pill is up to pure chance, and you will not be told which substance you are getting. Even your 
doctors will not know until the end of the study. 
 
It is very important that you take the supplements every day, as this is the only way to be sure whether or not they will work. For 
this reason it is also very important that the supplements are only taken by you and not shared with or given to anyone else. 
Although the supplements are very safe in healthy adults, we do not know what their effects are in children, or in people that we 
have not assessed. 
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The supplements can be taken by themselves, or mixed into or sprinkled on top of nshima or water. It is important that you take all 
of the supplements every day. It is probably easiest for you to take them with your main meal, but you can take them at another 
time of day if you forget. 
 
 
The investigations you will have 
Before you enter the study, you will have a full medical assessment and examination. We will also ask for a stool sample to make 
sure you don't have a worm infection. If you do, we will give you treatment for this. 
 
If we identify any medical problems, we will give you treatment for this, or refer you to a specialist at UTH. 
 
We will bring you to UTH before you start and after you finish the supplements after four months. At UTH, we will examine the 
inside of your food pipe, stomach and start of your small bowel using a small flexible camera (endoscopy), and take some tiny 
tissue samples of the lining of your bowel at the same time. We will also take two blood samples (which is about half a mouthful), 
two urine samples, a saliva sample and a stool sample on the same day. Finally, we will do some specialist tests of body 
composition, to see how much of your body is made up of water, muscle and fat. All these tests are completely safe and painless. 
 
These tests will take most of a day and we will give you 80K to compensate you for the time you have given to come for them. 
 
 
About the endoscopy camera test 
The endoscopy test feels strange but is not painful. It is a very safe test. Professor Kelly and his team are very experienced and 
have performed over 2500 endoscopies on people from Misisi without any major problems. 
 
You will have the endoscopy test lying down on your side. You can keep your clothes on. We will give you some numbing spray 
to swallow and give you an injection to make you feel sleepy and relaxed. Many people fall asleep and can’t remember the test 
afterwards. The flexible camera is about as thick as your finger and so can be easily swallowed, although it will feel strange. We 
will take some tiny tissue samples of the lining of the bowel, which you won't feel as there is no sensation in this part of the 
bowel. The tissue samples are about the size of a small scratch, and are so small that they don't damage your bowel at all.  
 
Your stomach must be empty for the test to be done safely, so you can't have anything to eat or drink on the day of the endoscopy 
until after the procedure, but we will give you lunch afterwards. 
 
If you are interested, we can show you the endoscopy unit and equipment at UTH so you have a better idea of what is involved. 
 
 
HIV testing 
Effective medicine for HIV is now freely available in Zambia, and it is much more effective if discovered and treated before it 
gets advanced and causes symptoms. Knowing your HIV status is important for your health and the health of your family. It is 
therefore a good idea to have an HIV test regardless of whether or not you want to take part in the study, and whether or not you 
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feel unwell. To take part in the study, you will need to have an HIV blood test, because HIV can affect bowel inflammation and 
how it reacts to the supplements. If you are found to have HIV, we will refer you to specialists who will investigate you further 
and start treatment if you need it. 
 
The result of the HIV test is completely private and confidential. We are not allowed to tell your friends or family, or anyone else, 
what the result is without your permission, even if it is negative.  
 
 
Who can take part in the study 
Most adults who live in Misisi B section can take part. We cannot include children, women who are pregnant or breast feeding, or 
people who are unable to have an endoscopy test. 
 
 
What we do with your samples 
We only use the samples you provide for research. Any samples that we do not need for research will be destroyed. We have no 
need to use the samples you provide for any other purpose, including selling them or giving them to people who are not involved 
in the research. It is also against the law to do so. 
 
We do many of the research analysis in the laboratories at UTH. Some of the experiments will need to be done by Professor 
Kelly's research team in the UK, so some of your samples may be sent there. His team in the UK will also either use the samples 
for research, return them to Zambia, or destroy them. Like in Zambia, his UK team is not allowed to do anything with the samples 
that isn’t to do with research, including selling them or giving them to people who aren’t involved in the research. 
 
We do not use all the samples immediately, and we often have to store them for use in the future. Samples are normally stored in 
freezers which are kept securely in the laboratories, which only Professor Kelly and his team have access to. When we have 
completed all the experiments that we need for the study, we will see if any samples are left over. If so, we would like to keep 
them for use in future research studies, so that we may not need to repeat the procedures to get more samples. The same rules on 
what we can do with the samples, and who can use them, will apply in any future research. Before we could use your samples for 
research in the future, we would first need to ask permission from the Ethics Committee in the University of Zambia who will 
make sure that it is ethical to do so. 
 
We do many different experiments on the samples you provide, and if you are interested we can demonstrate and explain some of 
these to you, including how the samples are stored. 
 
 
What we do with the information you provide 
During the research we collect information about you, for example how much you weigh, how old you are and how much 
inflammation is in your bowel. We store the information on computers and remove your name and other ways of identifying you, 
so that there is no way of telling who the information refers to. The only way we can find out is by looking up your research 
number in a book which is kept in a locked office at UTH, which only Professor Kelly has access to. The researchers who analyse 
your samples will not be able to tell whose samples they are analysing. 
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Any and all information you give us is confidential. This means that we are not allowed to tell anyone about you, even if they are 
friends or family. When the information we collect is analysed, it becomes impossible to tell who gave the samples, so it is not 
possible for you to be identified from your samples. 
 
We think that the knowledge we gain in this study will give us a lot of important information into what causes the bowel 
inflammation and what can be done about it. We would like to share this information with other scientists and governments in 
conferences and publications. Nobody who hears or reads about the research will be able to tell that the information or samples 
came from you. 
 
How this study might benefit you 
While you are in the study, you and your family will have free health care at the Misisi clinic. If you have an illness that we 
cannot treat at the clinic, we will send you for further tests or treatment by specialists at UTH, which you will not have to pay for. 
 
The camera endoscopy test is the best test for examining your food pipe and stomach. Sometimes people have problems like 
ulcers that don't cause any symptoms, but which can sometimes still be serious. If we find that you have any of these problems 
when we do the endoscopy camera test we will investigate and treat them. 
 
It is important for your health and the health of your family that you know your HIV status, even if you feel completely well. 
Effective medicine for HIV is now freely available in Zambia, and it is much more effective if discovered and treated before it 
gets advanced. 
 
Insurance and what to do if you have questions or concerns 
Queen Mary University of London has agreed that if you are harmed as a result of your participation in the study, you will be 
compensated, provided that, on the balance of probabilities, an injury was caused as a direct result of the intervention or 
procedures you received during the course of the study. These special compensation arrangements apply where an injury is caused 
to you that would not have occurred if you were not in the trial. These arrangements do not affect your right to pursue a claim 
through legal action. 
 
It is up to you to decide whether or not to take part. If you do decide to take part you will be given this information sheet to keep 
and be asked to sign a consent form.  
 
If you have any questions or concerns about the study or how it is conducted, you can contact Professor Kelly's team in the Misisi 
clinic at any point. If you are not happy to do this, or are not happy with the advice you get from Professor Kelly's team, you can 
contact the University of Zambia Biomedical Research Ethics Committee, University of Zambia School of Medicine Ridgeway 
Campus, PO box 50110. 
 
Thank you. 
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Consent form (English) 
 
Please complete this form after you have read or listened to the Information Sheet and/or listened to an explanation about 
the research. 
 
Amino acids and / or multiple Micronutrients in Adult Zambians with environmental Enteropathy: effects on 
intestinal structure & function and host-microbiome interactions. A randomised placebo controlled trial. (AMAZE) 
 
UNZABREC reference: 007-11-14 
 
1. I have read or listened to the Participant Information Sheet for this study (version 2.1, dated 18th December 2014). 
2. The research has been explained to me. I understand what the research involves and what is required of me. 
3. I understand that I will have a blood test for HIV. 
4. I understand that samples I provide may be sent abroad for research purposes only, and that after use the 
samples will either be returned to Zambia for storage or destroyed. 
5. I consent to the long term storage of any samples I provide (including blood, urine, stool, small bowel fluid and 
endoscopic biopsies) in secure facilities at the University of Zambia after this research study has finished, for 
possible ethically approved research projects in the future. 
6. I understand that there is no obligation for me to participate in the research, and that I do not have to give a 
reason for not participating. 
7. I understand that if I decide at any time during the research that I no longer wish to participate, I can notify the 
researchers involved and be withdrawn from it immediately, without giving a reason. 
8. I consent to the processing of my personal information for the purposes of this research study. I understand that 
such information will be treated as strictly confidential at all times and that any identifiable information about me 
will be available only to members of the study team. 
 
 
Participant’s Statement:  
 
I ___________________________________________ have read or listened to statements 1-8 above and I agree to 
take part in the study. 
 
Signed:      Date:  
 
Witnessed:     Date: 
 
 
Investigator’s Statement:  
 
I ___________________________________________ confirm that I have carefully explained the nature, demands and 
any foreseeable risks of the proposed research to the volunteer. 
 
Signed:      Date:  
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TROPGAN AMAZE study: Misisi baseline case report form      ID__ __ __ __ 
p. 1/6   v2.1 / 3rd Nov 2014 
 
Name ____________________________________________________________________ 
House number B __ __ __ 
Date __ __ / __ __ / __ __ (dd/mm/yy) 
 
 
Inclusion criteria (TICK IF CRITERIA MET) 
c AGED BETWEEN 18 AND 60 YEARS 
c ABLE TO GIVE INFORMED CONSENT 
c RESIDENT IN MISISI STUDY AREA 
 
 
Exclusion criteria (TICK IF CRITERIA MET THEN DO NOT RECRUIT) 
c NOT WILLING TO UNDERGO HIV TEST 
c WARFARIN OR BLEEDING DISORDER 
c UNABLE TO HAVE ENDOSCOPY SAFELY 
c PREGNANT OR BREAST FEEDING 
c BMI < 18 
c UNWILLING TO CONSENT FOR LONG TERM STORAGE OF SAMPLES 
 
 
Temporary exclusion criteria (POSTPONE FURTHER INVESTIGATIONS UNTIL CRITERIA NO LONGER APPLY) 
c DIARRHOEA IN THE LAST 4 WEEKS (>3 WATERY STOOLS FOR >24 HOURS) 
c USED ANTIBIOTICS OR NSAIDs WITHIN LAST 4 WEEKS (TAKEN REGULARLY FOR >72 HOURS) 
c HELMINTH / WORM INFECTION 
 
 
Date eligible to start study (if not today) __ __ / __ __ / __ __ 
4 WEEKS AFTER LAST LOOSE STOOL 
4 WEEKS AFTER LAST ANTIBIOTIC OR NSAID USE 
6 MONTHS AFTER FINISHED ANTI-HELMINTHIC COURSE 
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p. 2/5   v2.1 / 3rd Nov 2014 
 
Demographics and social history 
Age   ___ ___ years      Sex  Male  /  Female  
Occupation  ____________________________________  Time in Misisi  ___ ___ years 
Marital status   Single  /  Married  /  Widowed  /  Divorced  /  Separated  /  Co-habiting  
Smoking  Never  /  Ex  /  Rarely  /  Weekly  /  Daily  
   Year started ___ ___ ___ ___ / Year stopped ___ ___ ___ ___ 
Alcohol  Never  /  Monthly or less  /  2-3 times a month  /  Weekly  /  2-3 times a week  /  Daily 
Alco drink  Beer  /  Kachasu  /  Other  __________________ 
Level of education None  /  Primary  /  Secondary  /  College  /  University  
 
Household characteristics 
Does someone in your household own the house you live in? No  / Yes  
Do you have electricity?   No  / Yes  
Do you have a radio?    No  / Yes  
Do you have a cell phone?    No  / Yes  
Do you have any pets which live indoors? No  / Yes  
 
How often do you… 
Boil water  Never  /  Cholera  /  Rains  /  Most days  /  Always  
Add chlorine  Never  /  Cholera  /  Rains  /  Most days  /  Always  
 
Household hygiene score 
Cleanliness  0 / 1 / 2 
Water storage  0 / 1 / 2 
Food storage  0 / 1 / 2 
Hand washing  0 / 1 / 2 
Sanitation  0 / 1 / 2   HHS total  ___ ___ / 10
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p. 3/5   v2.1 / 3rd Nov 2014 
 
Please complete food frequency questionnaire for last month (see separate sheet) 
 
Past medical history          Year diagnosed (yyyy) 
HIV status  Negative  / Positive  / Unknown   __ __ __ __ 
TB No  /  Pulmonary  /  Abdominal  /  Meningitis  /  Other  __________________ __ __ __ __ 
Hepatitis / jaundice No  / Yes          __ __ __ __ 
Stroke   No  / Yes         __ __ __ __ 
Surgery  No  / Yes  _____________________________________  __ __ __ __ 
Diabetes  No  /  Diet controlled  /  Tablet  /  Insulin  /  Both    __ __ __ __ 
Heart disease  No  /  MI  /  Heart failure  /  Other  _______________  __ __ __ __ 
Hypertension  No  /  Yes         __ __ __ __ 
Asthma  No  /  Yes – no admissions  /  Yes – previous admissions   __ __ __ __  
 
Other major illness 1 _____________________________________________ __ __ __ __  
Other major illness 2 _____________________________________________ __ __ __ __  
Other major illness 3 _____________________________________________ __ __ __ __  
 
Current symptoms 
Current symptom 1 _________________________________ Duration 1  (days) __ __ / (weeks) __ __ 
Current symptom 2 _________________________________ Duration 2  (days) __ __ / (weeks) __ __  
Current symptom 3 _________________________________ Duration 3  (days) __ __ / (weeks) __ __ 
 
Current medications         Year started (yyyy) 
Drug 1 ______________________ Dose 1___________ prn / od / bd / tds / qds __ __ __ __  
Drug 2 ______________________ Dose 2___________ prn / od / bd / tds / qds __ __ __ __  
Drug 3 ______________________ Dose 3___________ prn / od / bd / tds / qds __ __ __ __  
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AMAZE            ID__ __ __ __ 
p. 4/5   v2.1 / 3rd Nov 2014 
 
Antihypertensives No   / Yes       __ __ __ __  
Heart failure  No   / Yes       __ __ __ __  
Diabetes  No   / Tablets  /      Insulin      /    Both  __ __ __ __  
ART   No   / Yes       __ __ __ __  
Aspirin  No   / Yes       __ __ __ __  
Asthma  No   / Yes       __ __ __ __ 
Other ___________________________ Indication ________________________ __ __ __ __  
 
Do you take any unprescribed / self-prescribed / over-the-counter / traditional medicines? 
No   / Yes  ____________________________________________________________ 
 
Observations 
Height  __ __ __ cm    HR  __ __ __ 
Weight  __ __ . __ kg    BP  __ __ __ / __ __ __ 
MUAC  __ __ . __ cm     RR  __ __ 
Karnofsky ___ ___ ___ / 100   Grip strength __ __ . __ kg  LEFT  /  RIGHT 
            (TEST NON-DOMINANT SIDE)
  
Physical examination (CIRCLE ALL THAT APPLY) 
Breathlessness None   / After exertion   /  At rest  
Lymphadenopathy None   / Cervical      /     Axillary      /     Inguinal      /     Multiple  
Skin & hair  Normal   /  Pellagra   /  Silky hair   /  Keloid  
Jaundice / Pallor / Oedema / Clubbing / Cyanosis / Goitre 
BCG scar / Smallpox jab scar  
Oral candida / Oral KS 
Other  _________________________________________________________________________________ 
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p. 5/5   v2.1 / 3rd Nov 2014 
 
CVS Normal  / Abnormal  ______________________________________________ 
 Signs of rheumatic heart disease / Signs of LVF  / Signs of RVF 
RS Normal  / Abnormal  ______________________________________________ 
 Wheeze / Fibrosis / Effusion / Consolidation  
GI Normal  / Abnormal  ______________________________________________ 
 Surgical scars    /    Hepatomegaly    /    Splenomegaly    /    Palpable kidneys    /    Mass    /    Ascites 
Peripheral neuropathy No  / Yes  
Other   _____________________________________________________________________ 
 
Test results 
HIV 
Date of test __ __ / __ __ / __ __ (dd/mm/yy) 
Negative  / Positive    CD4 count (if positive) __ __ __ 
 
Stool  
Date of test __ __ / __ __ / __ __ (dd/mm/yy) 
Result  Negative  / Asc.  / Strong.  / Enterobius  / Taenia  / Schisto.  / Trich.  / Hook.   
Other  _______________________ 
Treatment Albendazole  / Mebendazole  / Praziquantel  / Other  _______________________ 
Treatment started __ __ / __ __ / __ __ (dd/mm/yy) 
 
Notes 
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Date ___ ___ / ___ ___ / ___ ___ Pre   /   Post   /   Control ID ___ ___ ___ ___ 
 
 
TROPGAN AMAZE study: Endoscopy visit case report form 
Confocal laser endomicroscopy  Y / N   Settings           (Default)  
Pethidine (mg)  0 / 25 / 50 /   ____ Gamma __ . __ __  (1.74) 
Diazepam (mg)  0 / 5 / 7.5 /   ____ Bright __ . __ __ (0.47)  
Midazolam (mg)  0 / 2.5 / 5 /   ____  Laser __ __ __ (380) 
Buscopan (mg)  0 / 10 / 20    Operator PK   /   JLA 
 
Indication (controls only) Dysphagia | GORD | Dyspepsia/Abdo pain | Wt loss | Abn. radiology | Planned rpt |  
Other ________________________________________________________ 
 
Oesophagus Not seen / Normal / Stricture / Candida / Varices / Cancer / Ulcer / Other _______________ 
  Passable / Impassable (if relevant)     Benign / Malignant (if relevant) 
Stomach  Not seen / Normal / Varices / Cancer / GU / Gastritis / Pyloric stenosis / Other ___________ 
  Passable / Impassable (if relevant)     Benign / Malignant (if relevant) 
Duodenum Not seen / Normal / Stricture / DU / Duodenitis / Other _______________________________ 
  Passable / Impassable (if relevant) 
 
iScan grade   Normal  /  Leaves  /  Ridges  /  Convolutions  /  Atrophic  
Micro grade  Normal  /  Leaves  /  Ridges  /  Convolutions  /  Atrophic  
 
Timings checklist     Intubation depth <D1/2 | D1/2 | D2 | D2/3 | D3 | >D3 
c Baseline blood ___ ___ : ___ ___ 
c Baseline urine  ___ ___ : ___ ___ 
c Fluorescein  ___ ___ : ___ ___ 
c Biopsies  ___ ___ : ___ ___ 
c Solutions  ___ ___ : ___ ___ 
c 3h blood  ___ ___ : ___ ___ 
c 3h urine   ___ ___ : ___ ___ 
c Digest started  ___ ___ : ___ ___   ADVERSE EVENTS / NOTES: PTO 
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Date ___ ___ / ___ ___ / ___ ___ Pre   /   Post   /   Control ID ___ ___ ___ ___ 
 
TROPGAN AMAZE study 
 
Anthropometry 
 
Grip strength   Y / N  ____ ____ . ____ kg 
 
BodPod   Y / N 
 
Bioelectrical impedance Y / N 
 
NOTES 
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TROPGAN AMAZE study: Monthly follow-up case report form     ID ___ ___ ___ ___ 
Date ___ ___ / ___ ___ / ___ ___ (dd/mm/yy)   Study week number 4 8 12 End 
 
Weight (end-of-study visit only) ___ ___ ___ . ___ kg  MUAC (end-of-study visit only) ___ ___ . ___ cm 
 
MM tabs remaining   ____ ____    AA packets remaining   ____ ____ 
How easy is it for you to remember to take both your medicines every day? Very easy | Quite easy | Quite difficult | Very difficult 
How easy is it for you to take all your medicines? Very easy | Quite easy | Quite difficult | Very difficult 
How often have you forgotten to take your medicines? 
Most days | 2 or 3 times a week | About once a week | Less than once a week | Once or twice | Never 
Describe any side effects ______________________________________________________________________________________ 
Describe any problems with taking the medicines _________________________________________________________________ 
 
In the last month (since your last visit) have you had... 
Diarrhoea (liquid stool at least 3 times a day) No  | Yes  
 How long did it last?   3 days or less | More than three days 
 Was there blood?   No  | Yes  
Time off your usual activities?  No  | Yes  
 Treatment given    None | ORS | Abx (self-prescribed) | Abx (clinic/hospital) | Admitted | Other 
 
Any other symptoms / illnesses No  | Yes  
 Details   _______________________________________________________________________________ 
 Treatment given  _______________________________________________________________________________ 
 Medical attention None | St Lawrence or other clinic (not admitted) | Admitted 
 
In the last month (since your last visit) have you taken... 
Antibiotics / antimalarials No  | Yes  
 Name   _____________________________________ | Unknown  
 For how many days? 1 | 2-3 | Up to a week | More than a week 
 Prescriber  Self | Clinic/hospital 
 Indication  Fever | Cough | Diarrhoea | Malaria (no blood tests) | Malaria (confirmed with tests) | Other 
 Details   _______________________________________________________________________________ 
 
Pain killers No | Paracetamol | Ibuprofen | Diclofenac | Indomethacin | Other_____________________ | Unknown 
 For how many days? 1 | 2-3 | Up to a week | More than a week 
 Prescriber  Self | Clinic/hospital 
 
Have you taken any other medicines or remedies (apart from your regular medicines)? No | Yes 
Details   _______________________________________________________________________________ 
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AMAZE  Unplanned clinic attendance questionnaire  ID __ __ __ __ 
 
Date (dd/mm/yy) __ __ / __ __ / __ __ 
Current problem(s) 
 
 
 
 
 
 
 
 
 
Clinical findings 
 
 
 
 
 
 
 
Impression 
 
 
Plan 
 
 
 
 
 
 
 
Related to study? 
 Definitely /  Probably /  Possibly  /  Remote / Not 
SAE? 
 No (0)  / Yes (1) 
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Appendix	4.	ImageJ	morphometry	macro.		
//Morphometry of intestinal biopsy sections v1 (C) 2016 John Louis-
Auguste (j.l.auguste@qmul.ac.uk) 
 
//.csv results file headings: 
//Base length ('B') = 'Perim.' or 'Length' 
//Villus area ('VA/VP') = 'Area' 
//Villus perimeter ('VA/VP') = 'Perim.' [base length needs to be 
subtracted from this value] 
//Villus height ('VH/VW') = 'Width' 
//Villus width ('VH/VW') = 'Height' 
//Muscularis mucosae length ('MM') = 'Perim.' or 'Length' 
//Crypt depth ('CD') = 'Perim.' or 'Length' 
//All other values should be ignored / deleted 
 
run("Open..."); 
//run("Enhance Contrast...", "saturated=5"); 
run("8-bit"); 
run("Set Scale...", "distance=1.1 known=1 pixel=1 unit=um global"); 
//Sets scale for 10X objective 
run("Set Measurements...", "area perimeter bounding display 
redirect=None decimal=3"); 
run("Colors...", "foreground=black background=white selection=red");  
run("8-bit"); //Converts to 8-bit image for thresholding 
rename(File.nameWithoutExtension); 
 
//Select all villi to be measured as a group on duplicated 8-bit image 
run("Select All"); 
run("Copy"); 
newImage(File.nameWithoutExtension, "8-bit white", 1680, 1056, 1); 
run("Paste"); 
newImage(File.nameWithoutExtension, "8-bit white", 1680, 1056, 1); 
run("Paste"); 
run("Select None"); 
setTool("polygon");  
waitForUser("Draw round all villi to be measured (double click to 
complete) then press OK. Draw across villus bases accurately!");  
run("Make Inverse");  
run("Cut"); //Leaves villi only 
 
//Define function to rename last RoI and leave it selected 
function roiRenameLast(name) { 
last = roiManager("count")-1; 
roiManager("select", last); 
roiManager("Rename", name); 
} 
 
//Draw and measure all bases first 
var n = 0 
run("Select None"); 
while (getBoolean("Draw a villus base?") == 1) { 
 setTool("polyline"); 
 run("Line Width...", "line=5"); 
 waitForUser("Draw villus base (double click to start & complete) 
then press OK"); 
 roiManager("Add"); 
 n++; 
 roiRenameLast(" B"+n); 
 roiManager("Measure"); 
 setForegroundColor(0, 0, 0); 
 run("Fill", "slice"); 
} 
 
//Delete all bases from ROI manager 
selectWindow("ROI Manager"); 
run("Close"); 
 
//Threshold villi for automated measurements 
run("Auto Threshold", "method=Default white"); 
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setTool("wand"); 
waitForUser("Check thresholding by clicking on each villus in turn. 
Correct defects etc. using PENCIL TOOL then press OK. [F1 or Edit-
>Options->Colors...->'Foreground': white=delete / black=draw]");  
 
//VP, VA, VH, VW measurements for each villus 
n=0; 
while (getBoolean("Measure villus parameters?") == 1) { 
 run("Select None"); 
 setTool("wand"); 
 waitForUser("VA/VP measurement: Click on a villus then press OK. 
Ensure correct villus perimeter is outlined in red."); 
 roiManager("Add"); 
 n++; 
 roiRenameLast(" VA/VP"+n); 
 roiManager("Measure"); 
 setTool("polyline"); 
 run("Line Width...", "line=500"); 
 waitForUser("VH/VW measurement (1/3): Draw villus long axis 
(double click to start & complete) then press OK"); 
 run("Straighten..."); 
 setTool("wand"); 
 waitForUser("VH/VW measurement (2/3): Click on selected villus 
then press OK. Ensure correct villus perimeter is outlined in red."); 
 run("To Bounding Box"); 
 waitForUser("VH/VW measurement (3/3): Adjust bounding box if 
required, then press OK"); 
 rename(File.nameWithoutExtension); 
 roiManager("Add"); 
 roiRenameLast(" VH/VW"+n); 
 roiManager("Measure"); 
 roiManager("Delete"); 
 run("Close"); //Closes bounding box image 
 } 
 
run("Close"); //Closes thresholded image 
 
//Draw MM 
roiManager("Show All"); //Shows all measured villi for assessing MM 
setTool("polyLine"); 
run("Line Width...", "line=1"); 
waitForUser("Draw MM (double click to complete) then press OK"); 
roiManager("Add"); 
roiRenameLast(" MM"); 
roiManager("Measure"); 
 
//Draw crypts 
n=0; 
while (getBoolean("Draw crypt?") == 1) { 
 setTool("polyline"); 
 run("Line Width...", "line=1"); 
 waitForUser("Draw crypt (double click to start & complete) then 
press OK"); 
 roiManager("Add"); 
 n++; 
 roiRenameLast(" CD"+n); 
 roiManager("Measure"); 
 } 
 
//Save 8-bit image with overlays, save results as csv, tidy up 
roiManager("Show All"); 
run("Line Width...", "line=1"); 
run("Flatten"); 
rename(File.nameWithoutExtension+"_overlay"); 
saveAs("tiff"); // Use saveAs(format, path) to save to specific 
directory 
saveAs("results"); // Use saveAs(format, path) to save to specific 
directory 
selectWindow("ROI Manager"); 
run("Close"); 
run("Close All"); 
runMacro("/Applications/Fiji.app/macros/AutoRun/Morpho.ijm"); 
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Appendix	5.	Incubation	media	for	MTORC1	flow	cytometry	assay.	 	
	
	
	
	
	
	
	
	
	
	
	
	
	
										
Table	S1.	In	addition,	RPMI	in	the	nutrient	rich	solution	contains	a	number	of	vitamins,	and	
both	solutions	contained	balanced	inorganic	chloride,	phosphate,	bicarbonate	salt	solutions	
(calcium,	magnesium,	potassium,	sodium).		
		 Nutrient	deprived	 Nutrient	rich	
FBS	(lot	specific)	 –	 10%	
Glucose	 5.56mM	 11.11mM	
L-Glutamine	 1mM	 4mM	
L-Glycine	 –	 0.13mM	
L-Arginine	 –	 1.15mM	
L-Asparagine	 –	 0.38mM	
L-Aspartic	acid	 –	 0.15mM	
L-Cysteine	 –	 0.21mM	
L-Glutamic	acid	 –	 0.14mM	
L-Histidine	 –	 0.10mM	
L-Hydroxyproline	 –	 0.15mM	
L-Isoleucine	 –	 0.38mM	
L-Leucine	 –	 0.38mM	
L-Lysine	 –	 0.22mM	
L-Methionine	 –	 0.10mM	
L-Phenylalanine	 –	 0.09mM	
L-Proline	 –	 0.17mM	
L-Serine	 –	 0.29mM	
L-Threonine	 –	 0.17mM	
L-Tryptophan	 –	 0.02mM	
L-Tyrosine	 –	 0.11mM	
L-Valine	 –	 0.17mM	
Gentamicin	 50μg/mL	 50μg/mL	
Penicillin	G	 100U/mL	 100U/mL	
Streptomycin	 100mg/mL	 100mg/mL	
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